publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
armengol
j
calvo
l
martinezmartinez
santand
es
object
evalu
reliabl
microscan
walkaway
system
wa
determin
suscept
test
gramneg
bacteria
isol
clinic
sampl
quinolon
includ
organ
total
resist
low
level
resist
method
evalu
clinic
isol
per
patient
differ
phenotyp
resist
quinolon
includ
e
coli
p
mirabili
k
pneumonia
morganii
c
freundii
enterobacteria
p
aeruginosa
baumannii
non
ferment
enterobacteria
select
includ
consecut
isol
follow
phenotyp
clsi
definit
group
e
coli
none
coli
suscept
nalidix
acid
nal
ciprofloxacin
cip
group
e
coli
none
coli
nalresist
r
mic
cip
rang
mgl
group
e
coli
none
coli
nalr
cipr
wa
test
done
combo
urin
panel
contain
nal
mgl
cip
mgl
norfloxacin
mgl
ofloxacin
ofl
mgl
refer
method
microdilut
md
clsi
mgl
nal
mgl
other
result
wa
md
compar
calcul
agreement
clinic
categori
number
minor
major
fals
resist
major
error
vme
fals
suscept
essenti
agreement
dilut
consid
disagr
mic
wa
md
limit
clinic
microbiolog
infect
volum
supplement
concentr
wa
panel
nal
evalu
enterobacteria
result
agreement
clinic
categori
essenti
agreement
nal
cip
ofl
organismquinolon
combin
vme
cip
ofl
p
aeruginosa
nal
e
coli
p
mirabili
cip
p
mirabili
maltophilia
ofl
marcescen
minor
error
cip
p
mirabili
p
aeruginosa
marcescen
other
p
aeruginosa
marcescen
other
ofl
p
mirabili
morganii
other
conclus
wa
system
reliabl
use
test
gramneg
bacteria
quinolon
includ
isol
resist
decreas
suscept
antimicrobi
agent
fals
resist
amikacin
pseudomona
aeruginosa
microscan
walkaway
system
f
unda
j
calvo
armengol
l
santand
es
object
determin
reliabl
suscept
test
result
p
aeruginosa
strain
report
resist
amikacin
amk
microscan
walkaway
system
wa
method
evalu
consecut
non
duplic
p
aeruginosa
strain
isol
februari
resist
amk
accord
wa
system
identif
suscept
test
perform
accord
manufactur
instruct
two
type
panel
follow
concentr
mgl
aminoglycosid
use
neg
combo
panel
gentamicin
gen
tobramycin
tob
amk
urin
combo
panel
gen
tob
amk
result
compar
obtain
refer
microdilut
clsi
guidelin
mic
also
obtain
etest
comparison
mic
etest
within
two
valu
dilut
scale
round
next
higher
dilut
percentag
agreement
clinic
categori
calcul
disagr
defin
major
error
vme
resist
microdilut
suscept
wa
etest
major
error
suscept
microdiluiton
resist
wa
etest
minor
error
intermedi
one
method
suscept
resist
one
agreement
mic
etest
within
one
within
two
dilut
step
obtain
microdilut
also
calcul
result
percentag
agreement
clinic
categori
wa
microdilut
gen
tob
amk
etest
microdilut
correspond
valu
vme
obtain
wa
observ
strain
wa
obtain
strain
obtain
etest
gen
amk
agreement
within
one
within
two
dilut
step
mic
etest
microdilut
amk
tob
gen
conclus
studi
wa
system
reliabl
suscept
test
p
aeruginosa
amk
strain
report
amkresist
actual
suscept
antibiot
lesser
extent
major
error
also
note
gen
tob
hand
etest
agre
well
refer
microdilut
three
aminoglycosid
object
evalu
system
franc
use
card
suscept
abstract
clinic
microbiolog
infect
volum
supplement
issn
test
recognit
phenotyp
resist
clinic
isol
escherichia
coli
eco
klebsiella
pneumonia
kpn
resist
betalactam
contain
specif
test
extendedspectrum
betalactamas
esbl
detect
method
test
organ
eco
kpn
produc
tem
shv
ctxm
esbl
eco
hyperproduc
chromosom
ampc
hampc
kpn
esbl
lack
porin
por
kpn
plasmidmedi
ampc
betalactamas
pacbl
mic
determin
microdilut
md
clsi
guidelin
resist
mechan
studi
betalactamas
character
isoelectr
focus
gene
sequenc
sdspage
outer
membran
protein
mic
amoxicillinclv
amc
piperacillintazobactam
ptz
cefoxitin
fox
cefotaxim
ctx
ceftazidim
caz
cefepim
fep
determin
card
compar
refer
md
presum
phenotyp
resist
advanc
expert
system
ae
suggest
chang
clinic
categori
also
compar
card
result
strain
mic
amc
ptz
fox
card
within
one
dilut
step
strain
mic
ctx
caz
fep
dilut
higher
strain
revers
note
strain
mic
fep
dilut
lower
refer
md
esbl
organ
kpn
por
pacbl
agre
eco
hampc
phenotyp
suggest
ae
card
agre
refer
result
esbl
strain
esbl
por
pacbl
valu
respect
eco
hampc
ae
suggest
sever
phenotyp
includ
esbl
report
resist
ctx
caz
fep
card
correctli
discard
presenc
esbl
strain
conclus
differ
mic
ctx
caz
fep
obtain
card
organ
esbl
pacbl
note
comparison
refer
result
usual
translat
chang
clinic
categori
ae
suggest
ae
show
excel
agreement
underli
mechan
resist
card
suggest
fals
presenc
esblin
eco
hampc
object
unusu
speci
enterobacteriacea
caus
clinic
infect
human
rare
occas
howev
studi
evalu
accuraci
suscept
test
method
organ
object
studi
determin
whether
disk
diffus
dd
vitek
gave
accur
suscept
test
result
unusu
isol
compar
clinic
laboratori
standard
institut
clsi
broth
microdilut
bmd
refer
method
method
sixtyon
isol
repres
genera
differ
speci
includ
buttiauxella
cedecea
ewingella
kluyvera
leminorella
rahnella
yokenella
strain
collect
center
diseas
control
prevent
test
dd
bmd
refer
method
use
muellerhinton
mh
agar
cationadjust
mh
broth
h
antimicrobi
agent
includ
aminoglycosid
carbapenem
cephalosporin
fluoroquinolon
penicillin
trimethoprimsulfamethoxazol
clsi
interpret
criteria
enterobacteriacea
use
identif
suscept
isol
also
test
vitek
describ
manufactur
identif
result
compar
convent
biochem
test
result
drug
test
bmd
dd
show
categor
agreement
ca
ca
lower
ampicillin
cefazolin
three
major
error
cefazolin
one
resolv
repeat
test
one
major
error
also
cefazolin
minor
error
thirtyfour
isol
cover
speci
vitek
databas
identifi
correctli
speci
level
correct
genu
level
five
report
unidentifi
vitek
gener
mic
result
isol
categor
interpret
r
provid
drug
test
bmd
vitek
essenti
agreement
isol
rang
ca
isol
rang
ampicillin
twelv
drug
exhibit
ca
conclus
dd
often
backup
method
laboratori
autom
system
provid
accur
suscept
test
result
unusu
organ
vitek
identifi
subset
isol
correctli
provid
mic
interpret
thu
dd
provid
reliabl
altern
bmd
test
unusu
enterobacteriacea
test
autom
method
h
rodriguezvillalobo
j
smet
c
nonhoff
crevecoeur
r
de
struelen
brussel
object
vitek
biomerieux
develop
novel
gramneg
suscept
card
improv
accuraci
esbl
detect
among
e
coli
klebsiella
spp
card
contain
specif
esbl
test
combin
cefotaxim
cefepim
ceftazidim
alon
clavulan
evalu
card
advanc
expert
system
ae
abil
detect
esbl
mediat
resist
well
character
collect
esblproduc
e
coli
klebsiella
spp
clinic
isol
method
total
e
coli
strain
esbl
ampc
produc
e
coli
klebsiella
spp
isol
esbl
strain
includ
presenc
esbl
confirm
doubl
disc
synergi
test
combin
disc
three
substrat
pcr
bla
tem
bla
shv
bla
ctxm
gene
esbl
character
isoelectricfocus
andor
dna
sequenc
esbl
strain
includ
e
coli
harbour
ctxm
group
enzym
ctxm
group
tem
enzym
shv
enzym
esbl
produc
klebsiella
spp
harbour
ctxm
enzym
combin
tem
shv
betalactamas
organ
subcultur
twice
bloodsheep
agar
load
card
accord
manufactur
recommend
result
discord
observ
two
card
mean
time
obtain
result
h
rang
overal
agreement
enzym
detect
esbl
vitek
test
posit
esblproduc
strain
sensit
specif
e
coli
respect
k
pneumonia
k
oxytoca
respect
disagr
concern
mainli
ctxm
produc
k
oxytoca
esbl
posit
card
test
systemat
interpret
ae
highlevel
penicillinas
product
esblproduc
k
pneumonia
ae
infer
express
imperm
mechan
addit
esbl
product
conclus
new
ast
vitek
card
show
accur
rapid
detect
esblproduc
e
coli
kpneumonia
includ
strain
harbour
ctxm
enzym
lower
sensit
ae
detect
ctxm
produc
k
oxytoca
indic
difficulti
detect
emerg
phenotyp
organ
object
vitek
card
biomerieux
gramneg
suscept
test
includ
specif
esbl
detect
test
combin
cefotaxim
cefepim
ceftazidim
alon
clavulan
test
valid
manufactur
e
coli
klebsiella
spp
result
report
speci
determin
abil
vitek
advanc
expert
system
ae
detect
esbl
mediat
resist
enterobact
clinic
isol
use
card
method
total
enterobact
isol
esbl
produc
strain
e
aerogen
e
cloaca
non
esbl
produc
strain
e
aerogen
e
cloaca
inocul
vitek
card
accord
manufactur
recommend
product
esbl
confirm
doubl
disc
synergi
test
ceftazidim
cefotaxim
cefepim
combin
disc
method
oxoid
pcr
bla
tem
bla
shv
bla
ctxm
gene
e
cloaca
harbour
combin
e
aerogen
esbl
includ
tem
enzym
shv
combin
enzym
result
grade
agreement
ae
infer
esbl
mechan
partial
agreement
ae
suggest
sever
mechan
includ
esbl
disagr
ae
conclud
differ
mechan
result
result
summar
tableoveral
sensit
e
aerogen
e
cloaca
specif
e
aerogen
e
cloaca
mean
time
obtain
result
h
rang
conclus
studi
show
ae
provid
rapid
sensit
tool
detect
possibl
esbl
product
enterobact
spp
use
card
confirmatori
analysi
frequent
necessari
effici
autom
method
develop
distinguish
esbl
product
ampc
hyperproduct
genu
enterobacteriacea
absolut
must
antimicrobi
therapi
guid
suscept
result
organ
present
studi
evalu
vitek
esbl
test
consist
indic
antibiot
without
clavulan
acid
set
esblposit
clinic
isol
method
eighti
e
coli
k
pneumonia
strain
obtain
dr
soetomo
hospit
surabaya
indonesia
strain
origin
mainli
urin
n
blood
specimen
n
isol
esblposit
abstract
clinic
microbiolog
infect
volum
supplement
issn
doubl
disc
test
method
esbl
combin
disc
oxoid
isol
blactamas
enzym
isol
isoelectr
point
determin
strain
test
vitek
panel
contain
cefepim
ceftazidim
cefotaxim
alon
combin
clavulan
acid
result
vitek
esbl
test
confirm
e
coli
k
pneumonia
esbl
posit
two
e
coli
strain
vitek
gave
indetermin
result
six
e
coli
esblneg
strain
consist
isol
contain
temlik
enzym
n
tem
chromosom
betalactamas
n
shv
chromosom
betalactamas
n
temtyp
betalactamas
n
preval
e
coli
esblposit
isol
k
pneumonia
esblneg
isol
consist
isol
contain
plasmid
encod
betalactamas
n
shvlike
enzym
n
temlik
enzym
n
ctxm
shvlike
n
esblposit
isol
n
ctxm
like
enzym
demonstr
isol
conclus
esbl
vitek
r
test
give
rapid
conclus
result
howev
discrep
result
resolv
order
give
true
accuraci
vitek
esbl
test
method
accuraci
evalu
compar
test
panel
clsi
refer
ref
panel
strain
test
includ
staphylococci
obtain
narsa
strain
reduc
suscept
va
vrsa
enterococci
cdc
challeng
set
vre
addit
isol
agalactia
bovi
recent
staphylococci
enterococci
evalu
test
includ
turbid
prompt
inocula
three
read
method
walkaway
instrument
manual
addit
three
narsa
vrsa
one
addit
vrsa
test
cdc
microscan
panel
read
manual
result
test
revis
va
formul
show
vrsa
mic
lgml
h
walkaway
manual
read
lgml
h
test
fourth
vrsa
cdc
show
stabli
resist
morphotyp
give
mic
lgml
manual
read
result
obtain
equival
ref
sensit
detect
vrsa
isol
combin
result
strain
test
essenti
agreement
categor
agreement
ref
major
major
error
conclus
revis
formul
va
microscan
dri
overnight
panel
show
excel
sensit
specif
va
resist
detect
vrsa
avail
time
compar
test
vre
without
overcal
resist
vasuscept
gpc
aim
studi
rapid
identif
antibacteri
suscept
test
microorgan
isol
blood
cultur
bc
valuabl
clinic
manag
sepsi
present
studi
evalu
perform
scheme
base
direct
identif
suscept
test
gramposit
cocci
direct
inocul
special
treat
fluid
collect
posit
bactec
cultur
bottl
bd
phoenix
autom
microbiolog
system
phx
system
bd
result
compar
obtain
usual
standard
procedur
materi
method
posit
monomicrob
blood
cultur
show
gramposit
cocci
streptococcu
spp
exclud
collect
march
august
assess
studi
shortli
serum
separ
tube
vacutain
sstii
bd
fill
fluid
aspir
posit
bc
bottl
centrifug
swing
bucket
rotor
discard
supernat
bacteri
layer
resuspend
inocul
dropwis
phx
system
id
broth
order
obtain
suspens
match
mcfarland
standard
remain
panel
setup
load
perform
accord
manufactur
instruct
result
comparison
identif
obtain
standard
procedur
direct
method
phoenix
system
correctli
identifi
staphylococcu
aureu
staphylococcu
epidermidi
coagulaseneg
staphylococcu
epidermidi
enterococcu
spp
among
antibioticisol
combin
antimicrobi
suscept
test
show
categori
agreement
number
major
major
minor
error
fals
suscept
fals
resist
antibioticorgan
combin
respect
conclus
gramposit
cocci
rapid
direct
method
combin
bd
phoenix
system
bactec
cultur
provid
accept
bacteri
identif
suscept
result
obtain
rapidli
accur
routin
use
valuabl
clinic
manag
sepsi
evalu
microscan
walkaway
suscept
test
gramneg
bacilli
quinolon
evalu
identif
antimicrobi
suscept
test
bacteri
pathogen
vitek
compact
system
e
stefaniuk
mrowka
w
hryniewicz
warsaw
pl
object
aim
studi
evalu
vitek
compact
system
identif
antimicrobi
suscept
determin
import
bacteri
clinic
pathogen
result
analys
compar
obtain
microbiolog
method
method
total
clinic
signific
gramneg
n
gramposit
n
bacteri
pathogen
includ
studi
isol
collect
patient
hospitalis
differ
medic
centr
poland
epidemiolog
relat
identifi
speci
level
accord
standard
method
result
compar
identif
data
use
vitek
compact
gni
dpi
card
mic
variou
antimicrobi
evalu
agar
broth
dilut
method
accord
clsi
guidelin
wide
varieti
clinic
import
antimicrobi
resist
mechan
repres
isol
includ
extendedspectrum
betalactamas
enterobacteriacea
methicillin
resist
staphylococci
decreas
pneumococc
suscept
penicillin
resist
vancomycin
high
concentr
aminoglycosid
enterococci
antimicrobi
agent
test
present
vitek
compact
card
use
studi
characterist
featur
automat
method
identif
drug
suscept
determin
defin
total
accord
resist
categori
accuraci
sensit
specif
error
result
high
rate
id
agreement
vitek
compact
convent
method
observ
rang
gramposit
cocci
gramneg
rod
studi
shown
high
correl
result
n
obtain
aid
vitek
compact
drug
sensit
test
result
obtain
aid
refer
method
total
accord
resist
categori
estim
level
high
concord
two
method
also
achiev
respect
detect
bacteri
resist
mechan
conclus
vitek
compact
system
esthet
function
easi
use
devic
vitek
compact
system
appear
reliabl
tool
detect
interpret
read
clinic
import
mechan
resist
recommend
routin
work
evalu
new
vitek
ast
card
detect
esbl
mediat
resist
e
coli
klebsiella
spp
comparison
etest
method
vitek
antimicrobi
suscept
detect
system
screen
extendedspectrum
betalactamas
klebsiella
e
coli
strain
greek
univers
hospit
vasilaki
c
manolopoulo
g
rapti
alexioudaniel
thessaloniki
gr
object
extendedspectrum
betalactamas
esbl
rapidli
evolv
group
betalactamas
share
abil
hydrolyz
thirdgener
cephalosporin
aztreonam
yet
inhibit
clavulan
acid
present
detect
esbl
frequent
plasmid
encod
klebsiella
escherichia
coli
strain
carri
trumend
clinic
signific
relat
extrem
limit
antibiot
option
treatment
method
studi
total
clinic
isol
e
coli
klebsiella
strain
examin
presumpt
detect
extendedspectrum
betalactamas
esbl
product
tow
method
vitek
autom
detect
system
biomerieux
commerci
avail
esbl
screen
etest
strip
ab
biodisk
solna
sweden
result
percentag
esblproduc
klebsiella
e
coli
strain
identifi
vitek
system
klebsiella
strain
e
coli
strain
common
infect
associ
esblproduc
pathogen
urinari
tract
infect
follow
wound
infect
bloodstream
infect
contrari
use
etest
strip
base
evalu
differ
antimicrobi
activ
ceftazidim
alon
compar
ceftazidim
plu
clavulan
acid
esbl
product
detect
e
coli
strain
klebsiella
strain
data
demonstr
e
coli
klebsiella
strain
alert
esbl
posit
vitek
system
also
posit
etest
method
conclus
data
indic
even
vitek
esbl
test
reliabl
detect
esbl
e
coli
k
pneumonia
precari
directli
assum
sole
criterion
defin
esbl
product
two
bacteria
esbl
becom
complex
divers
widespread
likelihood
singl
test
univers
appropri
detect
must
diminish
conclus
assum
clinic
microbiolog
laboratori
reli
rapid
autom
system
also
use
anoth
method
screen
esbl
produc
etest
evalu
vitek
esbl
test
detect
esblposit
clinic
escherichia
coli
klebsiella
pneumonia
isol
instrument
combin
cefoxitin
disc
diffus
kirbybau
foxkb
devis
strategi
solv
discrep
method
month
period
januari
june
clinic
signific
staphylococci
isol
laboratori
except
blood
cultur
isol
test
simultan
ast
card
advanc
expert
system
ae
foxkb
use
clsi
guid
line
interpret
criteria
discrep
three
test
ox
calcul
mic
oxmic
growth
presenc
mgl
ox
nacl
oxsalt
sa
disc
diffus
foxkb
resolv
detect
meca
gene
pcr
phenotyp
identif
speci
level
coagulaseneg
staphylococci
cn
result
aureu
sa
mrsa
cn
mr
cn
test
present
discrep
result
sa
cn
saprophyticu
lugdunensi
epidermidi
homini
haemolyticu
warneri
xylosu
sa
three
fals
mssa
mssa
flag
ae
discord
oxmic
oxsalt
strain
foxkb
interpret
correl
meca
gene
determin
cn
fals
mr
fals
ms
oxmic
comparison
foxkb
miss
four
mr
epidermidi
homini
saprophyticu
thu
exclus
result
flag
ae
ppvnpv
detect
mr
sa
vs
cn
vs
comparison
figur
foxkb
vs
conclus
mr
result
obtain
ast
combin
foxkb
correl
staphylococci
analys
among
discord
result
foxkb
interpret
criteria
could
replac
meca
gene
determin
sa
cn
oxmic
overcal
mr
saprophyticu
lugdunensi
mainli
meca
gene
determin
mandatori
solv
discrep
result
ast
card
staphylococci
includ
fox
capabl
vitek
system
screen
betalactamas
produc
enterococcu
faecali
n
bal
v
monnin
murray
g
zambardi
canard
c
davena
p
dufour
la
balm
le
grott
fr
houston
us
object
first
report
betalactamaseproduc
bla
enterococc
isol
recogn
earli
sinc
time
nearli
bla
enterococci
report
enterococcu
faecali
betalactamas
detect
use
dilut
method
known
difficult
nitrocephinbas
betalactamas
test
gener
recommend
purpos
studi
evalu
capabl
system
screen
bla
e
faecali
strain
use
mic
benzylpenicillin
method
nitrocefinbas
betalactamas
test
perform
e
faecali
isol
strain
test
use
three
lot
vitek
card
two
lot
one
lot
three
vitek
instrument
three
subcultur
nine
benzylpenicillin
vitek
mic
obtain
strain
refer
mic
determin
broth
microdilut
accord
clinic
laboratori
standard
institut
clsi
guidelin
base
result
nitrocefin
test
cutoff
differenti
bla
bla
betalactamas
nonproduc
e
faecali
strain
set
mic
determin
method
result
nitrocefin
test
posit
strain
modal
median
benzylpenicillin
vitek
mic
determin
strain
compar
broth
microdilut
essenti
agreement
slight
overestim
modal
vitek
mic
compar
refer
mic
observ
choos
benzylpenicillin
vitek
mic
cutoff
lgml
bla
strain
blastrain
sensit
specif
respect
comparison
sensit
specif
obtain
benzylpenicillin
microdilut
mic
cutoff
lgml
conclus
benzylpenicillin
vitek
mic
help
screen
bla
e
faecali
strain
benzylpenicillin
mic
lgml
indic
presumpt
bla
e
faecali
confirm
nitrocefin
test
furthermor
optim
benzylpenicillin
mic
rang
wild
acquir
penicillinas
resist
phenotyp
vitek
advanc
expert
systemtm
ae
would
increas
discrimin
phenotyp
nitrocefin
test
would
perform
acquir
penicillinas
phenotyp
propos
consequ
ae
would
allow
lab
drastic
decreas
number
offlin
nitrocefin
test
perform
e
faecali
perform
evalu
streptococcu
pneumonia
antimicrobi
suscept
investig
use
card
vitek
system
object
purpos
studi
demonstr
effect
pneumonia
spn
antimicrobi
suscept
test
ertapenem
ert
garenoxacin
gar
telithromycin
tel
platform
clinic
set
method
multicentr
trial
test
spn
strain
use
investig
use
iuo
card
contain
ert
gar
tel
test
card
inocul
standard
inoculum
spn
strain
challeng
isol
reproduc
isol
qualiti
control
spn
atcc
isol
test
automat
manual
dilut
use
iuo
card
clinic
isol
test
automat
dilut
broth
microdilut
refer
test
assay
challeng
qualiti
control
clinic
isol
standard
inoculum
use
card
reproduc
test
perform
triplic
daili
three
day
twenti
replic
test
spn
atcc
perform
site
qualiti
control
result
essenti
agreement
clinic
isol
categori
agreement
ert
gar
tel
respect
bestcas
reproduc
result
reveal
essenti
agreement
automat
manual
dilut
respect
ert
gar
tel
qc
inrang
result
card
three
antibiot
essenti
agreement
automat
manual
dilut
method
challeng
experi
ert
gar
tel
major
error
observ
conclus
evalu
provid
convinc
evid
perform
antimicrobi
suscept
test
ert
gar
tel
platform
compar
convent
test
clinic
laboratori
type
mlst
sccmec
type
antimicrobi
suscept
test
pcr
detect
pantonvalentin
leukocidin
pvl
gene
result
number
frequent
found
mrsa
denmark
finland
sweden
respect
pvl
gene
detect
ten
isol
isol
gave
indistinguish
pfge
pattern
follow
five
found
two
countri
uk
uk
pvl
neg
finland
sweden
ii
uk
variant
pvl
neg
finland
sweden
iii
uk
variant
pvl
posit
denmark
sweden
iv
berlin
iv
variant
pvl
neg
finland
sweden
v
franc
b
variant
pvl
posit
denmark
sweden
although
indistinguish
mani
pfge
pattern
close
relat
belong
intern
wellknown
mrsa
clone
conclus
mani
frequent
found
mrsa
type
three
nordic
countri
clonal
relat
howev
singl
mrsa
type
seen
three
countri
overal
result
show
nation
differ
rather
high
divers
among
mrsa
isol
within
limit
geograph
region
object
use
sever
molecular
genotyp
method
aureusto
analyz
clonal
group
emrsa
strain
finland
purpos
renew
nomenclatur
object
refin
genotyp
scheme
better
support
local
outbreak
investig
method
finnish
epidem
mrsa
strain
year
test
sever
molecular
genotyp
method
puls
field
gel
electrophoresi
pfge
use
primari
method
distinguish
differ
emrsa
strain
addit
multi
locu
sequenc
type
mlst
seven
housekeep
gene
allel
staphylococc
cassett
chromosom
mec
sccmec
analysi
mobil
methicillinresist
genet
element
iv
spatyp
identifi
polymorph
xregion
protein
aureu
use
clonal
complex
analysi
base
spa
mlst
result
perform
burp
eburst
program
respect
result
pfge
identifi
differ
emrsa
strain
strain
repres
sccmec
element
iv
spatyp
found
differ
spatyp
among
emrsa
strain
six
new
spatyp
found
previous
ridom
spaserv
spatyp
divid
four
differ
clonal
complex
six
singleton
mlst
abl
find
differ
allel
profil
divid
differ
clonal
complex
type
result
combin
emrsa
strain
cluster
close
relat
group
base
pfge
sccmec
spatyp
mlst
result
mlst
spatyp
result
support
specifi
clonal
group
finnish
emrsa
strain
conclus
pfge
use
primari
molecular
method
name
mrsa
strain
finland
sscmec
mlst
spatyp
need
verifi
clonal
complex
usag
sever
differ
molecular
type
method
necessari
accur
nomenclatur
mrsa
also
outbreak
situat
hospitaland
communityacquir
methicillinresist
staphylococcu
aureu
germani
c
von
eiff
f
hasenberg
ander
f
kipp
aw
friedrich
g
peter
sg
gatermann
k
becker
munster
bochum
de
object
ongo
emerg
methicillinresist
staphylococcu
aureu
mrsa
germani
gener
consider
concern
among
medic
public
health
profession
addit
communityacquir
mrsa
camrsa
becom
import
public
health
problem
howev
repres
nationwid
data
preval
mrsa
clone
pathogen
potenti
well
preval
camrsa
avail
method
learn
preval
characterist
mrsa
includ
camrsa
centr
throughout
germani
laboratori
associ
univers
gener
hospit
outpati
clinic
enrol
collect
consecut
mrsa
isol
respond
questionnair
one
isol
per
patient
includ
isol
spagenotyp
among
other
staphylococc
cassett
chromosom
mec
sccmec
accessori
gene
regul
agr
allel
possess
exotoxin
gene
determin
result
overal
mrsa
patient
male
femal
includ
infectionassoci
mrsa
repres
colon
analyz
isol
recov
inpati
outpati
confirm
mrsa
detect
meca
gene
aureusspecif
nuc
gene
follow
distribut
sccmec
type
agr
allel
found
sccmec
ii
iii
iv
v
nontyp
agr
agr
ii
agr
iii
agr
iv
nontyp
altogeth
isol
found
posit
gene
lukspvlukfpv
encod
panton
valentin
leukocidin
pvl
superantigen
gene
encod
staphylococc
enterotoxin
toxic
shock
syndrom
found
sea
seb
sec
sed
sec
seg
seh
sei
sej
tst
mrsa
isol
exfoliativeencod
gene
detect
follow
eta
etb
etd
conclus
data
mrsa
collect
throughout
countri
offer
overview
strain
current
circul
germani
accord
preval
pvlposit
isol
camrsa
isol
seem
still
rare
germani
analys
data
given
questionnair
allow
detail
view
demograph
clinic
background
molecular
spa
sccmec
type
mrsa
isol
northern
germani
n
wies
h
mueller
fenner
k
lunkenheim
fenner
hamburg
lubeck
de
object
past
mrsa
epidem
known
primarili
clinic
problem
last
year
dramat
increas
number
communityassoci
mrsa
infect
cmrsa
isol
mostli
associ
small
sccmec
type
iv
atyp
resist
profil
recent
data
indic
sccmec
type
iv
may
infiltr
clinic
set
aim
aim
present
studi
molecular
characteris
mrsa
isol
clinic
nonclin
set
northern
germani
year
period
epidemiolog
data
gener
spatyp
correl
result
multiplex
pcr
sccmec
type
method
clinic
communityaquir
mrsa
isol
differ
sourc
northern
germani
collect
strain
repeat
region
saureu
protein
sequenc
abi
sequenc
analys
ridom
staph
softwar
sccmec
type
characteris
multiplex
pcr
assay
describ
result
domin
spatyp
frequenc
alway
harbour
type
iv
sccmec
isol
present
clinic
commun
patient
isol
spatyp
previous
categoris
typic
cmrsa
isol
detect
clinic
case
harbour
mostli
sccmec
type
ii
overal
differ
spatyp
hererogen
multiplex
sccmec
type
pattern
observ
howev
isol
harbour
type
v
type
sccmec
cassett
conclus
type
mrsa
molecular
method
reveal
complex
pattern
spatyp
differ
sccmec
cassett
typic
associ
hmrsa
cmrsa
observ
vast
major
isol
spatyp
correspond
barnim
epidem
clone
integr
small
sccmeciv
classic
cmrsa
cassett
may
indic
spread
success
epidem
clone
commun
vice
versa
adapt
cmrsa
characterist
clinic
set
object
preval
methicillin
resist
aureu
mrsa
increas
german
hospit
resist
phenotyp
chang
decreas
number
resist
marker
want
examin
chang
resist
mrsa
recent
year
use
dataset
genarsproject
german
network
antimicrobi
resist
surveil
prospect
multicentr
surveil
studi
design
provid
epidemiolog
data
german
univers
hospit
method
analysi
base
nondupl
isol
mrsa
five
laboratori
continu
data
collect
januari
june
antimicrobi
suscept
determin
minim
inhibitori
concentr
broth
microdilut
method
perform
autom
qualiti
control
test
system
antibiot
variou
class
resist
rate
evalu
use
breakpoint
accord
din
guidelin
result
percentag
aureu
isol
n
test
resist
oxacillin
increas
first
half
consider
variat
hospit
total
mrsa
isol
analys
resist
rate
ciprofloxacin
cip
erythromycin
eri
clindamycin
cli
remain
high
level
littl
fluctuat
wherea
alreadi
low
rate
doxycyclin
dox
rifampicin
ram
quinupristindalfopristin
syn
tend
declin
gentamicin
gen
signific
decreas
extrem
variat
hospit
resist
observ
teicoplanin
vancomycin
linezolid
analysi
resist
pattern
includ
cip
eri
cli
dox
ram
syn
result
six
main
pattern
account
percent
strain
two
frequent
pattern
show
revers
trend
frequenc
oxacipclieri
increas
oxacipclierygen
decreas
hospit
level
result
heterogen
two
centr
pattern
oxacipclierygen
still
domin
proport
mrsa
strain
conclus
data
genarsproject
show
chang
resist
phenotyp
mrsa
report
continu
observ
period
remark
decreas
resist
gentamicin
main
featur
howev
find
pool
data
mask
substanti
divers
local
level
object
univers
hospit
nant
bed
tertiari
care
teach
hospit
offer
medic
surgic
acutecar
servic
bed
popul
approxim
adult
non
traumat
patient
admit
medic
emerg
ward
mew
year
purpos
studi
determin
proport
commun
hospitalacquir
mrsa
method
case
patient
defin
patient
admit
mew
mrsa
isol
clinic
sampl
januari
decemb
one
strain
per
patient
includ
systemat
screen
colon
done
studi
period
result
among
patient
mrsa
identifi
hospit
studi
period
isol
admiss
mew
proport
aureu
resist
methicillin
hospit
mew
resist
antibiot
test
report
tabl
nineteen
patient
male
mean
age
year
rang
patient
transfer
anoth
hospit
came
hous
nurs
home
hospit
last
year
mean
delay
day
rang
prior
mrsa
isol
clinic
microbiolog
infect
volum
supplement
conclus
studi
suggest
mrsa
carriag
patient
discharg
hospit
mrsa
isol
clinic
sampl
upon
hospit
readmiss
commun
earli
discharg
prolong
portag
low
virul
explain
spread
hospit
mrsa
commun
find
indic
mrsa
isol
admiss
mew
communityacquir
mrsa
acquisit
could
link
prior
hospitalis
usual
epidemiolog
definit
commun
hospit
mrsa
acquisit
clear
without
systemat
screen
colon
object
spanish
multicent
studi
hospit
perform
analys
total
clinic
isol
aureu
resist
methicillin
mrsa
studi
analyz
presenc
virul
factor
pantonvalentin
leukocidin
pvland
accesori
gen
regul
agr
among
isol
well
clone
sccmec
type
involv
method
methicillinresist
confirm
detect
meca
gene
pcr
sccmec
type
agr
allel
type
determin
previous
describ
multiplex
pcr
strategi
pvl
gene
detect
pcr
amplif
lukspv
lukfpv
gene
assess
specif
amplif
pcr
product
subject
dna
sequenc
isol
analys
pfge
dna
digest
smai
result
among
isol
isol
pvl
posit
meca
neg
correspond
children
young
adult
skin
softtissu
infect
abscess
conjunct
presenc
agr
gene
evalu
mrsa
isol
methicillinsuscept
aureu
mssa
isol
agr
allel
mrsa
isol
type
type
type
agr
allel
mssa
isol
type
type
type
type
pvl
posit
isol
show
differ
agr
type
one
isol
type
two
isol
type
two
isol
type
five
differ
pfge
pattern
pfge
analysi
mrsa
isol
demonstr
presenc
electrophoret
profil
majoritari
clone
two
domin
sccmec
type
type
ii
iiia
iva
iv
conclus
spain
show
low
preval
pvl
posit
aureu
isol
belong
differ
genotyp
identifi
presenc
two
domin
clone
mrsa
carri
type
iva
iv
sccmec
mainli
agr
type
high
variabl
agr
allel
observ
among
mssa
studi
financ
red
ola
de
n
en
infecciosareipi
first
report
infect
communityacquir
methicillinresist
staphylococcu
aureu
spain
e
cercenado
vindel
b
padilla
cueva
navarro
e
bouza
madrid
majadahonda
es
object
presenc
communityacquir
methicillinresist
staphylococcu
aureu
camrsa
produc
pantonvalentin
leukocidin
pvl
never
report
spain
describ
first
four
case
infect
due
typic
camrsa
institut
madrid
method
septemb
octob
detect
institut
four
mrsa
isol
four
patient
commun
histori
previou
mrsa
isol
hospit
surgeri
mrsa
isol
suscept
test
perform
diskdiffus
method
methicillinresist
confirm
detect
meca
gene
pcr
sccmec
type
agr
allel
type
determin
previous
describ
multiplex
pcr
strategi
pvl
gene
detect
pcr
amplif
lukspv
lukfpv
gene
assess
specif
amplif
pcr
product
subject
dna
sequenc
isol
analys
pfge
dna
digest
smai
result
four
isol
camrsa
show
resist
betalactam
one
also
resist
erythromycin
heteroresist
oxacillin
isol
correspond
four
children
male
month
year
present
skinand
softtissu
infect
pyogen
abscess
patient
need
surgic
drainag
antimicrobi
treatment
recoveri
three
isol
contain
type
iv
sccmec
one
case
present
type
sccmec
pfge
analysi
show
presenc
two
differ
pattern
one
includ
three
case
three
differ
subtyp
differ
nosocomi
clone
isol
pvlposit
conclus
detect
pvlposit
camrsa
spain
although
three
isol
present
type
iv
sccmec
presenc
type
sccmec
one
isol
indic
spread
differ
sccmec
type
commun
studi
financ
red
ola
de
n
en
infecciosa
result
total
isol
belong
patient
identifi
period
studi
distribut
isol
recov
sampl
well
sampl
camrsa
infect
diagnos
patient
isol
hospit
acquir
methicillinresist
staphylococcu
aureu
hamrsa
patient
sampl
mrsa
isol
resist
fluoroquinolon
erythromycin
clindamycin
gentamycin
hamrsa
main
sampl
hmrsa
acquir
infect
skin
soft
infect
respiratori
tract
infect
blood
arthriti
preval
highest
medic
ward
orthopaed
surgeri
ward
follow
otorhinolaryngolog
ward
plastic
surgeri
ward
vascular
surgeri
ward
intens
care
unit
proport
male
femal
mean
age
studi
colon
nasophariynx
perineum
skin
hmrsa
posit
patient
carriag
rate
camrsa
origin
frequent
sampl
outpati
depart
hospit
hospit
emerg
servic
proport
malefemal
mean
age
camrsa
sampl
recov
frequent
outpati
depart
situat
casco
viejo
txurdinaga
patient
depart
hospit
skin
infect
soft
infect
frequent
wound
urinari
tract
infect
otiti
invas
diseas
occur
case
hemocultur
posit
conclus
epidemiolog
mrsa
bilbao
chang
rapidli
increas
number
notif
number
camrsa
urinari
tract
infect
otiti
mrsa
frequent
commun
occur
age
group
includ
paediatr
infect
identif
epidem
methicillinresist
aureu
russian
hospit
multicentr
studi
object
last
year
dramat
increas
preval
methicillinresist
staphylococcu
aureu
mrsa
hospit
russia
multicentr
studi
done
investig
epidem
situat
method
saureu
isol
collect
hospit
differ
region
russia
mrsa
isol
hospit
patient
period
select
laboratori
collect
studi
antibiogram
phage
type
phage
intern
type
set
use
phenotyp
analysi
molecular
featur
mrsa
isol
analys
use
coa
spaand
sccmec
type
presenc
sea
seb
sec
tsth
investig
pcr
method
result
mrsa
identifi
hospit
rate
recov
pu
respiratori
tract
blood
cultur
multiresist
typabl
phage
rtd
discov
two
epidem
genotyp
everi
one
circul
hospit
one
genotyp
similar
coa
type
spa
type
carri
sccmec
iii
isol
epidem
strain
carri
sea
discov
resembl
isol
among
laboratori
collect
mrsa
strain
anoth
epidem
strain
spa
type
isol
strain
produc
pcr
product
primer
identif
ccr
type
mec
complex
class
b
region
primer
set
identif
ccr
type
propos
carri
two
differ
copi
sccmec
isol
sea
isol
carri
sec
mrsa
isol
laboratori
collect
coa
type
carri
sccmec
type
ivb
sea
seb
conclus
progress
increas
proport
mrsa
isol
hospit
russia
result
dissemin
much
two
epidem
strain
resembl
intern
one
circul
sinc
second
appear
new
epidem
strain
carri
two
differ
copi
sccmec
probabl
methicillinresist
staphylococcu
aureu
nasal
colonis
rehabilit
nurs
home
itali
object
evalu
preval
mrsa
nasal
colon
nurs
home
rehabilit
activ
itali
method
studi
conduct
azienda
cremona
solidal
nurs
home
locat
cremona
itali
bed
preval
mrsa
nasal
colon
evalu
perform
nasal
swab
patient
swab
cultiv
columbia
cna
mutton
blood
agar
put
incub
hour
coloni
probabl
staphylococcu
aureu
growth
cultiv
mannitol
salt
agar
oxacillin
screen
agar
final
identif
sensit
test
break
point
panel
id
staphylococci
perform
posit
patient
treat
applic
nasal
mupirocin
bath
shampoo
chlorexidin
three
microbiolog
control
perform
one
week
end
treatment
data
match
mrsa
databas
hospit
cremona
hold
data
regard
mrsa
carrier
identifi
onward
order
identifi
previous
known
mrsa
subject
result
patient
involv
studi
among
nasal
staphylococcu
aureu
colon
particular
mrsa
methicillinsensit
staphylococcu
aureu
mrsa
nasal
colon
rate
overal
popul
specif
treatment
permit
germ
erad
patient
two
mrsa
colon
patient
identifi
within
cremona
hospit
databas
conclus
mrsa
nasal
carriag
rate
nurs
home
shown
signific
patient
seem
differ
popul
compar
hospit
one
treatment
permit
erad
colon
high
percentag
case
methicillinresist
staphylococcu
aureu
airway
secret
patient
cystic
fibrosi
affect
significantli
pulmonari
function
mrsa
colonizationinfect
emerg
problem
result
burden
glycopeptid
consist
rel
contraind
lung
transplant
object
aim
studi
determin
epidemiolog
featur
mrsa
airway
colon
infect
patient
cf
institut
review
retrospect
clinic
demograph
laboratori
data
patient
cf
attend
hospit
least
one
year
period
sputum
deep
throat
specimen
cultur
identif
perform
standard
methodolog
catalas
dnase
product
api
staph
biomerieux
antibiot
resist
evalu
vitek
ii
autom
system
biomerieux
disk
diffus
method
kirbybau
accord
nccl
recommend
result
mrsa
posit
cultur
correspond
patient
male
femal
mean
age
patient
isol
mrsa
sd
eleven
patient
persist
colonizedinfect
mrsa
year
patient
contemporari
colon
month
short
time
colon
eight
differ
antibiot
resist
phenotyp
observ
preval
phenotyp
one
resist
oxacillin
follow
resist
oxacillin
plu
aminoglycosid
oxacillin
plu
erythromycin
three
patient
colonizedinfect
multidrug
resist
phenotyp
suscept
linezolid
dalfopristin
quinopristin
conclus
mean
annual
incid
rate
period
show
chang
mean
age
acquisit
seem
decreas
time
multidrugresist
phenotyp
rare
time
although
mrsa
strain
often
isol
patient
cf
small
proport
popul
remain
chronic
colon
new
comput
softwar
methicillinresist
staphylococcu
aureu
type
base
spasequenc
comparison
mlst
k
boy
md
bartel
mellmann
harmsen
h
westh
hvidovr
dk
munster
de
object
worldwid
increas
number
mrsa
infect
enhanc
need
fast
reliabl
type
method
order
investig
local
outbreak
well
global
spread
phylogeni
two
molecular
approach
proven
especi
use
aureu
type
multilocu
sequenc
type
mlst
sequenc
repeat
region
variabl
xregion
staphylococcu
protein
spatyp
comput
softwar
time
avail
phylogenet
analysi
base
mlst
data
recent
softwar
develop
phylogenet
interpret
spatyp
appli
softwar
collect
clinic
mrsa
isol
compar
result
method
mrsa
isol
collect
copenhagen
area
spasequ
isol
amplifi
use
amplitaq
spatyp
one
two
isol
select
mlst
seven
mlst
gene
sequenc
amplifi
use
amplitaq
gold
purif
pcr
product
sequenc
abi
sequenc
mlst
analysi
eburst
v
softwar
appli
http
saureusmlstneteburst
spa
analysi
newli
develop
burp
softwar
wwwridom
destaphtypesupport
use
result
mrsa
isol
exhibit
differ
spatyp
differ
mlst
sequenc
type
st
spabas
burp
softwar
group
isol
six
clonal
complex
six
singleton
mlst
isol
fell
nine
wellknow
clonal
complex
five
singleton
gener
good
agreement
two
method
seen
mlst
clonal
complex
identifi
spabas
clonal
complex
well
case
mismatch
howev
discrep
seen
mlst
base
st
best
connect
isol
tripl
locu
variant
spabas
burp
place
isol
togeth
one
extend
clonal
complex
manual
inspect
spatyp
involv
confirm
connect
sequenc
conclus
singl
locu
spa
seem
use
reliabl
mrsa
type
sevengen
base
mlst
sequenc
one
gene
faster
cheaper
sequenc
seven
gene
spatyp
might
replac
mlst
type
method
choic
new
softwar
burp
spabas
analysi
relationship
mrsa
type
perform
well
easi
use
multiplex
pcr
easi
screen
methicillinresist
staphylococcu
aureu
sccmec
type
v
k
boy
md
bartel
ar
larsen
h
westh
hvidovr
copenhagen
dk
object
worldwid
increas
number
mrsa
infect
enhanc
need
fast
reliabl
type
method
one
type
system
mrsa
determin
sccmectyp
staphylococc
chromosom
cassett
contain
resist
gene
meca
gold
standard
sccmectyp
multiplex
pcr
develop
oliveira
de
lencastr
howev
multiplex
primarili
design
character
hospitalacquir
type
iiii
current
increas
mrsa
infect
caus
communityonset
mrsa
carri
smaller
sccmec
type
iv
v
creat
multiplex
pcrdetect
method
routin
screen
mrsa
isol
five
sccmec
type
iv
detect
method
base
literatur
sequenc
found
genbankembl
primer
design
detect
sccmecspecif
sequenc
multiplex
pcr
design
ensur
sccmec
type
iv
v
two
common
mrsa
type
copenhagen
show
two
band
analys
gel
electrophoresi
seldom
type
ii
iii
show
one
band
confirm
addit
pcr
collect
clinic
mrsa
isol
use
test
pcr
isol
previous
test
mecaposit
pcr
character
spatyp
control
isol
also
sccmectyp
use
oliveira
multiplex
pcr
result
test
mrsa
isol
sccmec
type
type
ii
type
iii
type
iv
type
v
three
isol
nontyp
analys
oliveira
pcr
gave
ident
result
except
type
v
untyp
pcr
half
type
iv
repres
three
mrsa
clone
spatyp
isol
isol
isol
contact
swab
taken
nose
throat
perineum
person
live
household
inocul
enrich
broth
broth
incub
overnight
cultur
use
pcr
realtim
pcr
perform
describ
huletski
et
al
except
use
one
specif
primerset
taqman
probe
mrsa
coloni
test
duplex
pcr
presenc
spa
meca
gene
patient
interview
find
possibl
link
result
patient
agre
particip
left
denmark
swab
taken
person
household
seventeen
sampl
mrsa
posit
thirteen
person
six
new
patient
eight
household
found
epidemiolog
connect
three
eight
famili
philippin
via
children
contact
remain
five
famili
anoth
five
household
connect
philippin
one
household
australia
one
spain
thirteen
specimen
found
cultur
pcr
posit
three
specimen
mrsa
posit
cultur
pcr
repeatedli
neg
enrich
broth
posit
pure
coloni
two
three
case
one
isol
pcr
posit
cultur
neg
twice
becam
cultur
posit
repeat
cultur
enrich
broth
three
sampl
pcr
posit
cultur
neg
spa
meca
pcr
enrich
broth
found
mssa
spa
type
conclus
interview
gave
use
epidemiolog
inform
known
south
pacif
clone
found
strong
initi
connect
philippin
household
erad
ongo
cultur
sensit
compar
pcr
three
cultur
posit
pcr
neg
sampl
could
caus
low
number
mrsa
one
case
variabl
sequenc
amplifi
primer
set
ppv
cultur
pcr
pcr
optim
could
possibl
achiev
higher
ppv
result
show
cultur
still
best
method
detect
mrsa
carriag
methicillinresist
staphylococcu
aureu
pigfarm
b
van
dijk
h
koppen
w
wannet
x
huijsden
h
de
neel
voss
weert
bilthoven
nijmegen
nl
object
sporad
case
camrsa
person
without
riskfactor
mrsa
carriag
increas
report
mrsa
cluster
among
famili
member
pigfarm
cowork
pig
initi
young
mother
seen
mastiti
due
mrsa
six
month
later
babi
daughter
admit
hospit
pneumococc
otiti
stay
day
hospit
babi
found
mrsa
posit
point
decid
look
possibl
sourc
famili
member
household
anim
includ
pig
farm
sinc
report
possibl
sourc
mrsa
earlier
method
swab
taken
throat
nare
famili
member
cowork
veterinarian
obtain
swab
nare
throat
perineum
pig
swab
cultur
follow
nation
protocol
detect
mrsa
includ
use
enrich
broth
anim
human
strain
sent
nation
mrsa
refer
centr
rivm
type
genet
analysi
includ
pfge
spatyp
mlst
analysi
result
three
four
famili
member
three
cowork
pig
mrsa
posit
except
initi
case
mother
person
sign
clinic
infect
colonizedaft
digest
smai
none
strain
show
band
use
pfge
isol
belong
spa
type
isol
farmer
wife
mlst
type
conclus
report
clearli
show
clonal
spread
transmiss
human
pig
netherland
mlst
type
might
intern
import
pigmrsa
sinc
type
shown
earlier
present
epidemiolog
unrel
french
pig
pigfarm
research
need
evalu
whether
local
problem
new
sourc
mrsa
put
success
search
destroy
polici
netherland
risk
methicillinresist
coagulaseneg
staphylococci
isol
hors
corrent
g
greco
v
martella
g
normanno
e
tarsitano
c
buonavoglia
valenzano
object
methicillinresist
coagulaseneg
staphylococci
mrcn
isol
hors
osteolysi
nare
healthi
hors
isol
character
genotyp
analysi
evalu
antimicrobi
suscept
method
saddl
hors
affect
osteolysi
hors
metacarp
bone
subject
surgeri
remov
bone
fragment
strain
staphylococcu
epidermidi
isol
found
mr
pcr
specif
meca
gene
nare
skin
swab
hors
nare
swab
healthi
hors
hous
stabl
collect
addit
nare
swab
personnel
stabl
sampl
swab
inocul
mannitol
salt
agar
msa
plu
oxacillin
isol
grown
msa
identifi
biochem
method
test
meca
pcr
evalu
suscept
non
betalactam
drug
also
strain
test
presenc
virul
marker
icaa
gene
type
multiplex
pcr
specif
sccmec
type
ccrb
subtyp
result
hors
found
colonis
mrcn
nare
skin
nare
isol
exhibit
phenotyp
genotyp
featur
bone
tissu
isol
ie
strain
characteris
epidermidi
resist
nalidix
acid
erythromycin
cotrimoxazol
typeabl
nt
sccmec
pcr
assay
ccrb
type
posit
icaa
gene
total
mrcn
isol
nare
swab
hors
test
sccmec
type
strain
type
ii
strain
type
strain
type
iv
isol
nt
thirteen
strain
ccrb
subtyp
subtyp
strain
one
resist
least
class
non
betalactam
drug
four
strain
posit
pcr
gene
mr
found
nare
swab
human
origin
conclus
infect
mr
consid
emerg
problem
anim
survey
hors
test
found
carrier
mrcn
strain
display
invas
potenti
stabl
personnel
mr
carrier
human
origin
mrcn
strain
may
rule
detect
new
sccmec
type
ccrb
type
well
support
hypothesi
hors
mrcn
repres
potenti
sourc
resist
gene
may
transmit
aureu
first
report
nonprototyp
among
vana
vancomycinresistantenterococci
isol
domest
chicken
korea
evid
commun
vre
nich
human
chicken
background
vre
rate
abruptli
increas
tertiarycarehospit
sinc
late
even
though
avoparcin
ban
korea
studi
perform
estim
preval
vana
vancomycinresistantenterococci
vre
among
domest
chicken
character
epidemiolog
vana
vre
strain
use
transposon
type
element
puls
field
gel
electrophoresi
pfge
elucid
epidemiolog
dissemin
vre
korea
method
januari
februari
fresh
faec
collect
chicken
worker
freerangechicken
farm
frcf
cagedchickenfarm
ccf
locat
kyunggi
provinc
inocul
bile
esculin
azid
agar
contain
lgml
vancomycin
result
almost
isol
sensit
ampicillin
strain
show
highlevel
gentamicin
resist
isol
two
case
one
pig
one
cattl
similarli
low
rate
streptomycin
resist
observ
cattl
somewhat
higher
anim
number
strain
reduc
suscept
erythromycin
nearli
high
number
tetracyclin
resist
strain
nonsensit
still
retain
anim
speci
resist
tetracyclin
highest
chicken
rang
around
pig
around
cattl
interestingli
lowest
resist
rate
observ
addit
total
isol
resist
tetracyclin
erythromycin
vancomycin
resist
increas
steadili
chicken
disappear
total
pig
cattl
intermedi
resist
fulli
resist
strain
among
vancomycin
tetracyclin
nonsuscept
isol
strain
resist
erythromycin
well
conclus
although
ampicillin
amoxicillin
often
use
veterinari
practic
resist
rate
rel
low
high
resist
found
tetracyclin
macrolid
increas
anim
speci
may
due
higher
rate
consumpt
drug
anim
treatment
ban
growth
promot
annual
data
vancomycin
resist
point
associ
recoveri
vancomycinresist
enterococci
vre
test
anim
use
avoparcin
studi
indic
could
possibl
reduc
antimicrobi
resist
food
anim
reduc
use
antibiot
although
variat
occur
differ
strain
analysi
mortal
septic
shock
patient
j
martinez
alario
j
villega
huidobro
c
christoph
henri
r
santacreu
ml
mora
tenerif
es
object
septic
shock
common
caus
death
intens
care
unit
mortal
predict
may
help
identifi
patient
may
benefit
given
treatment
strategi
aim
work
assess
mortal
septic
shock
perform
sequenti
organ
failur
assess
sofa
score
predict
mortal
method
prospect
observ
studi
patient
meet
criteria
septic
shock
defin
american
colleg
chest
physician
societi
critic
care
medicin
consensu
confer
clinic
physiolog
data
model
prospect
collect
appli
criteria
describ
develop
statist
analys
perform
use
spss
spss
inc
chicago
il
predict
hospit
mortal
calcul
compar
actual
mortal
perform
assess
evalu
calibr
hosmerlemeshow
goodnessoffit
test
discrimin
area
receiv
oper
characterist
auroc
curv
result
sex
ratio
men
women
mean
age
year
mean
sofa
score
rang
mortal
rate
lemeshowhosm
chisquar
auroc
curv
ci
conclus
experi
mortal
septic
shock
patient
remain
high
sofa
score
perform
well
calibr
discrimin
high
appropri
tool
assess
predict
mortal
signific
clinic
present
evolut
recurr
e
coli
bloodstream
infect
sanz
fernandez
p
oz
e
cercenado
j
feyjoo
e
bouza
madrid
es
background
knowledg
incid
clinic
signific
recurr
escherichia
coli
bloodstream
infect
recbsi
spars
assess
aspect
review
experi
institut
last
year
method
institut
episod
bsi
due
e
coli
overal
select
recbsi
episod
separ
least
day
order
assess
risk
factor
recbsi
perform
casecontrol
studi
randomli
select
popul
analys
multivari
logist
regress
test
result
episod
e
coli
bsi
ecbsi
least
recurr
episod
assess
risk
factor
recurr
randomli
select
case
control
patient
rcebsi
predominantli
male
median
age
year
rapidli
ultim
fatal
underli
condit
mccabe
ii
immunosupress
haematolog
malign
origin
rcebsi
uti
intraabdomin
biliari
primari
bacteremia
catheterrel
median
time
recurr
day
iqr
mortal
among
recbsi
attribut
survivor
episod
case
univari
analysi
factor
significantli
associ
recbsi
male
sex
immunosupress
haematolog
malign
nonurinari
origin
mccabe
ii
factor
significantli
differ
popul
age
presenc
indwel
devic
adequaci
antibiot
therapi
place
acquisit
first
episod
multivari
analysi
show
independ
factor
predict
rcebsi
follow
male
sex
immunosupress
nonurinari
origin
conclus
rcebsi
rel
frequent
diseas
complic
mainli
immunosupress
particularli
haematolog
malign
abl
show
relationship
rcebsi
inadequaci
antimicrobi
therapi
first
episod
influenc
sir
criteria
outcom
gramneg
versu
gramposit
sepsi
lups
bica
slavcovici
radulescu
c
bondor
tatulescu
clujnapoca
ro
clinic
signific
system
inflammatori
respons
septic
patient
remain
unclear
aim
studi
compar
outcom
patient
document
gramposit
versu
gramneg
sepsi
criteria
sir
materi
method
perform
retrospect
studi
base
case
record
year
period
select
adult
patient
admitt
icu
teach
hospit
infecti
diseas
diagnosi
criteria
sepsi
accord
accpsccm
expert
panel
recommend
compar
short
term
outcom
till
hospit
discharg
confirm
bacteri
septic
patient
regard
number
sir
criteria
use
epiinfo
excel
statist
analysi
result
adult
patient
non
hiv
median
age
year
male
commun
acquir
hospit
acquir
sepsi
etiolog
gramposit
gramneg
anaerob
fungi
polymicrobi
case
without
document
etiolog
frequent
isol
strain
aureu
gramposit
e
coli
gramneg
percent
patient
gramposit
sepsi
sir
criteria
sir
criteria
sir
criteria
patient
gramneg
sepsi
met
criteria
sir
criteria
criteria
hospit
mortal
sepsi
gramposit
aureu
gramneg
e
coli
sepsi
outcom
unaffect
number
inflammatori
respons
criteria
gramposit
versu
gramneg
sepsi
p
two
criteria
p
three
criteria
p
four
criteria
signific
differ
aureu
versu
e
coli
sepsi
outcom
sir
criteria
conclus
character
septic
patient
presenc
sir
criteria
prognost
implic
differ
outcom
gramposit
versu
gram
neg
sepsi
sort
sir
criteria
haemophilu
influenza
bloodstream
infect
reapprais
g
oz
l
cuadra
e
calbo
xercavin
j
garau
terrassa
es
introduct
h
influenza
hi
wellknown
caus
diseas
children
adult
local
impair
host
defenc
mechan
copd
first
predispos
condit
immunocompet
adult
common
clinic
present
pneumonia
howev
bloodstream
infect
bsi
due
hi
uncommon
aim
studi
review
experi
hi
bsi
last
year
materi
method
jan
april
patient
bsi
due
hi
identifi
record
clinic
microbiolog
laboratori
hospit
demograph
comorbid
clinic
present
antimicrobi
resist
serotyp
outcom
review
medic
chart
result
hi
bsi
bsi
identifi
male
adult
median
age
rang
communityacquir
global
common
clinic
present
pneumonia
biliari
tract
infect
primari
bacteraemia
pb
mening
gynecolog
infect
adult
comorbid
copd
smoke
habit
enol
hiv
present
respect
betalactamas
produc
serotyp
b
identifi
adult
children
respect
last
case
serotyp
b
diagnos
mortal
adult
children
highest
fatal
rate
found
adult
pb
streptococcu
pneumonia
bsi
document
time
period
conclus
hi
bsi
uncommon
commun
less
frequent
invas
pneumococc
diseas
adult
comorbid
repres
three
quarter
case
hi
bloodstream
infect
rare
caus
hi
type
b
mortal
remain
high
especi
pb
case
protein
c
level
plasma
apach
ii
score
system
risk
evalu
patient
sepsi
e
doyuk
kartal
e
karkac
n
erben
nayman
alpat
ne
z
gulba
g
usluer
eskisehir
tr
object
concentr
protein
c
reduc
septic
patient
reduct
associ
poor
outcom
aim
studi
investig
relat
protein
c
level
apach
ii
score
prognosi
patient
sepsi
method
prospect
studi
conduct
patient
includ
patient
classifi
sepsi
n
sever
sepsi
septic
shock
n
accord
establish
concensu
definit
patient
infect
select
control
group
n
acut
physiolog
chronic
health
evalu
apach
ii
score
determin
begin
studi
blood
sampl
obtain
patient
protein
c
level
begin
hour
initi
studi
protein
c
measur
plasma
enzymelink
immunoabsorb
assay
elisa
patient
observ
clinic
outcom
allcaus
mortal
durat
icu
stay
presenc
absenc
mechan
ventil
result
apach
ii
score
patient
sepsi
sever
sepsi
septic
shock
control
group
protein
c
level
begin
hour
initi
studi
seen
tabl
initi
protein
c
level
lower
patient
die
surviv
one
howev
protein
c
level
hour
initi
studi
associ
mortal
neg
correl
apach
ii
score
initi
hour
initi
studi
protein
c
level
conclus
patient
protein
c
concentr
begin
studi
correl
poor
prognosi
septic
patient
reduct
relat
poor
outcom
septic
patient
initi
protein
c
level
significantli
lower
apach
ii
score
significantli
higher
patient
die
compar
surviv
one
apach
ii
score
system
measur
initi
protein
c
level
signific
prognost
factor
septic
patient
role
plasma
bnp
level
earli
prognost
stratif
septic
patient
emerg
depart
g
ruggiano
r
camajori
tedeschini
rosselli
florenc
myocardi
dysfunct
observ
patient
sever
sepsi
septic
shock
high
plasma
bnp
level
could
associ
poor
outcom
sepsi
investig
whether
plasma
bnp
level
could
repres
prognost
marker
septic
patient
start
two
phase
project
first
retrospect
studi
factor
influenc
poor
clinic
outcom
septic
patient
conduct
review
clinic
record
patient
age
year
karnofski
score
pt
presenc
pulmonari
edema
tradit
chest
x
ray
result
independ
correl
death
prospect
studi
start
decemb
enrol
adult
patient
present
ed
sir
esclus
criteria
presenc
caus
sir
persist
immunodefici
presenc
preexist
condit
known
increas
plasma
bnp
level
enrol
patient
complet
clinic
laboratori
instrument
examin
includ
bnp
cardiac
troponin
l
plasma
level
carri
use
nonradiometr
bedsid
test
triag
bnp
test
panel
biosit
cut
valu
pgml
today
patient
enrol
studi
result
survivor
show
valu
bnp
plasma
level
pgml
ci
compar
nonsurvivor
pgml
ci
differ
statist
highli
signific
p
despit
small
number
patient
progress
studi
reach
larger
figur
order
evalu
independ
influenc
bnp
prognosi
gener
accept
pathogenesi
sepsi
evolut
septic
shock
abrupt
passag
revers
diseas
irrevers
condit
lead
death
left
ventricular
failur
might
repres
one
underli
event
lead
multiorgan
failur
thu
bnp
plasma
level
earli
marker
may
consist
contribut
predict
unfavour
clinic
evolut
myocardi
failur
evid
hypothesi
confirm
earli
aggress
therapi
recommend
patient
sever
sepsissept
shock
could
properli
set
without
delay
target
high
risk
patient
allow
appropri
clinic
manag
togeth
improv
human
econom
resourc
alloc
object
patient
sepsi
low
membranebound
monocyt
express
level
high
solubl
concentr
level
report
separ
predictor
poor
outcom
howev
result
mutual
relationship
publish
far
measur
marker
patient
sever
communityacquir
bacteri
infect
studi
predict
valu
day
mortal
method
studi
compris
acut
ill
patient
male
femal
communityacquir
pneumonia
andor
blood
cultureposit
sepsi
express
level
whole
blood
flow
cytometri
elisa
measur
blood
sampl
obtain
admiss
hospit
clinic
data
collect
retrospect
medic
record
mortal
enquiri
made
nation
popul
regist
centr
result
signific
correl
express
level
surviv
rate
lowest
tertil
express
significantli
lower
middlehighest
tertil
surviv
rate
highest
middlelowest
tertil
level
compar
hazard
ratio
confid
interv
ci
p
ci
p
respect
hazard
ratio
appear
improv
stratif
signific
posit
correl
detect
creactiv
protein
level
provid
evid
may
serv
acut
phase
reactant
conclus
low
level
monocyt
concurr
circul
level
predict
mortal
patient
sever
communityacquir
infect
background
tigecyclin
member
new
class
antimicrobi
glycylcyclin
shown
potent
broad
spectrum
activ
commonli
encount
speci
respons
commun
hospit
acquir
infect
test
program
determin
vitro
activ
tigecyclin
compar
commonli
prescrib
broad
spectrum
antimicrobi
gramneg
gramposit
speci
collect
hospit
global
throughout
method
total
clinic
isol
identifi
speci
level
site
confirm
central
laboratori
minimum
inhibitori
concentr
mic
determin
site
use
suppli
broth
microdilut
panel
interpret
accord
clsi
guidelin
result
result
tabl
follow
tigecyclin
suscept
defin
accord
fda
packag
insert
tygacil
avail
tigecyclin
acinetobact
suscept
breakpoint
defin
lgml
compar
purpos
conclus
tigecyclin
vitro
activ
compar
greater
commonli
prescrib
antimicrobi
without
demonstr
chang
activ
inand
outpati
bacteri
studi
strain
present
data
suggest
tigecyclin
may
effect
reliabl
therapeut
option
nosocomi
commun
pathogen
tigecyclin
antibacteri
activ
current
background
tigecyclin
first
member
new
class
glycylcyclin
antimicrobi
class
reach
clinic
trial
shown
potent
broad
spectrum
activ
commonli
encount
speci
respons
hospit
acquir
infect
crossresist
sever
class
antimicrobi
often
seen
nosocomi
pathogen
test
program
determin
vitro
activ
tigecyclin
strain
enterobacteriacea
crossresist
one
follow
antimicrobi
amoxicillinclavulan
acid
piperacillintazobactam
levofloxacin
ceftriaxon
cefepim
ampicillin
amikacin
minocyclin
ceftazidim
imipenem
isol
collect
investig
sti
countri
throughout
method
total
clinic
enterobacteriacea
identifi
speci
level
site
confirm
central
laboratori
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
broth
microdilut
panel
antimicrobi
resist
interpret
accord
clsi
breakpoint
tig
fda
suscept
resist
breakpoint
defin
lgml
respect
result
e
coli
klebsiella
spp
collect
test
esbl
product
isol
found
esbl
produc
resist
cephalosporin
betalactam
betalactambetalactamas
inhibitor
combin
strain
present
cross
resist
levofloxacin
minocyclin
amikacin
imipenem
tigecyclin
enterobact
spp
marcescen
collect
present
resist
ceftriaxon
ceftazidim
suscept
cefepim
suggest
ampc
phenotyp
isol
show
degre
nonsuscept
tigecyclin
mic
rang
lgml
tigecyclin
also
show
excel
inhibitori
activ
member
enterobacteriacea
resist
amikacin
levofloxacin
imipenem
inhibit
isol
respect
lgml
conclus
present
data
suggest
tigecyclin
littl
affect
crossresist
mechan
present
select
strain
enterobacteriacea
tigecyclin
may
effect
therapeut
option
enterobacteriacea
regardless
resist
pattern
commonli
use
antimicrobi
agent
background
enhanc
activ
agent
tig
may
offer
antibacteri
coverag
common
pathogen
includ
multidrug
resist
gramnegativesposit
test
program
monitor
vitro
activ
tig
compar
current
european
pathogen
method
thirtythre
hospit
site
european
countri
collect
signific
isol
commun
hospit
infect
site
mic
determin
tig
compar
use
broth
microdilut
panel
clsi
specifi
interpret
background
tigecyclin
glycylcyclin
new
gener
tetracyclin
significantli
differ
classifi
separ
antimicrobi
class
glycylcyclin
develop
overcom
problem
bacteri
resist
tetracyclin
antimicrobi
tigecyclin
better
toler
activ
tetracyclin
wide
varieti
gramposit
gramneg
bacteria
includ
acinetobact
spp
test
program
determin
vitro
activ
tig
acinetobact
resist
one
piperacillintazobactam
pt
levofloxacin
lvx
ceftriaxon
cax
cefepim
cpe
amikacin
ak
minocyclin
min
ceftazidim
caz
imipenem
imp
studi
strain
collect
hospit
global
throughout
method
total
clinic
isol
acinetobact
spp
identifi
speci
level
particip
site
confirm
central
laboratori
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
suppli
broth
microdilut
panel
interpret
accord
clsi
guidelin
tigecyclin
suscept
breakpoint
defin
lgml
result
tig
inhibit
acinetobact
resist
two
drug
class
inhibit
imipenemand
minocyclineresist
strain
respect
resist
rate
compar
drug
acinetobact
cax
caz
lvx
cpe
pt
ak
imp
min
one
strain
mic
lgml
tig
modal
tig
mic
strain
resist
two
drug
class
lgml
compar
lgml
strain
resist
paramet
indic
eightfold
diminish
activ
conclus
seen
speci
exist
multidrug
efflux
pump
may
also
pump
tig
spite
tig
remain
effect
inhibit
acinetobact
strain
resist
two
drug
studi
although
higher
tig
mic
seen
strain
suggest
linkag
resist
mechan
drug
tig
remain
effect
inhibit
multidrug
resist
acinetobact
spp
broaden
wide
spectrum
activ
vs
drugresist
bacteria
evalu
crossresist
enterobacteriacea
compar
tigecyclin
test
program
europ
background
tigecyclin
tig
first
glycylcyclin
enter
clinic
trial
shown
potent
broad
spectrum
activ
commonli
encount
speci
respons
commun
hospit
acquir
infect
crossresist
sever
class
antimicrobi
often
seen
nosocomi
pathogen
test
program
determin
vitro
activ
tigecyclin
compar
amoxicillinclavulan
acid
ac
piperacillintazobactam
pt
levofloxacin
lv
ceftriaxon
cx
cefepim
cp
ampicillin
amp
amikacin
ak
minocyclin
mn
ceftazidim
cz
imipenem
imp
multipledrug
resist
drug
class
enterobacteriacea
isol
collect
investig
sti
countri
throughout
europ
method
total
clinic
enterobacteriacea
identifi
speci
level
particip
site
confirm
central
laboratori
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
suppli
broth
microdilut
panel
interpret
accord
clsi
guidelin
antimicrobi
resist
interpret
accord
clsi
breakpoint
tig
fda
suscept
resist
breakpoint
defin
lgml
lgml
respect
result
enterobacteriacea
multiresist
two
drug
class
resist
strain
resist
tig
mic
compar
amp
ac
cz
lv
mn
cx
pt
cp
imp
ak
enterobact
spp
marcescen
collect
present
resist
cx
cz
suscept
cp
suggest
ampc
phenotyp
isol
demonstr
mic
lgml
tig
tig
show
excel
inhibitori
activ
member
enterobacteriacea
resist
ak
n
lv
n
imp
n
inhibit
isol
respect
lgml
conclus
present
data
suggest
tig
littl
affect
crossresist
mechan
present
select
strain
enterobacteriacea
tig
may
effect
therapeut
option
enterobacteriacea
regardless
resist
pattern
commonli
use
antimicrobi
agent
background
test
program
determin
vitro
activ
tigecyclin
compar
commonli
prescrib
broad
spectrum
antimicrobi
gramneg
gramposit
speci
collect
patient
european
center
throughout
tigecyclin
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
commonli
encount
speci
respons
commun
hospit
acquir
infect
method
total
clinic
isol
identifi
speci
level
particip
site
confirm
central
laboratori
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
suppli
broth
microdilut
panel
interpret
accord
clsi
guidelin
result
result
tabl
follow
tigecyclin
suscept
defin
accord
fda
packag
insert
tygacil
avail
tigecyclin
acinetobact
suscept
breakpoint
defin
lgml
compar
purpos
conclus
tigecyclin
vitro
activ
compar
greater
commonli
prescrib
antimicrobi
clinic
pathogen
outpati
inpati
set
present
data
suggest
tigecyclin
expand
broadspectrum
antimicrobi
may
effect
empir
therapeut
option
nosocomi
commun
pathogen
background
tigecyclin
tig
new
glycylcyclin
promis
enhanc
activ
mani
multidrug
resist
phenotyp
commun
nosocomi
pathogen
caus
seriou
diseas
test
program
design
elucid
activ
tig
vs
compar
clinic
use
organ
asiapacif
rim
method
organ
isol
inpati
outpati
asiapacif
rim
collect
six
centr
deem
clinic
signific
underw
site
direct
clsi
specifi
mic
test
util
suppli
broth
microdilut
panel
result
select
asiapacif
rim
pathogen
test
tig
shown
ec
e
coli
ko
k
oxytoca
kp
k
pneumoniaea
esbl
produc
ec
ko
kp
conclus
tigecyclin
lgml
gramposit
pathogen
includ
resist
phenotyp
lgml
gramneg
pathogen
exclud
p
aeruginosa
valid
potent
activ
tig
communityhospit
pathogen
isol
six
asiapacif
rim
countri
tig
may
add
valu
therapeut
challeng
geograph
region
acinetobact
resist
clinic
isol
unit
state
evalu
tigecyclin
compar
background
tigecyclin
tig
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
commonli
encount
speci
respons
commun
hospit
acquir
infect
test
program
determin
vitro
activ
tig
acinetobact
resist
one
piperacillintazobactam
pt
levofloxacin
lvx
ceftriaxon
cax
cefepim
cpe
amikacin
ak
minocyclin
min
ceftazidim
caz
imipenem
imp
studi
strain
collect
hospit
unit
state
throughout
method
total
clinic
isol
identifi
speci
level
particip
site
confirm
central
laboratori
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
suppli
broth
microdilut
panel
interpret
accord
clsi
guidelin
tig
resist
breakpoint
defin
lml
result
resist
rate
compar
drug
caz
cax
lvx
cpe
pt
ak
imp
min
tig
inhibit
multidrug
resist
two
drug
class
strain
mic
lgml
tigresist
lgml
strain
found
tig
multidrug
resist
strain
lgml
includ
akand
impresist
strain
modal
tig
mic
multidrug
resist
strain
lgml
compar
lgml
strain
without
resist
paramet
indic
diminish
activ
conclus
seen
speci
exist
multidrug
efflux
pump
may
also
pump
tig
spite
tig
remain
effect
inhibit
acinetobact
strain
resist
one
drug
studi
although
higher
tig
mic
seen
strain
suggest
linkag
resist
mechan
drug
tig
remain
effect
inhibit
multidrug
resist
acinetobact
spp
broaden
wide
spectrum
activ
vs
drugresist
bacteria
background
tigecyclin
tig
new
glycylcyclin
shown
potent
broad
spectrum
activ
commonli
encount
speci
respons
commun
hospit
acquir
infect
test
program
determin
vitro
activ
tig
compar
respect
grampositiveneg
speci
isol
collect
hospit
site
countri
throughout
method
clinic
signific
isol
identifi
speci
level
particip
site
confirm
central
laboratori
mic
determin
site
use
suppli
broth
microdilut
panel
interpret
accord
nccl
guidelin
result
select
global
pathogen
test
tigecyclin
shown
tabl
tigecyclin
suscept
defin
accord
fda
packag
insert
tygacil
avail
tigecyclin
acinetobact
suscept
breakpoint
defin
lgml
compar
purpos
conclus
tig
demonstr
broad
spectrum
antimicrobi
consist
activ
enterobacteriacea
includ
esbl
phenotyp
aureu
includ
mr
strain
pneumonia
phenotyp
vs
vr
enterococcu
spp
tig
wide
spectrum
activ
promis
provid
enhanc
antimicrobi
coverag
seriou
nosocomi
commun
pathogen
method
total
clinic
isol
identifi
speci
level
particip
site
confirm
central
laboratori
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
suppli
broth
microdilut
panel
interpret
accord
clsi
guidelin
tigecyclin
suscept
fda
breakpoint
defin
lgml
result
studi
drug
mrsa
activ
tig
van
lzd
min
respect
differ
among
geograph
region
except
lower
activ
min
asia
middl
east
respect
compar
europ
north
america
wherea
tig
inhibit
strain
region
lgml
tig
van
lzd
min
respect
conclus
tig
potent
antimrsa
drug
studi
inhibit
mrsa
strain
mic
valu
lgml
tig
excel
expand
broad
spectrum
activ
mrsa
gramposit
neg
resist
bacteria
make
use
drug
treatment
difficult
staphylococc
infect
background
tigecyclin
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
commonli
encount
speci
respons
commun
hospit
acquir
infect
test
program
determin
vitro
activ
tigecyclin
compar
commonli
prescrib
broad
spectrum
antimicrobi
gram
neg
gramposit
speci
collect
hospit
within
asia
pacif
rim
countri
throughout
method
total
clinic
isol
identifi
speci
level
particip
site
confirm
central
laboratori
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
suppli
broth
microdilut
panel
interpret
accord
clsi
guidelin
result
result
tabl
follow
tigecyclin
suscept
defin
accord
fda
packag
insert
tygacil
avail
tigecyclin
acinetobact
suscept
breakpoint
defin
lgml
compar
purpos
conclus
tigecyclin
vitro
activ
compar
greater
commonli
prescrib
antimicrobi
present
data
suggest
tigecyclin
may
effect
reliabl
therapeut
option
nosocomi
commun
pathogen
inpati
outpati
clinic
set
background
tigecyclin
tig
member
new
class
antimicrobi
glycylcyclin
shown
potent
expand
broad
spectrum
activ
commonli
encount
speci
respons
commun
hospit
acquir
infect
test
program
determin
vitro
activ
tig
compar
amoxicillinclavulan
acid
piperacillintazobactam
pt
levofloxacin
ceftriaxon
cefepim
ampicillin
amp
amikacin
ak
minocyclin
ceftazidim
imipenem
imp
esbl
isol
collect
hospit
global
throughout
method
total
esbl
produc
clinic
enterobacteriacea
identifi
speci
level
lab
countri
confirm
central
laboratori
minimum
inhibitori
concentr
mic
determin
local
laboratori
use
custom
suppli
broth
microdilut
panel
interpret
accord
clsi
guidelin
tigecyclin
suscept
fda
breakpoint
defin
lgml
result
percentag
su
esblproduc
isol
vs
tig
imp
ak
respect
su
compar
rang
high
pt
low
amp
tig
lowest
percentag
resist
strain
compar
imp
ak
tig
imp
ak
lgml
drug
resist
rang
minor
region
differ
level
activ
either
tig
north
america
imp
europ
asiapacif
activ
conclus
tig
activ
vitro
imp
esbl
produc
strain
enterobacteriacea
tig
expand
broad
spectrum
activ
includ
strain
resist
multipleresist
agent
make
use
treatment
option
difficult
treat
group
gramneg
pathogen
object
tigecyclin
first
glycylcyclin
novel
compound
provid
medic
commun
potent
new
antimicrobi
treat
infect
caus
broad
spectrum
clinic
relev
pathogen
limit
therapeut
option
exist
studi
undertaken
assess
vitro
activ
tigecyclin
agalactia
pyogen
mrsa
e
faecali
e
faecium
isol
sssi
ii
identifi
resist
gene
method
strain
test
panel
antimicrobi
agent
includ
tigecyclin
broth
microdilut
method
perform
accord
clsi
guidelin
furthermor
vancomycin
vana
vanb
tetracyclin
tet
tet
tet
k
macrolid
resist
erm
b
erm
mef
gene
analys
pcr
meccomplex
character
result
overal
tigecyclin
activ
gramposit
cocci
show
mic
rang
mgl
abl
potent
inhibit
streptococci
enterococci
mr
aureu
tigecyclin
activ
antibiot
mrsa
enterococci
respect
linezolid
mic
mgl
respect
quinopristindalfopristin
mic
mgl
respect
respect
macrolid
amoxicillin
tetracyclin
streptococci
molecular
character
resist
determin
demonstr
concomit
presenc
differ
class
gene
particular
agalactia
predomin
gene
tet
eight
strain
erm
b
three
strain
mef
two
strain
pyogen
tet
tet
equal
distribut
three
frequent
class
erythromycin
gene
found
vanamedi
resist
e
faecali
possess
tet
strain
erm
b
four
strain
strain
mrsa
harbour
four
type
sccmec
dna
name
ia
strain
iiia
n
iv
strain
erythromycin
resist
six
strain
erm
gene
found
six
strain
tet
k
gene
respons
tetracyclin
minocyclin
resist
conclus
result
clearli
confirm
tigecyclin
excel
activ
multiresist
gramposit
tetracyclinesuscept
resist
isol
possess
three
differ
tetracyclineresist
gene
determin
includ
mec
vana
b
togeth
suggest
drug
may
play
import
role
treatment
infect
caus
gramposit
pathogen
object
identifi
character
type
esbl
among
clinic
signific
isol
enterobacteriacea
bulgarian
hospit
investig
distribut
differ
genera
enterobacteriacea
particip
centr
method
antibiot
suscept
determin
disc
diffus
method
clsi
standard
esbl
product
confirm
clsi
doubl
disc
esbl
confirmatori
method
conjug
perform
solid
medium
isoelectr
focus
follow
bioassay
esblgroup
specif
pcr
sequenc
esbl
gene
carri
rapd
eric
primer
plasmid
fingerprint
pst
restrict
perform
repres
strain
result
seven
medic
institut
five
sofia
one
pleven
one
stara
zagora
particip
studi
strain
posit
doubl
disk
synergi
test
collect
year
esblproduc
k
pneumonia
e
coli
enterobact
spp
marcescen
c
freundii
k
oxytoca
salmonella
corval
five
differ
betalactamas
identifi
among
bulgarian
isol
name
widespread
enzym
centr
follow
six
centr
found
rate
ctxm
enzym
harbour
strain
increas
rapidli
sinc
introduc
ceftriaxon
wide
bulgaria
rapd
plasmid
fingerprint
data
suggest
plasmid
transfer
main
mechan
spread
show
clonal
dissemin
one
centr
detect
remark
varieti
esbl
produc
pathogen
k
pneumonia
e
coli
enterobact
spp
marcescen
c
freundii
k
oxytoca
salmonella
corval
data
show
import
monitor
epidemiolog
resist
need
ration
antibiot
polici
surveil
produc
among
gramneg
bacilli
isol
tertiari
care
hospit
period
analysi
genet
locat
b
z
lay
izmir
tr
object
investig
preval
betalactamas
period
among
ceftazidim
resist
gramneg
bacteria
isol
tertiari
care
hospit
izmir
turkey
determin
whether
associ
integron
isol
method
betalactamas
product
sought
ceftazidim
resist
gramneg
bacteria
isol
isol
consist
pseudomoa
aeruginosa
acinetobact
baumanii
member
enterobacteriacea
presenc
determin
pcr
use
specif
primer
clonal
relationship
produc
determin
ericpcr
integronloc
analys
pcr
combin
primer
specif
conserv
region
integron
repres
ericpcr
pattern
direct
sequenc
pcrproduct
perform
strand
result
conclus
product
rate
period
respect
percentag
p
aeruginosa
strain
alway
higher
baumanii
strain
member
enterobacteriacea
neg
ericpcr
result
reveal
dissemin
two
endem
clone
p
aeruginosa
pattern
x
baumanii
pattern
b
respons
high
preval
conjug
experi
neg
repres
strain
bp
pcrproduct
obtain
combin
specif
primer
three
p
aeruginosa
isol
standard
perpcr
perform
use
bp
pcrproduct
previou
reaction
templat
bp
pcrproduct
specif
detect
p
aeruginosa
strain
show
differ
ericpcr
pattern
z
other
direct
sequenc
pcrproduct
strand
confirm
presenceto
knowledg
first
report
show
associ
integron
plasmidmedi
carbapenemhydrolys
oxacillinas
acinetobact
baumannii
itali
object
emerg
carbapenem
resist
acinetobact
baumannii
report
worldwid
outbreak
baumannii
occur
summer
intens
care
unit
icu
policlinico
umberto
rome
aim
studi
investig
genotyp
antibiot
resist
mechan
epidem
baumannii
isol
icu
outbreak
compar
sporad
baumannii
isol
hospit
differ
hospit
town
method
molecular
epidemiolog
epidem
sporad
isol
baumannii
investig
plasmid
analysi
pfgeand
rapdbas
genotyp
integron
identif
fiftytwo
isol
show
carbapenem
resist
imipenem
mic
lgml
intermedi
meropenem
mic
lgml
occurr
plasmidmedi
carbapenemhydrolyz
oxacillinas
detect
pcr
southern
blot
analysi
result
outbreak
involv
case
infect
multidrugresist
baumannii
isol
collect
period
uniqu
rapd
profil
observ
among
epidem
isol
twentyfour
isol
show
rapdprofil
epidem
clone
also
detect
among
sporad
strain
isol
differ
ward
hospit
anoth
hospit
town
period
outbreak
follow
month
analysi
also
show
second
rapd
profil
highli
repres
among
carbapenem
suscept
isol
differ
genotyp
observ
rapd
also
confirm
pfge
analysi
pcr
identif
character
integron
provid
character
isol
identifi
two
integron
carri
kb
kb
variabl
region
respect
associ
two
preval
rapd
profil
interestingli
carbapenem
resist
isol
found
posit
gene
gene
locat
differ
plasmid
variant
conclus
detect
plasmidmedi
oxacillinas
confer
imipenemresist
locat
differ
plasmid
variant
suggest
resist
may
spread
horizont
baumannii
find
seriou
implic
patient
manag
hospit
molecular
type
isol
use
monitor
spread
resist
within
hospit
help
detect
genotyp
resist
pattern
emerg
clone
outbreak
carbapenemresist
acinetobact
baumannii
isol
paediatr
univers
hospit
athen
greec
l
poirel
e
lebessi
c
patsoura
foustouk
p
nordmann
le
kremlin
bicetr
fr
athen
gr
purpos
character
clonal
relationship
betalactamas
content
carbapenemresist
acinetobact
baumannii
isol
recov
pediatr
hospit
athen
greec
materi
method
twelv
nonrepetit
carbapenemresist
acinetobact
baumannii
isol
recov
novemb
period
p
kyriak
children
hospit
athen
greec
speci
identif
done
biochem
gn
test
franc
rrna
sequenc
sensit
test
done
disk
diffus
method
minimum
inhibitori
concentr
mic
determin
agar
dilut
presenc
oxacillinas
metallo
betalactamas
gene
perform
pcr
particular
gene
code
carbapenemhydrolyz
subgroup
search
genotyp
done
puls
field
gel
electrophoresi
pfge
digest
apai
result
isol
identifi
baumannii
possess
gene
genotyp
reveal
eight
ten
baumannii
isol
correspond
singl
clone
gene
plasmidloc
conclus
studi
first
descript
gene
greec
identifi
carbapenemas
gene
european
countri
observ
franc
romania
gene
identifi
baumannii
strain
sourc
outbreak
period
characteris
conjug
plasmid
encod
ctxmtype
extendedspectrum
betalactamas
italian
clinic
isol
escherichia
coli
object
extendedspectrum
betalactamas
esbl
among
import
emerg
resist
determin
enterobacteriacea
dissemin
mostli
mediat
conjug
plasmid
ctxmtype
esbl
among
widespread
esbl
worldwid
recent
shown
rapid
dissemin
european
countri
current
knowledg
plasmid
encod
resist
determin
still
limit
report
character
ctxmencod
conjug
plasmid
escherichia
coli
clinic
isol
collect
nationwid
survey
carri
itali
method
repres
clonal
lineag
e
coli
produc
ctxmtype
esbl
obtain
hospitalassoci
clinic
microbiolog
laboratori
repres
differ
italian
region
crosssect
nationwid
survey
assay
transfer
ctxm
determin
mate
experi
plasmid
extract
conduct
alkalin
lysi
presenc
blactxm
determin
transconjug
confirm
pcr
plasmid
profil
tranconjug
determin
digest
psti
ecorv
endonucleas
pcrbase
method
use
assign
incompat
group
result
clonal
lineag
e
coli
produc
ctxmtype
enzym
produc
produc
one
produc
detect
across
italian
nation
territori
found
harbour
blactxm
gene
conjug
plasmid
transfer
frequenc
order
transconjug
per
recipi
observ
plasmid
analysi
reveal
strain
seven
differ
centr
carri
appar
ident
plasmid
encod
belong
incompat
group
incn
plasmid
strain
also
incn
group
remain
two
strain
incf
group
incfia
incfib
conclus
epidem
dissemin
singl
incn
plasmid
encod
appar
major
respons
spread
esbl
recent
observ
among
e
coli
circul
itali
although
plasmid
could
also
involv
dissemin
ctxmtype
esbl
determin
unusu
ctxm
enzym
variant
unit
kingdom
investig
rare
ctxm
type
method
mic
determin
british
societi
antimicrobi
chemotherapi
method
blactxm
gene
phylogenet
group
multiplex
pcr
clone
vector
sequenc
xbaidigest
genom
dna
profil
compar
pulsedfield
gel
electrophoresi
plasmid
extract
alkalin
lysi
electrophores
hybridis
blactxm
probe
plasmid
electropor
e
coli
result
three
group
one
group
blactxm
gene
detect
among
blactxmposit
clinic
isol
e
coli
collect
uk
sinc
sequenc
reveal
three
group
blactxm
allel
encod
classic
group
blactxm
gene
encod
one
unusu
e
coli
isol
five
isol
requir
mic
consist
product
ctxm
esbl
remain
suscept
carbapenem
except
produc
reduc
suscept
resist
aminoglycosid
two
produc
remain
suscept
ciprofloxacin
three
differ
hospit
unrel
pfge
isol
distinct
major
clone
plasmid
success
transform
encod
hybridis
suggest
chromosomallyencod
mediat
larg
plasmid
kb
conclus
report
first
uk
also
first
report
uk
product
two
ctxm
enzym
singl
clinic
isol
object
e
coli
ctxm
betalactamas
major
problem
uk
sever
outbreak
strain
well
mani
sporad
produc
one
outbreak
strain
widespread
across
england
second
preval
singl
centr
also
frequent
strain
gener
lowerlevel
cephalosporin
resist
strain
investig
basi
differ
method
three
repres
strain
investig
strain
repres
differ
centr
plasmid
transform
e
coli
mic
determin
british
societi
antimicrobi
chemotherapi
method
cultur
sonic
use
isoelectr
focus
assay
cefotaximas
specif
activ
rna
extract
clinic
isol
use
reversetranscriptas
rt
pcr
assess
express
region
upstream
sequenc
strain
repres
result
two
typic
strain
isol
requir
lower
cefotaxim
mgl
vs
mgl
ceftazidim
mgl
vs
mgl
mic
compar
three
strain
isol
third
strain
repres
cefotaximas
specif
activ
lower
strain
lower
case
transform
deriv
three
strain
repres
includ
requir
lower
cephalosporin
mic
compar
deriv
strain
repres
significantli
lower
cefotaximas
specif
activ
hardli
detect
electrofocus
isol
obviou
band
equal
intens
six
isol
similarli
rtpcr
show
band
lower
intens
isol
whilst
band
equal
intens
three
strain
isol
element
normal
promot
provid
dna
sequenc
indic
differ
immedi
upstream
conclus
express
betalactamas
strain
gener
lower
strain
explain
lower
cephalosporin
resist
normal
promot
may
respons
lower
express
also
appear
transact
factor
may
upregul
express
isol
object
class
extendedspectrum
betalactamas
esbl
ctxm
rapidli
expand
worldwid
aim
studi
establish
frequenc
resist
broadspectrum
cephalosporin
e
coli
strain
collect
algeria
character
type
esbl
produc
method
januaryjun
e
coli
strain
recov
consecut
separ
patient
mustapha
pacha
hospit
algier
algeria
esbl
produc
enzym
detect
disc
diffus
method
etest
esbl
cefotaxim
ctx
ceftazidim
caz
plu
clavulan
use
confirm
strain
esbl
produc
mic
antibiot
perform
microdilut
broth
method
esblposit
strain
isoelectr
focus
use
characteris
pi
betalactamas
pcr
perform
specif
primer
type
betalactamas
gene
esbl
produc
strain
blatem
blaoxa
blashv
blactxm
ampc
sequenc
identifi
esbl
enzym
pulsedfield
gel
electrophoresi
pfge
xbaidigest
genom
dna
establish
divers
esblposit
clone
specif
primer
use
screen
presenc
upstream
blactxm
result
sixteen
strain
confirm
esbl
produc
among
follow
biolog
product
urin
n
pu
n
csf
n
blood
n
sputum
n
strain
ubiquitari
ampc
gene
plu
blatem
blactxm
gene
sequenc
blatem
blactxm
amplicon
identifi
strain
encod
enzym
enzym
character
pi
respect
detect
e
coli
strain
produc
ctxm
enzym
pfge
profil
strain
indic
five
clone
relat
ctxm
produc
show
diminish
suscept
differ
antibiot
ctx
ceftriaxon
caz
aztreonam
trimethoprimsulfamethoxazol
gentamicin
amikacin
ciprofloxacin
among
other
strain
ctxm
produc
multidrugresist
conclus
show
high
frequenc
policlon
dissemin
resist
broadspectrum
betalactam
hospit
algeria
ctxm
esbl
probabl
facilit
mobil
element
result
suggest
therapeut
option
may
dramat
diminish
ctxm
enzym
continu
spread
hospit
environ
multidrugresist
demonstr
high
frequenc
extendedspectrum
betalactamas
plasmidmedi
ampc
enzym
among
clinic
isol
escherichia
coli
klebsiella
pneumonia
taiwan
total
escherichia
coli
klebsiella
pneumonia
isol
show
decreas
suscept
extendedspectrum
cephalosporin
collect
march
august
seven
medic
centr
examin
evalu
distribut
extendedspectrum
blactamas
esbl
plasmidmedi
ampc
enzym
e
coli
k
pneumonia
taiwan
overal
esbl
product
detect
e
coli
isol
k
pneumonia
isol
e
coli
isol
k
pneumonia
isol
exhibit
plasmidmedi
ampc
enzym
e
coli
ctxm
shv
esbl
ampc
enzym
detect
k
pneumonia
ctxm
shv
esbl
enzym
enzym
detect
thirtyf
e
coli
isol
k
pneumonia
isol
harbour
two
three
blactamas
involv
resist
extendedspectrum
cephalosporin
nucleotid
sequenc
blactxm
gene
reveal
presenc
seven
subtyp
novel
gene
among
seven
blactxm
subtyp
predomin
k
pneumonia
e
coli
respect
novel
blactxm
gene
firstli
identifi
taiwan
randomli
amplifi
polymorph
dna
analysi
reveal
genet
divers
among
isol
randomli
select
differ
hospit
conjug
experi
plasmid
analysi
suggest
interhospit
spread
similar
resist
plasmid
salmonella
enterica
serovar
enteritidi
produc
blactamas
first
report
spain
object
report
first
find
enterica
serovar
enteritidi
spain
materi
method
isol
obtain
stool
sampl
year
old
girl
gastroenter
one
month
receiv
amoxicillin
respiratori
infect
isol
identifi
use
wider
system
dadebehr
california
serotyp
use
difco
antisera
becton
dickinson
usa
mic
determin
agar
microdilut
method
esbl
phenotyp
determin
accord
clsi
guidelin
plasmid
dna
obtain
amplifi
pcr
use
primer
specif
tem
shv
ctxm
blactamas
e
coli
mrf
kan
blactamsuscept
kanamycinresist
use
recipi
conjug
experi
macconkey
agar
plate
contain
mgl
cefotaxim
mgl
kanamycin
use
select
pcr
sequenc
transconjug
perform
sinc
describ
associ
transposon
salmonella
pcr
primer
specif
transposon
perform
plasmid
dna
result
main
mic
obtain
salmonella
isol
follow
amoxicillin
mgl
amoxicillinclavulan
acid
mgl
cefuroxim
mgl
cefoxitin
mgl
ceftazidim
mgl
ceftazidimeclavulan
acid
mgl
cefotaxim
mgl
cefepim
mgl
amikacin
mgl
primer
tem
yield
fragment
whose
sequenc
ident
sequenc
avail
genebank
amplif
transconjug
strain
show
harbour
gene
salmonella
enteritidi
isol
transconjug
gave
expect
bp
pcr
product
suggest
presenc
gene
structur
carri
conjug
plasmid
conclus
first
describ
report
differ
salmonella
serotyp
greec
korea
report
salmonella
uk
first
time
also
found
predomin
esbl
gene
studi
esblresist
salmonella
obtain
human
poultri
netherland
nevertheless
infrequ
spain
two
e
coli
isol
produc
found
depart
among
esblproduc
isol
unpublish
data
found
salmonella
countri
previou
studi
structur
seem
genet
element
usual
includ
object
plasmidmedi
class
c
blactamas
eg
cmi
fox
moxor
acttyp
enzym
character
abil
hydrolys
cephalosporin
includ
cephamycin
poorli
inhibit
convent
blactamas
inhibitor
eg
clavulan
tazobactam
plasmidencod
class
c
blactamas
origin
identifi
clinic
isol
enterobact
cloaca
klebsiella
pneumonia
caus
outbreak
neonat
intens
care
unit
teach
univers
hospit
siena
itali
purifi
biochem
properti
investig
method
orf
amplifi
pcr
clone
vector
yield
plasmid
latter
use
transform
e
coli
highlevel
product
grown
autoinduc
medium
enzym
purifi
puriti
mean
two
chromatograph
step
cationexchang
ph
follow
anionexchang
ph
steadyst
kinet
paramet
hydrolysi
blactam
antibiot
determin
measur
spectrophotometr
initi
reaction
rate
low
km
valu
measur
ki
use
competit
inhibit
model
inactiv
imipenem
meropenem
aztreonam
investig
use
cephalothin
report
substrat
result
use
e
coli
blactamas
purifi
overal
yield
mg
per
litr
cultur
high
catalyt
effici
measur
test
substrat
kcatkm
measur
eg
ampicillin
benzylpenicillin
cephalothin
cefazolin
cephalexin
cefamandol
cefotaxim
ceftazidim
cepefim
hydrolys
less
effici
kcatkm
x
x
respect
km
valu
rang
lm
cefazolin
lm
cefotaxim
comparison
foxtyp
enzym
includ
exhibit
overal
higher
turnov
rate
lower
km
valu
penicillin
cephaloridin
cefotaxim
account
overal
high
catalyt
effici
observ
inhibit
aztreonam
imipenem
meropenem
latter
exhibit
best
inactiv
effici
conclus
detail
biochem
analysi
carri
blactamas
reveal
enzym
exhibit
broadspectrum
activ
particularli
activ
cefotaxim
comparison
foxtyp
enzym
object
analys
dna
sequenc
upstream
ampc
gene
clinic
isol
escherichia
coli
phenotyp
compat
ampchyperproduct
determin
frequenc
promot
attenu
mutat
occur
determin
possibl
clonal
spread
organ
method
escherichia
coli
clinic
sampl
obtain
servic
microbiolog
univ
hv
macarena
sevil
spain
evalu
refer
suscept
test
perform
microdilut
nccl
guidelin
seventyseven
organ
resist
amoxicillin
plu
clavulan
amc
cephalotin
cefoxitin
fox
lack
extendedspectrum
betalactamas
synergi
cefotaxim
ceftazidim
clavulan
acid
select
clonal
relationship
determin
reppcr
primer
gcg
ccg
ica
tca
pcr
amplif
promoterattenu
region
e
coli
ampc
gene
perform
use
primer
amplicon
purifi
sequenc
direct
nine
e
coli
clinic
isol
fulli
suscept
amc
fox
also
analys
result
fiftyseven
reppcr
profil
observ
pcr
sequenc
analysi
ampc
promoterattenu
region
reveal
differ
variant
among
e
coli
isol
ampc
phenotyp
mutat
frequent
found
isol
locat
posit
result
new
displac
perfect
consensu
sequenc
mutat
alway
associ
mutat
posit
addit
mutat
delet
nucleotid
contain
dyad
symmetri
region
ampc
attenu
also
observ
three
strain
two
isol
present
mutat
isol
higher
level
resist
blactam
present
bp
delet
attenu
region
ampc
without
mutat
among
nine
fulli
suscept
isol
two
present
wildtyp
promoterattenu
region
conclus
clinic
isol
e
coli
ampc
hyperproduct
phenotyp
area
present
mutat
promoterattenu
region
ampc
gene
creat
strong
consensu
promot
box
consider
clonal
variabl
among
isol
contribut
acquir
ampctyp
blactamas
resist
phenotyp
seem
relev
evalu
ampc
disk
test
genet
detect
import
ampcgen
norwegian
clinic
strain
e
coli
background
conveni
phenotyp
test
detect
clinic
signific
ampcproduct
e
coli
import
diagnost
purpos
infect
control
ensur
effect
therapi
object
aim
evalu
edtabas
disk
test
detect
ampcproduct
examin
import
ampcgen
norwegian
clinic
strain
e
coli
ampcsuscept
profil
method
includ
clinic
strain
e
coli
collect
norwegian
laboratori
ampcsuscept
profil
resist
aminopenicillin
ampicillin
mic
mgl
oxyimino
cephalosporin
without
clavulan
acid
synergi
cefpodoxim
cefotaxim
ceftazidim
mic
mgl
cephamycin
cefoxitin
mgl
suscept
cefepim
carbapenem
blactam
suscept
test
perform
etest
extend
suscept
test
done
vitek
ii
strain
neg
blashv
blactxm
consensu
pcr
strain
examin
blactamas
product
ief
phenotyp
detect
ampcexpression
perform
recent
describ
disk
test
base
use
trisedta
permeabil
bacteri
cell
caus
extracellular
releas
blactamas
black
et
al
j
clin
microbiol
strain
examin
multiplex
pcr
cover
six
famili
ampcspecif
gene
acc
cit
dha
ebc
fox
mox
well
specif
cmypcr
control
strain
includ
ampcposit
strain
n
suscept
e
coli
atcc
refer
strain
n
clinic
strain
e
coli
n
suscept
oxyiminocephalosporin
mic
mgl
cefoxitin
mic
mgl
result
clinic
strain
ampcprofil
produc
blactamas
pi
correspond
pi
ampcblactamas
cmygen
detect
strain
import
ampc
gene
sequenc
type
reveal
total
clinic
strain
posit
ampcdisk
test
includ
ten
cmyposit
strain
ampcprofil
neg
control
strain
neg
ampc
disk
test
trend
toward
multiresist
phenotyp
ampcposit
e
coli
strain
conclus
edtabas
ampc
disk
test
potenti
use
conveni
test
detect
clinic
signific
ampcproduct
clinic
strain
e
coli
ii
plasmidmedi
ampcgen
cmytyp
detect
norwegian
clinic
strain
e
coli
detect
extendedspectrum
blactamas
enterobacteriacea
ampc
blactamas
type
induc
resist
object
esbl
product
enterobacteriacea
induc
ampc
chromosom
enzym
rare
detect
problemat
studi
preval
concurr
product
enzym
clinic
enterobacteriacea
strain
determin
three
phenotyp
confirmatori
method
also
compar
method
fiftyf
nonrepetit
clinic
strain
enterobact
spp
n
citrobact
freundii
n
morganella
morganii
n
providencia
stuartii
n
exhibit
induc
ampc
blactamas
type
resist
isol
urin
blood
pu
period
cefoxitin
resist
identif
speci
level
cefoxitincefotaxim
ctx
disk
antagon
test
use
screen
like
induc
ampc
produc
three
confirmatori
phenotyp
methodolog
address
detect
esbl
use
combin
disk
test
ctx
clavulan
acid
ca
ceftazidim
caz
ca
cefepim
cef
ca
b
doubledisk
test
ctxca
cazca
cefca
c
modifi
doubledisk
test
cefpiperacillin
tazobactam
tzp
ampc
product
confirm
threedimension
test
result
isol
test
found
esbl
nonproduc
two
strain
e
aerogen
e
cloaca
resist
cefotaxim
appear
coproduc
esbl
ampc
blactamas
enzym
combin
disk
test
cef
ca
doubledisk
test
cefca
modifi
doubledisk
test
ceftzp
capabl
detect
esbl
posit
strain
other
test
fail
confirm
concomit
esbl
product
conclus
enterobacteriacea
product
induc
ampcbeta
lactamas
mask
esbl
activ
make
detect
challeng
use
cefepim
instead
cefotaxim
ceftazidim
inhibitorbas
confirmatori
test
seem
prefer
institut
occurr
coproduct
extendedspectrum
induc
chromosom
ampc
betalactamas
select
isol
studi
low
justifi
routin
use
detect
method
procedur
carri
strain
isol
seriou
infect
survey
complex
resist
mechan
model
effect
copi
number
plasmid
carri
esbl
gene
resist
level
blactam
antibiot
object
variabl
resist
blactam
among
esblproduc
strain
wide
discuss
literatur
attribut
mani
factor
differ
substrat
prefer
esbl
effici
esbl
gene
promot
outer
membran
permeabl
host
strain
studi
extens
use
clinic
laboratori
strain
studi
aim
demonstr
effect
copi
number
plasmid
carri
esbl
gene
resist
level
blactam
isogen
e
coli
strain
method
gene
variant
clone
natur
promot
vector
contain
singl
copi
f
factor
origin
replic
high
copi
oriv
origin
replic
plasmid
introduc
e
coli
strain
maintain
singl
copi
number
per
cell
standard
growth
condit
multipl
copi
number
upon
induct
larabinos
mic
ampicillin
amp
ceftazidim
caz
cefotaxim
ctx
cefepim
fep
aztreonam
azt
determin
strain
carri
recombin
plasmid
vector
without
insert
use
broth
microdilut
method
recommend
nccl
except
lb
broth
without
arabinos
final
concentr
use
test
medium
plasmid
copi
number
determin
realtim
qpcr
plasmidspecif
primer
sybr
green
relat
total
number
viabl
cell
yield
plasmid
copi
number
per
cell
result
induct
arabinos
result
increas
copi
number
plasmid
copi
per
cell
shown
tabl
multipl
esblcod
plasmid
parallel
signific
increas
resist
host
strain
antibiot
includ
known
weak
substrat
particular
esbl
eg
caz
ctx
resist
level
oxyiminobetalactam
rais
mic
dilut
strain
mic
dilut
ctxm
produc
time
induct
arabinos
affect
mic
betalactamas
neg
strain
conclus
model
experi
strong
correl
esbl
gene
copi
number
mic
oxyiminobetalactam
demonstr
observ
rais
import
accur
detect
esblmedi
resist
clinic
isol
object
object
compar
genet
background
sporad
mrsa
isol
success
epidem
mrsa
clone
materi
method
strain
repres
nine
frequent
belgian
epidem
clone
sporad
strain
select
ulbstaphylococcu
refer
laboratori
collect
mrsa
isol
recov
patient
hospitalis
belgian
acutecar
hospit
base
puls
field
gel
electrophoresi
pfge
type
smai
macrorestrict
pfge
pattern
consid
sporad
differ
dna
fragment
pfge
pattern
entir
databas
strain
strain
characteris
multilocu
sequenc
type
mlst
spa
type
sccmec
type
sporad
isol
classifi
mlst
sequenc
type
st
one
belong
clonal
complex
epidem
clone
sccmec
type
distribut
among
sporad
strain
follow
type
isol
type
iv
type
iii
type
ii
v
isol
sccmec
type
iv
associ
greatest
number
differ
st
base
mlst
combin
sccmec
type
clonal
type
identifi
ident
major
belgian
epidem
clone
sporad
isol
belong
spa
type
share
epidem
strain
conclus
major
sporad
epidem
mrsa
strain
identifi
period
belgian
hospit
share
common
genet
background
although
half
sporad
mrsa
strain
belong
stsccmec
type
epidem
strain
suggest
resist
cassett
type
epigenet
marker
involv
confer
epidem
behaviour
mrsa
analysi
polymorph
within
midregion
insert
vacuol
cytotoxin
allel
helicobact
pylori
identifi
genotyp
marker
geograph
adapt
rj
owen
london
uk
presenc
absenc
insert
vacuol
cytotoxin
vaca
gene
encod
vaca
toxin
key
pathogen
factor
h
pylori
provid
basi
wide
use
scheme
genotyp
aim
present
studi
determin
divers
insert
sequenc
midregion
vaca
includ
toxin
subunit
code
region
cell
bind
domain
order
find
genotyp
marker
indic
geograph
adapt
method
midregion
sequenc
vaca
n
new
public
databas
countri
analys
dataset
includ
sequenc
famili
sequenc
determin
hous
standard
procedur
isol
laboratori
collect
comparison
multipl
align
implement
bioedit
result
region
insert
mri
highli
conserv
size
bp
constitut
region
base
composit
typic
gc
sequenc
divers
evid
align
refer
strain
allel
famili
total
amino
acid
variant
defin
one
differ
type
refer
commonest
type
present
respect
geograph
divers
isol
allel
famili
mri
insert
characterist
contain
sdngln
motif
except
insert
chines
strain
sequenc
uniqu
grngid
motif
conclus
result
indic
despit
conserv
predict
amino
acid
level
sequenc
vaca
midregion
insert
suffici
divers
provid
addit
genotyp
marker
strain
discrimin
within
allel
famili
indic
possibl
hostassoci
adapt
chines
subgroup
method
prospect
includ
belgian
brazilian
children
attend
public
hospit
februari
octob
inclus
criteria
clinic
suspicion
ga
infect
microbiolog
ga
isol
exclud
children
current
antimicrobi
treatment
predesign
clinic
form
fill
microbiolog
sampl
perform
child
ga
strain
identifi
standard
laboratori
method
clsi
store
ga
emmtyp
use
cdc
sequenc
method
result
ga
strain
brussel
n
n
isol
children
brussel
n
n
brussel
pharyng
common
ga
infect
cutan
infect
pharyng
evenli
associ
ga
isol
mean
age
children
ga
pharyng
brussel
much
lower
versu
month
p
emmtyp
reveal
strike
differ
brazilian
belgian
ga
strain
differ
emmtyp
identifi
among
belgian
strain
wherea
differ
emmtyp
found
among
brazilian
strain
moreov
belgian
strain
belong
classic
emmtyp
recov
children
develop
countri
brazilian
emmtyp
rare
yet
report
brazilian
strain
present
novel
emm
gene
addit
patholog
associ
brazilian
emmtyp
differ
usual
describ
develop
countri
conclus
studi
highlight
import
differ
develop
develop
countri
term
ga
clinic
molecular
epidemiolog
besid
mean
age
children
ga
pharyng
differ
clinic
distribut
observ
expect
unexpectedli
emmtyp
distribut
total
differ
oligoclon
brussel
polyclon
correl
patholog
emmtyp
might
less
stringent
previous
thought
vaccin
strategi
take
account
major
variat
object
c
difficil
isol
patient
aad
pmc
usual
produc
toxin
toxin
b
tcdatcdb
increas
number
report
mention
infect
due
toxin
aneg
c
difficil
tcdatcdb
strain
carri
binari
toxin
gene
cdta
cdtb
produc
toxin
b
tcdatcdbcdt
identifi
well
mani
molecular
type
method
use
investig
genet
relationship
describ
popul
structur
c
difficil
strain
belong
differ
toxin
type
isol
patient
aad
poland
japan
use
aflp
method
method
obtain
c
difficil
strain
polish
patient
six
japanes
isol
four
refer
strain
c
difficil
belong
differ
toxin
profil
type
includ
toxin
type
determin
commerci
test
toxin
cytotox
test
toxin
b
tcda
tcdb
binari
toxin
cdta
cdtb
detect
pcr
analysi
two
primer
combin
result
reliabl
marker
marker
use
input
treecon
softwar
result
phylogenet
tree
show
highli
distinct
group
seven
polish
c
difficil
strain
belong
tcdatcdbcdt
clearli
distinct
strain
strain
could
divid
sever
toxin
typespecif
subgroup
japanes
strain
includ
clonal
group
share
toxin
type
suggest
common
evolutionari
origin
among
polish
tcdatcdb
strain
strain
show
ident
aflp
profil
case
japanes
polish
aflp
pattern
ident
conclus
polish
japanes
c
difficil
differ
toxin
profil
cluster
aflp
deriv
phylogram
suggest
highli
clonal
dissemin
singl
event
toxin
b
gene
lost
simultan
appar
success
c
difficil
toxin
type
dissemin
worldwid
import
epidemiolog
popul
structur
consequ
acknowledg
work
support
ministri
scientif
research
inform
technolog
grant
collect
clinic
isol
tuberculosi
pulmonari
tuberculosi
patient
live
okinawa
collect
studi
spoligotyp
reverselinebas
hybridis
assay
allow
studi
genet
divers
directrepeat
locu
infraspeci
classif
tuberculosi
result
isol
avail
seventytwo
clinic
isol
belong
beij
type
predomin
clade
okinawa
clinic
isol
belong
previous
describ
eastafricanindian
eai
clade
total
cluster
isol
uniqu
spoligotyp
describ
comparison
latest
avail
internationalspoligotyp
databas
allow
detect
two
ident
one
similar
isol
studi
previou
studi
perform
okayama
osaka
therebi
character
spoligotypinginternationaltyp
repres
new
low
genet
famili
tuberculosi
baptis
osakatyp
famili
matsumoto
character
genotyp
independ
genotyp
method
vntrmirutyp
provid
classic
miru
allel
valu
respect
vntrmiru
intern
type
previous
detect
turkey
rais
interest
hypothesi
genet
link
two
bacteri
popul
clinic
isol
beij
type
discrimin
use
qub
queenuniversitybelfast
marker
set
four
epidemiologicallyinform
miru
marker
search
epidemiologicallylink
cluster
within
beij
group
strain
arkhangelsk
region
russia
gonorrhoea
incid
estim
case
per
inhabit
howev
mani
easteuropean
countri
reliabl
incid
figur
still
lack
mainli
due
suboptim
diagnost
incomplet
case
report
regard
antibiot
resist
molecular
epidemiolog
characterist
n
gonorrhoea
strain
circul
russia
thorough
knowledg
yet
publish
object
phenotyp
genet
character
clinic
n
gonorrhoea
isol
arkhangelsk
russia
order
describ
n
gonorrhoea
popul
transmit
arkhangelsk
compar
characterist
n
gonorrhoea
popul
westeuropean
countri
materi
method
n
gonorrhoea
isol
n
cultur
junenovemb
mainli
consecut
patient
arkhangelsk
russia
includ
isol
character
use
antibiogram
see
present
vorobieva
et
al
serovar
determin
sequenc
entir
porb
gene
n
gonorrhoea
multiantigen
sequenc
type
ngmast
phylogenet
tree
construct
treecon
use
neighbourjoin
method
result
n
gonorrhoea
isol
assign
serovar
n
n
n
n
n
n
n
n
n
n
n
n
complet
result
correl
antibiot
suscept
test
porb
gene
sequenc
ngmast
includ
present
conclus
accord
previou
studi
diagnosi
n
gonorrhoea
need
optimis
qualiti
assur
sever
easteuropean
countri
furthermor
thorough
knowledg
gonorrhoea
incid
antibiot
resist
genet
characterist
n
gonorrhoea
strain
circul
easteuropean
countri
crucial
discrimin
e
coli
isol
use
pcrmediat
fingerprint
base
ser
element
g
kardo
antal
th
kiss
b
nagi
debrecen
budapest
hu
object
due
close
relationship
e
coli
strain
far
pulsedfield
gel
electrophoresi
pfge
found
method
suffici
discriminatori
power
pfge
timeconsum
suit
handl
high
sampl
number
need
fast
highthroughput
pcrbase
method
use
salmonella
enteritidi
repetit
element
sere
base
pcr
approach
type
hungarian
bovin
e
coli
isol
epec
ehec
stec
toxin
intimin
neg
strain
differ
herd
also
examin
rabbit
porcin
epec
isol
furthermor
includ
porcin
etec
strain
isol
hungari
austria
well
human
ehec
strain
isol
differ
countri
epidemiolog
independ
control
sere
result
compar
pfge
method
serepcr
use
primer
anneal
describ
earlier
alam
et
al
j
clin
microbiol
pfge
separ
fragment
perform
chef
driii
apparatu
vcm
h
ramp
switch
time
pattern
analys
use
fingerprint
ii
softwar
result
method
found
epidemiolog
independ
strain
unrel
pfge
reveal
presenc
four
cluster
unrel
isol
first
three
includ
exclus
bovin
isol
cluster
consist
epec
isol
cluster
includ
six
ehec
isol
stec
isol
cluster
compris
four
milkderiv
isol
herd
cluster
compris
three
rabbit
isol
serepcr
show
unrel
isol
three
cluster
cluster
includ
eight
bovin
strain
herd
contain
cluster
cluster
ident
cluster
rabbitderiv
strain
cluster
consist
bovin
cluster
also
includ
sever
bovin
isol
found
unrel
pfge
interestingli
sere
cluster
contain
eight
eleven
isol
herd
pfge
assign
four
cluster
find
four
independ
cluster
suggest
serepcr
may
less
sensit
microevolutionari
chang
conclus
serepcr
prove
use
altern
pfge
though
found
slightli
less
discriminatori
thu
serepcr
may
fulfil
need
pcrbase
type
e
coli
acknowledg
work
partial
support
nkfp
grant
object
mycobacterium
haemophilum
previous
rare
recogn
pathogen
netherland
howev
applic
specif
cultur
method
realtim
pcr
method
speci
identifi
involv
pathogen
sever
diseas
like
skin
inflamm
lymphaden
arthritisin
sudden
increas
patient
cervicofaci
lymphaden
caus
haemophilum
observ
amsterdam
region
part
epidemiolog
studi
investig
possibl
common
sourc
infect
genet
divers
strain
investig
compar
unrel
strain
method
total
haemophilum
isol
collect
european
strain
amsterdam
region
strain
differ
contin
among
australian
strain
usa
strain
genom
comparison
carri
amplifi
fragment
length
polymorph
aflp
methodolog
detect
intraspeci
variat
dna
extract
use
ultraclean
microbi
dna
kit
enzym
combin
ecori
msei
select
prime
use
obtain
high
discriminatori
power
result
analys
dice
calcul
result
aflp
method
enabl
differenti
haemophilum
close
relat
speci
well
strain
differenti
within
speci
gener
strain
belong
certain
contin
show
specif
aflp
pattern
australian
strain
repres
separ
cluster
encompass
strain
among
strain
usa
new
york
area
within
strain
aflp
discrimin
type
includ
larg
cluster
strain
differ
observ
aflp
pattern
amsterdam
strain
genet
divers
present
european
haemophilum
strain
conclus
haemophilum
seem
highli
conserv
speci
geograph
distanc
appear
correl
genet
divers
applic
aflp
demonstr
cluster
children
haemophilum
lymphaden
region
around
amsterdam
object
clostridium
difficil
common
agent
nosocomi
diarrhoea
aim
studi
character
clinic
strain
c
difficil
isol
hospit
period
toxinotyp
binari
toxin
gene
detect
method
tradit
method
includ
direct
detect
toxin
stool
sampl
use
immunolog
kit
c
difficil
toxin
test
anaerob
cultur
cycloserinecefoxitinfructos
agar
incub
day
c
difficil
strain
test
toxin
product
immunolog
method
toxinotyp
perform
describ
rupnik
et
al
fragment
binari
toxin
gene
detect
done
pcr
use
cdtb
po
cdtb
rev
primer
result
total
c
difficil
strain
collect
patient
januari
june
detect
toxin
posit
isol
stool
specimen
among
strain
toxinotyp
reveal
strain
phenotyp
ab
ab
ab
strain
ab
mainli
belong
toxinotyp
n
total
strain
identifi
variant
toxinotyp
iii
iv
v
vi
ix
xii
xxi
xxii
product
toxin
could
detect
commerci
kit
strain
toxinotyp
n
v
n
xxi
n
among
strain
ab
isol
nontoxigen
toxinotyp
xib
isol
ab
belong
toxinotyp
viii
n
x
n
detect
binari
toxin
gene
posit
strain
group
variant
toxinotyp
iii
iv
v
vi
ix
x
xxii
ident
toxinotyp
observ
patient
success
c
difficil
isol
wherea
differ
toxinotyp
found
remain
patient
conclus
data
confirm
tradit
method
less
effect
molecular
method
detect
c
difficil
toxin
total
toxinotyp
identifi
among
c
difficil
strain
high
preval
toxinotyp
previous
observ
variant
toxinotyp
detect
comparison
previou
european
studi
found
virul
ab
c
difficil
strain
rel
high
level
strain
binari
toxin
gene
observ
comparison
asian
data
french
data
toxinotyp
show
relaps
occur
case
reinfect
case
object
type
streptococcu
pneumonia
strain
isol
invas
infect
children
year
hungari
molecular
techniqu
establish
genet
mechan
erythromycin
resist
analys
relat
data
serotyp
antibiot
resist
profil
isol
determin
earlier
method
isol
countri
test
pulsedfield
gel
electrophoresispfg
strain
analys
multi
locu
sequenc
typingmlst
erythromycin
resist
isol
test
presenc
mef
erm
gene
pcr
result
isol
strain
belong
genet
relat
england
clone
respect
isol
carri
serotyp
capsul
altogeth
isol
belong
serotyp
show
resist
erythromycin
genet
mechan
erythromycin
resist
prove
characterist
two
group
england
strain
harbour
mef
gene
erythromycin
resist
isol
strain
erm
b
gene
could
demonstr
two
intern
clone
contribut
substanti
high
rate
erythromycin
resist
strain
two
serogroup
strain
belong
st
anoth
five
strain
prove
resist
erythromycin
carri
erm
b
gene
pneumonia
strain
st
type
characterist
hungari
also
detect
serotyp
strain
show
close
genet
related
pfge
one
isol
test
mlst
belong
novel
sequenc
type
howev
close
link
report
earlier
hungari
isol
retain
suscept
eryrthromycin
one
serogroup
strain
belong
anoth
st
characterist
hungari
strain
prove
sole
isol
show
high
level
resist
penicillin
conclus
pneumonia
strain
caus
invas
infect
children
belong
intern
local
clone
hungari
contribut
individu
clone
serotyp
high
rate
genet
mechan
erythromycin
resist
divers
vaccin
could
substanti
reduc
incid
infect
rate
macrolid
resist
acknowledg
studi
support
wyeth
preval
type
adenovirus
stool
iranian
children
acut
diarrhoea
compar
studi
molecular
serolog
assay
object
enter
adenoviru
ead
second
frequent
detect
viral
agent
childhood
diarrhoea
howev
due
emerg
new
variant
limit
detect
assay
diseas
burden
viru
well
defin
adenovirus
classifi
serotyp
within
subgenera
af
type
associ
sever
acut
diarrhoea
type
suppos
import
contribut
infantil
gastroenter
present
studi
applic
serolog
pcrbase
method
provid
data
compar
studi
determin
preval
ead
type
associ
diarrhoea
iranian
children
method
stool
sampl
iranian
children
less
year
old
acut
diarrhoea
collect
period
year
specimen
examin
adenolex
orion
diagnostica
finland
base
latex
agglutin
detect
ead
faec
genom
dna
extract
stool
nucleospinr
mnfranc
pcrrflp
method
base
amplif
conserv
region
hexon
gene
degener
primer
exploit
identif
type
ead
specimen
allard
et
al
result
could
screen
posit
sampl
pcr
base
method
rate
adenolex
assay
moreov
adenolex
detect
type
ead
pcrbase
assay
could
identifi
sampl
also
applic
pcr
method
ead
detect
one
stool
sampl
respect
could
also
identifi
specimen
belong
genu
c
one
genu
e
seven
posit
sampl
process
type
conclus
preval
rate
ead
iranian
children
acut
diarrhoea
might
higher
previous
report
data
base
applic
commerci
serolog
assay
reason
behind
differ
may
new
emerg
type
mutant
ead
differ
geograph
region
inabl
commerci
assay
detect
serotyp
final
despit
gener
anticip
type
consid
caus
childhood
gastroenter
result
indic
type
frequent
found
ead
iranian
children
acut
diarrhoea
object
trichoderma
spp
known
cosmopolitan
soil
inhabit
filament
fungi
certain
member
genu
emerg
caus
agent
opportunist
infect
human
present
discriminatori
power
differ
phenet
phylogenet
approach
appli
taxonom
character
clinic
trichoderma
isol
method
twelv
clinic
trichoderma
isol
involv
experi
molecular
phylogenet
analysi
perform
sequenc
intern
transcrib
spacer
region
rdna
cluster
larg
intron
gene
encod
translat
elong
factor
rflp
pattern
mtdna
gener
bsuri
phenotyp
profil
examin
isoenzym
analysi
enzym
system
celluloseacet
electrophoresi
cae
carbon
sourc
util
array
perform
biolog
ff
micropl
result
base
morpholog
charact
clinic
trichoderma
isol
origin
identifi
member
speci
section
longibrachiatum
longibrachiatum
pseudokoningii
citrinovirid
speci
section
trichoderma
virid
koningii
howev
barcod
identif
trichokey
wwwisthinfo
reveal
belong
triplet
speci
longibrachiatumhypocrea
orientali
h
cerebriformi
phylogenet
analysi
sequenc
show
strain
belong
clade
longibrachiatum
one
attribut
h
orientali
examin
nonclin
isol
indic
marker
clearli
separ
two
speci
rflp
mtdna
reveal
differ
pattern
bsuri
respect
result
group
dendrogram
cae
separ
strain
distinct
electrophoret
type
biolog
phenotyp
microarray
perform
clinic
seri
nonclin
isol
sever
close
relat
speci
comparison
done
time
point
temperatur
order
detect
possibl
physiolog
shift
specif
clinic
isol
conclus
result
support
fungal
opportunist
belong
genu
trichoderma
restrict
almost
exclus
section
longibrachiatum
besid
sequenc
analysi
method
cae
mtdna
rflp
biolog
phenotyp
microarray
prove
also
appropri
character
clinic
trichoderma
strain
object
seqnetorg
initi
current
laboratori
european
countri
order
establish
european
network
excel
sequenc
base
type
microbi
pathogen
principl
goal
seqnetorg
establish
unambigu
electron
portabl
easili
compar
type
data
local
infect
control
nation
european
surveil
sentinel
microorgan
describ
harmon
sequenc
method
sequenc
base
type
ii
capac
build
dna
sequenc
diagnost
microbiolog
iii
certif
trail
sequencebas
type
mrsa
method
kickoff
meet
nster
germani
novemb
particip
receiv
protocol
type
mrsa
staphylococcu
aureu
protein
gene
spa
type
subsequ
five
strain
dna
forward
revers
chromatogram
file
repres
well
character
mrsa
strain
distribut
particip
laboratori
type
end
type
result
analys
synchron
central
server
use
ridom
staphtyp
softwar
result
particip
european
laboratori
built
capac
sequencebas
type
establish
spa
type
method
type
mrsa
laboratori
today
type
result
certif
trial
submit
particip
laboratori
laboratori
determin
bp
rang
bp
per
strain
particip
report
exactli
spa
type
analys
isol
addit
chromatogram
therefor
intraand
interlaboratori
reproduc
sequenc
result
onlin
synchron
result
prove
rapid
exchang
high
qualiti
type
data
base
nucleotid
sequenc
conclus
seqnetorg
initi
enabl
laboratori
europeanwid
build
capac
sequencebas
method
spa
type
result
prove
unambigu
highli
reproduc
natur
high
portabl
sequenc
data
usag
standard
nomenclatur
base
softwar
enabl
easi
exchang
data
enterovirus
associ
wide
varieti
diseas
human
respons
summer
outbreak
acut
mening
children
adult
last
larg
mening
outbreak
enterovirus
continu
isol
april
viru
alert
french
health
ministri
declar
june
increas
number
occur
mening
case
object
genet
type
enterovirus
sequenc
specif
pcrbase
amplifi
portion
genom
encod
sequenc
follow
phylogenet
analysi
identifi
virus
isol
patient
hospitalis
year
method
virus
isol
patient
hospitalis
clermontferrand
n
pital
trousseau
n
recov
patient
mening
posit
rtpcr
cerebrospin
fluid
specimen
n
patient
cardiac
manifest
n
sudden
infant
death
syndrom
n
neonat
infect
n
handfootandmouth
diseas
n
pharyng
n
genet
type
method
reli
pcr
amplif
sequenc
complet
sequenc
design
three
set
speci
specif
primer
viru
identif
done
sequenc
comparison
blast
search
enteroviru
sequenc
genbank
confirm
phylogenet
analysi
sequenc
enteroviru
prototyp
strain
result
viru
isol
identifi
patient
one
set
primer
virus
assign
differ
type
within
human
enteroviru
b
speci
blast
search
phylogenet
analysi
confirm
identif
case
patient
mening
n
echoviru
involv
case
type
n
n
coxsackieviru
n
n
n
n
patient
symptom
type
observ
n
associ
cardiac
manifest
symptom
among
patient
infect
four
differ
viru
variant
evidenc
phylogenet
analysi
conclus
genet
type
allow
prospect
identif
isol
effect
rapidli
seroneutr
test
use
outbreak
clermontferrand
persist
major
type
involv
mening
despit
cocircul
enterovirus
outbreak
object
brucellosi
one
import
widespread
zoonot
diseas
therefor
rapid
unambigu
assay
detect
brucella
speci
essenti
describ
novel
snp
base
assay
speciat
brucella
isol
six
classic
recognis
speci
previous
molecular
approach
speciat
hamper
homogen
genu
made
identif
speciesspecif
marker
difficult
snp
assay
describ
develop
overcom
problem
present
genet
homogen
well
mitig
need
classic
cultur
base
biotyp
labori
time
consum
method
sever
housekeep
gene
sequenc
larg
number
brucella
isol
sequenc
data
analys
number
stabl
singl
nucleotid
polymorph
snp
identifi
appear
unambigu
defin
six
classic
recognis
member
genu
brucella
use
primer
extens
approach
snp
detect
singletub
multiplex
assay
develop
incorpor
six
snp
interrog
primer
result
date
cultur
confirm
isol
correctli
identifi
use
assay
includ
isol
human
blood
cultur
encompass
pathogen
speci
b
melitensi
b
sui
b
abortu
snp
multiplex
assay
use
rapidli
clearli
differenti
six
brucella
speci
conclus
comparison
current
molecular
base
assay
approach
encompass
identifi
member
current
recognis
biovar
within
brucella
speci
futur
object
involv
inclus
addit
snp
facilit
higher
resolut
beyond
speci
level
object
current
multi
locu
sequenc
type
mlst
method
offer
autom
fast
accur
workflow
determin
allel
profil
sequenc
type
bacteria
microorgan
current
manual
workflow
take
research
hour
analysi
time
alon
determin
allel
profil
one
bacteri
sampl
new
workflow
show
exampl
aureu
type
significantli
reduc
analysi
time
method
follow
seven
housekeep
gene
use
mlst
experi
carbam
kinas
arcc
shikim
dehydrogenas
aro
glycerol
kinas
glpf
guanyl
kinas
gmk
phosphat
acetyltransferas
pta
triosephosph
isomeras
tpi
acetyl
coenzym
acetyltransferas
yqil
specifi
mlst
web
site
wwwmlstnet
gene
amplifi
use
two
set
primer
one
set
primer
deriv
mlst
websit
second
set
mlst
primer
tail
forward
revers
primer
sampl
sequenc
use
appli
biosystem
seri
genet
analyz
termin
cycl
sequenc
kit
autom
data
analysi
librari
match
softwar
result
experi
accur
determin
sequenc
type
eight
unknown
sampl
provid
langvik
sampl
use
epidemiolog
studi
use
mlst
primer
instead
mlst
primer
sequenc
reaction
gave
uniform
result
significantli
streamlin
sequenc
workflow
furthermor
autom
analysi
data
collect
softwar
significantli
reduc
time
analys
type
allel
sampl
sever
aureu
strain
minim
sequenc
check
sequenc
type
bacteri
sampl
obtain
minut
less
conclus
sequenc
type
eight
unknown
aureu
sampl
correctli
determin
use
seqscap
softwar
amount
time
analys
sampl
fast
accur
elimin
labori
manual
sequenc
check
trim
align
allel
type
workflow
help
enabl
research
accur
determin
sequenc
type
quickli
pathogen
bacteria
organ
use
isoschizom
smai
xmai
gener
common
pfge
pattern
databas
mefneg
mefposit
pyogen
isol
object
pfge
choic
method
pyogen
subtyp
follow
mserotyp
sequencebas
successor
emmtyp
howev
observ
routin
use
restrict
endonucleas
smai
digest
erythromycinresist
strain
phenotyp
harbour
mef
gene
assum
could
due
inhibit
smai
activ
dna
cpg
methyl
recognit
site
investig
possibl
use
methylationinsensit
recognit
site
aim
doubl
obtain
pfge
pattern
mefposit
mef
isol
also
includ
pyogen
pfge
pattern
common
databas
molecular
epidemiolog
method
five
mef
isol
belong
emmtyp
eight
mefneg
mef
isol
belong
emmtyp
type
pfge
smai
fermenta
xmai
new
england
biolab
digest
total
dna
isoschizom
recognis
sequenc
smai
cut
third
cytosin
methyl
target
xmai
cut
first
result
although
smai
digest
dna
mefisol
xmai
digest
isol
dna
xmai
smai
pattern
mefisol
indistinguish
whilst
gener
isol
profil
cluster
accord
serotyp
mef
isol
cluster
group
conclus
shown
mefencod
lysogen
phage
also
encod
dna
cpg
methylas
euler
c
et
al
xvith
lancefield
intern
symposium
streptococci
streptococc
diseas
abstract
achiev
pfge
type
pyogen
isol
incorpor
profil
singl
databas
molecular
surveil
therefor
recommend
digest
mef
isol
xmai
expens
isoschizom
smai
smai
continu
use
mefisol
object
psittacosi
diseas
caus
infect
chlamydophila
psittaci
oblig
intracellular
bacterium
zoonot
infect
sinc
bird
main
reservoir
c
psittaci
c
psittaci
divid
serovar
af
wc
least
genotyp
genotyp
less
associ
specif
bird
group
predominantli
isol
genotyp
c
psittaci
pcr
posit
human
clinic
sampl
avail
laboratori
ompa
sequenc
distribut
genotyp
c
psittaci
caus
zoonot
infect
unknown
method
genotyp
c
psittaci
ten
human
clinic
sampl
determin
ompa
sequenc
gene
amplifi
primer
locat
conserv
region
ompa
enclos
four
variabl
domain
amplif
pcr
product
analyz
agaros
gel
electrophoresi
expect
fragment
neg
control
sampl
extract
gel
reamplifi
cycl
subsequ
overlap
sequenc
obtain
six
sequenc
primer
result
sequenc
align
similar
index
base
translat
bp
fragment
calcul
similar
calcul
use
pairwis
distanc
method
gener
refer
ompa
genotyp
af
c
psittaci
type
strain
avail
genbank
databas
includ
analysi
result
five
isol
ident
refer
genotyp
three
isol
ident
genotyp
b
one
isol
ident
genotyp
c
discov
one
new
genotyp
similar
genotyp
refer
even
similar
c
psittaci
type
strain
conclus
studi
ompa
sequenc
c
psittaci
identifi
genotyp
b
c
one
new
ompa
genotyp
human
psittacosi
case
new
discov
c
psittaci
ompa
variant
relat
c
psittaci
type
strain
genotyp
mainli
found
psittacin
bird
preval
genotyp
clinic
sampl
four
isol
genotyp
b
c
genotyp
b
c
predominantli
isol
european
nonpsittacin
bird
among
pigeon
b
duck
c
high
preval
genotyp
human
clinic
sampl
indic
nonpsittacin
bird
particular
pigeon
duck
consid
substanti
part
zoonot
reservoir
human
psittacosi
case
compar
studi
escherichia
coli
strain
isol
intestin
mucosa
crohn
diseas
patient
healthi
subject
object
analys
compar
e
coli
strain
present
cd
patient
healthi
controlsto
identifi
characteris
pathogen
strain
method
use
fresh
biopsi
subject
mild
sonic
order
discard
transient
loos
attach
bacteria
follow
mild
osmot
shock
releas
intracellular
bacteria
outer
epithelium
cell
isol
procedur
consist
incub
sampl
tbx
agar
medium
coloni
kept
first
confirm
screen
e
coli
indol
assay
type
isol
perform
reppcr
use
primer
set
target
describ
previous
clonal
check
pfge
result
total
presumpt
e
coli
cd
patient
healthi
control
patient
suffer
ulcer
coliti
isol
sever
subtyp
e
coli
found
specimen
screen
person
carri
uniqu
set
e
coli
subtyp
differ
other
e
coli
isol
transient
microbiota
differ
attach
counterpart
addit
applic
osmot
shock
addit
type
found
sampl
although
studi
sampl
underway
preliminari
result
suggest
cd
patient
harbour
higher
subtyp
number
healthi
subject
conclus
number
divers
e
coli
attach
intestin
mucosa
cd
patient
congruent
recent
hypothesi
implic
bacterium
pathogenesi
crohn
diseas
object
epidemiolog
featur
shigellosi
well
understood
sensit
molecular
type
method
appli
iranian
popul
organ
aim
studi
determin
drug
resist
pattern
sonnei
isol
well
character
genet
relationship
random
amplifi
polymorph
dna
rapdpcr
ribotyp
method
studi
conduct
patient
acut
diarrhoea
visit
tehran
hospit
oct
feb
eightysix
sonnei
isol
sporad
case
shigellosi
slide
agglutin
test
use
serotyp
isol
standard
antisera
mast
group
ltd
isol
screen
suscept
differ
antibiot
kirbybau
method
isol
subtyp
ribotyp
accord
standard
method
coimbra
et
al
isol
subject
rapdpcr
use
primer
yumi
bando
et
result
accord
result
percentag
multidrug
resist
isol
higher
comparison
previou
report
iran
resist
rate
tetracyclin
trimetoprimsulphametaxazol
ampicilin
respect
figur
previou
studi
tetracyclin
trimetoprimsulphametaxazol
respect
isol
suscept
ciprofloxacin
nalidix
acid
endonucleas
muli
best
enzym
differenti
isol
ribotyp
produc
dna
pattern
high
resolut
isol
group
differ
pattern
ribotyp
rapd
analysi
highest
discriminatori
power
type
sonnei
primer
analysi
isol
primer
yield
differ
pattern
isol
within
genet
pattern
belong
specif
drug
resist
pattern
conclus
rapd
analysi
show
higher
discriminatori
power
type
sonnei
isol
ribotyp
suitabl
tool
clinic
practic
could
use
complement
tradit
method
ribotyp
techniqu
use
reproduc
method
subtyp
sonnei
epidemiolog
phylogenet
studi
shigellosi
result
reveal
multiresist
strain
sonnei
highli
preval
iran
emphas
import
maintain
surveil
strain
order
ass
local
suscept
pattern
empir
therapi
object
stenotrophomona
maltophilia
opportunist
pathogen
ubiquit
natur
genet
divers
restrict
fragment
length
polymorph
rflp
analysi
polymeras
chain
reactionamplifi
gyrb
gene
previous
shown
identifi
broad
genom
group
within
speci
aim
studi
evalu
method
use
type
collect
clinic
environment
maltophilia
isol
determin
whether
particular
gyrb
rflptype
domin
hospit
set
like
caus
infect
use
gyrb
rflp
analysi
type
clinic
maltophilia
isol
two
western
australian
hospit
environment
maltophilia
isol
hospit
ward
unrel
site
nonhospit
result
isol
typabl
method
fifteen
genom
group
identifi
similar
level
isol
identifi
singl
gyrb
rflptype
second
common
type
includ
isol
test
maltophilia
type
strain
atcc
environment
isol
nonhospit
site
divers
isol
hospit
site
may
indic
select
certain
gyrb
rflptype
hospit
set
two
gyrb
rflptype
found
exclus
hospit
environment
sampl
clinic
specimen
type
may
involv
nosocomi
infect
second
common
gyrb
rflptype
clinic
isol
also
common
environment
sampl
intens
care
unit
environment
sampl
addit
four
gyrb
rflptype
found
clinic
specimen
five
gyrb
rflptype
may
like
caus
infect
three
type
found
environment
sampl
conclus
type
system
maltophilia
gyrb
rflp
analysi
show
excel
typabl
reproduc
rapid
easi
perform
easi
interpret
rel
low
discriminatori
power
mean
broad
genom
group
identifi
characterist
group
investig
studi
gyrb
rflp
analysi
reveal
distinct
differ
gyrb
rflptype
present
hospit
nonhospit
set
clinic
specimen
object
mycobacterium
kansasii
opportunist
pathogen
human
diseas
aim
studi
analys
clinic
isol
kansasii
isol
taiwan
pulsefield
gel
electrophoresi
pfge
restrict
enzym
asei
compar
result
europ
japan
unit
state
method
august
januari
total
clinic
isol
kansasii
patient
collect
clinic
microbiolog
laboratori
chang
gung
memori
hospit
tertiari
referr
medic
centr
taoyuan
taiwan
control
strain
atcc
obtain
american
type
cultur
collect
atcc
clinic
isol
analys
pcr
restrict
enzym
analysi
pra
telenti
fragment
gene
pfge
genom
dna
restrict
endonucleas
asei
isol
consid
clonal
exhibit
six
less
band
differ
defin
tenov
et
al
outbreak
strain
gene
profil
program
scanalyt
inc
va
usa
calcul
similar
index
set
fragment
length
error
toler
dna
differ
result
asei
clinic
isol
typabl
separ
cluster
genotyp
isol
gener
one
major
cluster
includ
similar
genotyp
pattern
figur
genet
relat
accord
definit
describ
tenov
et
al
major
clone
indistinguish
major
pattern
seen
studi
europ
japan
unit
state
conclus
studi
demonstr
one
major
clone
kansasii
present
taiwan
indistinguish
pattern
compar
studi
europ
japan
unit
state
major
genotyp
spread
worldwid
potenti
pathogen
bacteri
pathogenesi
object
metallobetalactamas
mbl
emerg
resist
determin
gramneg
nosocomi
pathogen
includ
pseudomona
aeruginosa
known
colimycin
colistin
old
polymyxin
deriv
activ
vitro
panresist
p
aeruginosa
strain
work
present
outbreak
due
colistin
carbapenem
resist
p
aeruginosa
intens
care
unit
icu
greek
tertiari
hospit
method
six
multiresist
p
aeruginosa
isol
recov
four
patient
twoweek
period
septemb
octob
icu
sourc
specimen
blood
cultur
bronchial
secret
pleural
fluid
pu
iv
cathet
commerci
id
panel
identifi
strain
suscept
broad
panel
antimicrobi
agent
determin
broth
microdilut
method
accord
clsi
guidelin
etest
also
determin
resist
colistin
carbapenem
isol
investig
presenc
allel
pcr
class
integron
detect
molecularli
character
sequenc
result
isol
found
resist
follow
antimicrobi
agent
test
aminoglycosid
amikacin
gentamicin
tobramycin
netilmicin
piperacillin
piperacillin
tazobactam
ticarcillin
ticarcillinclavoulan
carbapenem
imipenem
meropenem
quinolon
ciprofloxacin
ofloxacin
pefloxacin
moxifloxacin
trimethoprimsulfa
colistin
three
isol
found
suscept
aztreonam
mic
aztreonam
mcgml
gene
detect
strain
class
integron
found
strain
sequenc
analysi
reveal
presenc
antibiot
resist
gene
apart
allel
conclus
rare
report
nosocomi
outbreak
caus
colistin
resist
p
aeruginosa
produc
mbl
resist
colistin
correl
increas
use
colistin
last
year
icu
due
preval
mbl
mediat
carbapenem
resist
p
aeruginosa
icu
patient
isol
harbour
class
integron
mean
rapid
spread
resist
gene
nosocomi
environ
control
measur
hand
hygien
restrict
colistin
use
result
disappear
colistin
resist
p
aeruginosa
isol
introduct
pseudomona
aeruginosa
ubiquit
bacteria
preval
natur
microorgan
opportunist
pathogen
p
aeruginosa
often
report
caus
outbreak
nosocomi
infect
hospit
unit
p
aeruginosa
strain
exhibit
high
rate
resist
antibiot
frequent
multidrugresist
object
aim
paper
epidemiolog
investig
group
twenti
p
aeruginosa
strain
isol
patient
treat
intens
care
unit
icu
materi
method
twenti
p
aeruginosa
strain
isol
respiratori
track
wound
urin
eleven
deriv
three
patient
six
came
patient
two
three
isol
differ
time
hospitalis
isol
identifi
atb
system
biomerieux
use
id
gn
strip
antibiot
suscept
perform
use
diskdiffus
method
rapdpcr
analysi
investig
strain
carri
primer
result
examin
rapd
fingerprint
use
primer
group
six
strain
isol
patient
reveal
differ
genotyp
despit
fact
present
differ
phenotyp
antibiot
suscept
wherea
primer
reveal
two
cluster
genotyp
rapd
analysi
two
strain
obtain
patient
use
two
primer
enabl
character
strain
nondistinguish
genotyp
genotyp
strain
patient
use
primer
show
differ
isol
wherea
primer
confirm
occurr
two
cluster
genotyp
group
nine
p
aeruginosa
strain
isol
differ
patient
analysi
fingerprint
display
seven
cluster
genotyp
one
includ
three
isol
differ
patient
show
six
uniqu
pattern
one
includ
two
strain
second
genotyp
includ
three
p
aeruginosa
strain
isol
acquir
differ
patient
strain
number
isol
remain
patient
nondistinguish
use
primer
conclus
current
studi
indic
high
degre
genet
divers
among
p
aeruginosa
strain
isol
patient
icu
investig
confirm
among
patient
subject
longer
treatment
stay
icu
lack
chang
genotyp
comparison
phenotyp
connect
antibiot
suscept
increas
incid
serogroup
c
invas
meningococc
diseas
itali
rise
decreas
suscept
penicillin
p
mastrantonio
c
fazio
neri
sofia
p
stefanelli
rome
object
monitor
rapid
increas
proport
serogroup
c
strain
circul
itali
rise
decreas
suscept
penicillin
mic
mcgml
see
whether
link
circul
specif
phenotyp
method
strain
serotyp
specif
antisera
suscept
penicillin
perform
etest
realtim
pcr
protocol
also
appli
discrimin
penicillin
suscept
intermedi
strain
sequenc
analysi
pena
gene
perform
monitor
mosaic
mlst
follow
methodolog
describ
maiden
et
al
http
neisseriaorgnmtypingmlst
perform
assess
lineag
complex
isol
belong
object
studi
investig
use
cultureindepend
pcr
subsequ
dna
sequenc
establish
aetiolog
infect
endocard
ie
surgic
remov
valv
method
cardiac
valv
patient
undergo
valvular
replac
due
clinic
necess
examin
cultur
pcrdna
sequenc
valv
ten
patient
without
suspicion
ie
control
patient
ie
patient
includ
valv
divid
one
part
cultur
use
standard
method
subject
pcr
target
part
bacteri
rrna
gene
dna
sequenc
determin
product
result
pcr
bacteri
ident
establish
use
blast
search
ncbi
databas
result
result
cultur
pcr
dna
sequenc
shown
tabl
bacteri
dna
identifi
valv
nine
patient
speci
identifi
repres
typic
endocard
bacteria
eight
patient
six
dna
base
identif
accord
previou
blood
isol
patient
dna
propionibacterium
acn
detect
two
ten
control
may
repres
contamin
conclus
detect
identif
bacteri
dna
seem
promis
method
establish
aetiolog
ie
studi
requir
final
valid
object
amplif
dna
bacteri
fungal
pathogen
increasingli
use
microbiolog
diagnosi
infect
endocard
ie
molecular
techniqu
mostli
base
pcr
amplif
demonstr
use
achiev
precis
rapid
identif
infecti
aetiolog
endocard
episod
appli
heart
valv
tissu
sampl
aim
studi
determin
common
bacteri
pathogen
caus
ie
endocard
hospit
method
dna
isol
homogenis
heart
valv
tissu
sampl
fiftynin
ie
patient
suspect
ie
collect
year
undergo
valv
replac
surgeri
broadrang
rrna
pcr
techniqu
follow
sequenc
sequenc
similar
analysi
use
result
pcr
result
demonstr
presenc
bacteri
dna
heart
valv
obtain
patient
suspect
ie
largest
portion
ie
case
repres
two
bacteri
group
streptococci
case
staphylococci
case
frequent
pathogen
identifi
staphylococcu
aureu
case
rest
case
caus
less
common
bacteri
pathogen
like
corynebacterium
diptheria
abiotrophia
elegan
actinobacillu
actinomycetemcomitan
bartonella
sp
caus
microorgan
one
patient
definit
cultur
neg
endocard
identifi
rare
report
aerococcu
urina
conclus
pcrbase
molecular
detect
pathogen
valv
sampl
surgic
treat
ie
patient
fast
sensit
reliabl
technolog
along
thorough
valid
clinic
interpret
promis
tool
routin
test
ie
background
tick
ixod
ricinu
involv
transmiss
mainten
wide
varieti
pathogen
speci
borrelia
ehrlichiaanaplasma
babesia
infect
initi
inocul
bacterium
skin
tick
bite
lyme
borreliosi
promin
human
infecti
diseas
ehrlichiaanaplasma
babesia
also
regard
human
pathogen
object
purpos
present
studi
determin
preval
borrelia
ehrlichia
babesia
ricinu
tick
molecular
genet
method
method
tick
collect
west
north
east
south
region
lithuania
wl
nl
el
sl
detect
b
burgdorferi
sl
infect
tick
adult
nymph
analys
individu
pcr
fla
gene
specif
primer
borrelia
genotyp
use
multiplex
pcr
genospeciesspecif
primer
b
burgdorferi
ss
b
garinii
b
afzelii
presenc
ehrlichiaanaplasma
group
determin
use
pcr
specif
primer
posit
sampl
reamplifi
biotinyl
ehrlichiaanaplasma
pcr
product
hybridis
differ
oligonucleotid
probe
revers
line
blot
assay
babesia
divergen
detect
rtpcr
abi
prism
system
result
b
burgdorferi
sl
detect
lithuanian
region
wl
nl
sl
el
common
countri
nl
tick
infect
distinctli
could
explain
zone
sympatri
ixod
speci
biodivers
vector
could
caus
intens
infect
individu
process
tick
posit
babesia
divergen
posit
ehrlichiaanaplasma
hge
hge
variant
e
schottii
identifi
borrelia
genotyp
absolut
domin
b
afzelii
observ
b
garinii
b
burgdorferi
ss
accord
data
baltic
region
russia
kurish
spit
norway
conclus
known
pathogen
speci
borrelia
ehrlichiaanaplasma
babesia
found
europ
also
present
lithuanian
hostseek
tick
popul
detect
b
afzelii
domin
genospeci
lithuanian
tick
ehrlichiaanaplasma
babesia
found
tick
might
caus
human
diseas
acknowledg
studi
support
lithuanian
scienc
studi
foundat
object
three
spot
fever
group
sfg
rickettsios
transmit
hard
tick
bite
known
russia
includ
siberian
tick
typhu
stt
caus
rickettsia
sibirica
sensu
stricto
r
sibirica
sensu
stricto
asian
part
countri
astrakhan
spot
fever
asf
caus
r
conorii
subspeci
caspia
astrakhan
far
eastern
rickettsiosi
caus
r
heinlinjangensi
russian
far
east
recent
addit
tickborn
rickettsia
detect
tick
russia
herein
collect
tick
five
region
russia
european
part
countri
far
east
detect
identifi
use
pcr
sequenc
sfg
rickettsia
method
attempt
amplif
sequenc
fragment
ompa
gene
well
complet
glta
gene
tick
ompa
amplifi
use
primer
wherea
amplif
glta
gene
perform
use
two
primer
pair
pcr
product
sequenc
use
abi
prism
autom
sequenc
appli
biosystem
foster
citi
ca
usa
sequenc
perform
twice
direct
sequenc
identifi
use
blastn
softwar
comparison
sequenc
avail
genbank
result
detect
r
sibirica
sensu
stricto
six
tick
speci
collect
eastern
siberia
zauraly
russian
far
east
r
heilongjangensi
identifi
tick
siberia
far
east
also
detect
three
new
speci
known
pathogen
countri
ie
r
slovaca
marginatu
tick
european
part
russia
zauraly
r
helvetica
ixod
persulcatu
tick
collect
western
siberia
r
aeschlimannii
strain
stavropol
hyalomma
marginatum
stavropol
region
addit
rickettsia
unknown
pathogen
detect
includ
r
sibirica
strain
silvarum
collect
far
east
rickettsia
sp
strain
candidatu
rickettsia
tarasevichia
conclus
minimum
rickettsia
distribut
hard
tick
russia
includ
human
pathogen
addit
classic
r
sibirica
sensu
stricto
therefor
clinician
awar
spot
fever
rickettsios
russia
may
caus
sever
speci
differ
sever
object
part
strepeuro
project
ct
enhanc
surveil
sever
group
streptococc
ga
infect
undertaken
uk
obtain
diseas
burden
estim
characteris
strain
isol
microbiolog
characteris
invas
ga
isol
collect
describ
alongsid
clinic
risk
factor
data
identifi
signific
associ
method
invas
ga
isol
laboratori
england
wale
northern
ireland
sent
streptococcu
diphtheria
refer
unit
characteris
case
defin
isol
ga
normal
steril
site
andor
clinic
inform
indic
sever
infect
microbi
data
avail
includ
emmm
type
spea
b
c
gene
antibiot
resist
profil
analys
perform
use
stata
softwar
test
signific
associ
laboratori
clinic
data
use
chisquar
logist
regress
analys
result
total
invas
ga
case
report
isol
avail
characteris
total
differ
memm
type
identifi
compris
invas
ga
isol
spe
toxin
result
avail
isol
speab
posit
possess
spebc
speb
speabc
posit
signific
associ
spe
gene
type
p
notabl
speab
spebc
suscept
result
antibiot
avail
none
resist
penicillin
clindamycin
resist
erythromycin
resist
tetracyclin
resist
tetracyclin
resist
isol
correl
p
toxic
shock
syndrom
necrotis
fasciiti
significantli
associ
isol
contain
spea
p
intraven
drug
user
compris
case
tetracyclin
resist
strongli
link
major
risk
group
p
conclus
uk
observ
chang
ga
type
distribut
emerg
higher
type
especi
characteris
isol
use
techniqu
spe
gene
toxin
detect
antimicrobi
suscept
enrich
capac
understand
relationship
clinic
manifest
microbiolog
characterist
detect
pcaa
gene
tuberculosi
strain
isol
clinic
specimen
r
ramazanzadeh
tehran
ir
background
aim
studi
investig
preval
pcaa
gene
tuberculosi
strain
isol
type
spoligotyp
associ
risk
factor
among
patient
differ
nation
resid
iran
also
determin
studi
popul
involv
total
patient
refer
nritld
referr
tuberculosi
centr
iran
march
march
isol
mycobacterium
tuberculosi
strain
character
perform
suscept
test
four
firstlin
antituberculosi
drug
subject
spoligotyp
character
pcr
use
detect
pcaa
gene
nucleotid
sequenc
also
determin
result
spoligotyp
tuberculosi
strain
result
differ
pattern
divid
three
evolutionari
group
one
hundr
twentytwo
spoligotyp
isol
uniqu
report
first
time
spoligotyp
pattern
previous
report
geograph
region
world
interestingli
strain
belong
beij
famili
mdr
multi
drug
resist
doubl
tripl
resist
seen
group
evolutionari
scenario
pcaa
gene
detect
tuberculosi
clinic
isol
saprophyt
strain
kansasi
result
show
multi
drugresist
preval
bacteria
isol
afghani
tb
patient
resid
iran
addit
spread
tuberculosi
strain
belong
beij
famili
among
iranian
patient
consid
serious
studi
confirm
widespread
exist
pcaa
gene
almost
clinic
isol
also
import
undertak
studi
identifi
factor
signific
consid
tuberculosi
control
program
isol
identif
legionella
legionnair
diseas
agent
fish
pond
environment
water
sourc
cultur
pcr
method
object
legionella
caus
agent
pneumonia
human
report
case
legionnair
diseas
due
legionella
pneumophila
organ
ubiquit
distribut
natur
man
made
water
sourc
spread
human
inhal
contamin
aerosol
origin
sourc
studi
manmad
water
sourc
view
presenc
legionella
two
method
cultur
pcr
method
water
sampl
one
ml
collect
differ
sourc
fish
pond
swim
pool
cool
tower
studi
sourc
locat
ahwaz
citi
citi
khoozestan
provinc
iran
centrifug
water
sampl
pellet
treat
hclkcl
buffer
ph
resuspend
pellet
inocul
bcye
bmpa
oxoid
media
isol
coloni
identifi
morpholog
biochem
test
dna
extract
bacteria
anoth
portion
pellet
use
templat
pcr
techniqu
dna
pattern
legionella
identifi
electerophoresi
dna
product
result
survey
water
sampl
fish
pond
swim
pool
cool
tower
result
strain
legionella
pneumophila
cultur
identif
strain
pcr
highest
rate
legionella
pneumophila
isol
cultur
pcr
respect
bioz
fish
pond
around
ahwaz
citi
suscept
specif
pcr
survey
respect
result
studi
show
legionnair
diseas
agent
wide
spread
examin
water
sourc
treatment
sourc
chlorin
heat
refresh
water
necessari
elimin
agent
three
femal
asymptomat
infect
object
establish
chronic
infect
may
caus
hematolog
disturb
aim
studi
show
persist
asymptomat
infect
mycoplasma
pneumonia
produc
clinic
pictur
similar
chronic
fatigu
syndrom
even
stimul
gene
involv
hematolog
malign
disord
patient
method
work
report
presenc
chronic
fatigu
syndrom
three
femal
patient
age
year
old
respect
whole
blood
checkup
normal
except
low
valu
igg
immunoglobulin
mgdl
normal
rang
mgdl
titr
mycoplasma
pneumoniaigm
type
antibodi
use
elisa
techniqu
bone
marrow
aspir
trephin
biopsi
diagnost
special
diseas
ct
neck
thorax
abdomen
normal
sign
diseas
peripher
blood
lymphocyt
cultur
prepar
use
standard
techniqu
appli
fish
techniqu
metaphas
chromosom
use
lsi
spectrum
oarng
lsi
spectrum
orang
spectrum
green
probe
search
myelodysplast
syndrom
md
lsi
dual
fusion
transloc
probe
lsi
dual
colour
dual
fusion
transloc
probe
lymphoma
vysi
result
karyotyp
cell
use
gtg
band
techniqu
normal
fish
reveal
one
pt
delet
chromosom
present
md
bad
prognosi
factor
two
cell
carri
transloc
found
nonhodgkin
lymphoma
conclus
three
pt
serolog
mycoplasma
pneumonia
infect
igmtyp
without
sign
activ
diseas
fatigu
syndrom
exist
year
essenti
mechan
mycoplasma
pneumonia
infect
low
igg
unclear
sinc
includ
even
rare
extra
pulmonari
complic
studi
larger
sampl
done
better
evalu
involv
human
malign
diseas
chronic
asymptomat
infect
probabl
act
stimul
gene
respons
preor
malign
hematolog
diseas
aim
investig
aetiolog
asept
mening
method
asept
mening
defin
csf
cytosi
exceed
leukocytesl
neg
standard
bacteri
cultur
herp
simplex
viru
hsv
epstein
barr
viru
ebv
cytomegaloviru
cmv
west
nile
viru
wnv
enteroviru
ev
detect
commerci
avail
pcr
reagent
leptospira
spp
hous
real
time
pcr
test
hous
commerci
pcr
test
use
detect
toscana
viru
tv
varicella
zoster
viru
vzv
mump
viru
coxiella
burnetii
infect
diagnosi
base
clinic
sign
andor
serolog
result
year
studi
csf
sampl
two
hundr
nineteen
patient
younger
year
male
csf
pleocytosi
rang
cellsll
bacteriolog
studi
neg
sampl
etiolog
diagnosi
achiev
molecular
method
patient
pcr
detect
ev
hsv
leptospira
ebv
tv
cmv
infect
sampl
test
neg
west
nile
viru
serolog
detect
one
ebv
one
coxiella
burnetii
infect
eighteen
patient
diagnosi
vzv
mump
infect
base
clinic
ground
overal
diagnosi
clarifi
conclus
sensit
specif
versatil
pcr
make
methodolog
ideal
tool
investig
aetiolog
central
nervou
system
infect
studi
ev
common
aetiolog
asept
mening
investig
toscana
viru
although
less
frequent
go
summer
case
asept
mening
portug
mediterranean
region
vector
west
nile
viru
present
countri
case
infect
viru
detect
agent
need
consid
futur
studi
clarifi
clinic
situat
characteris
recombin
sadenosylhomocystein
hydrolas
cryptosporidium
parvum
cryptosporidium
parvum
unicellular
obligatori
intracellular
parasit
protist
infect
mammalian
gastrointestin
epithelium
produc
selflimit
diarrhoea
healthi
adult
children
potenti
lifethreaten
infect
immunocompromis
person
effect
cure
known
sadenosylhomocystein
hydrolas
sahh
catalys
hydrolysi
sadenosylhomocystein
sah
yield
adenosin
homocystein
regul
methionin
cycl
synthesi
sadenosylmethionin
sam
sam
major
donor
methyl
group
methyl
reaction
decarboxyl
form
donor
aminopropyl
group
polyamin
synthesi
polyamin
metabol
c
parvum
differ
substanti
mammalian
host
drug
develop
would
target
enzym
methionin
cycl
polyamin
synthesi
effect
human
cryptosporidiosi
c
parvum
sahh
cpsahh
clone
cpsahh
singl
copi
intronless
gene
bp
encod
protein
amino
acid
contain
conserv
amino
acid
aa
residu
necessari
enzymat
activ
contrast
mammalian
host
cpsahh
contain
plantslik
aa
insert
rtpcr
analysi
prove
cpsahh
express
c
parvum
sporozoit
intracellular
stage
cpsahh
clone
express
vector
yield
pmalcpsahh
fusion
maltosebind
protein
mbp
fusion
express
compet
e
coli
strain
affin
purifi
amylos
column
recombin
protein
expect
size
kd
examin
sdspage
mbpcpsahh
fusion
cleav
use
factor
xa
proteas
cpsahh
final
divid
mbp
hydroxyapatit
column
assay
cpsahh
activ
hydrolyt
direct
perform
spectroscop
nm
measur
rate
product
homocystein
form
reaction
dinitrilodithiodibenzo
acid
dntb
reaction
mixtur
contain
unit
sadenosyldeaminas
lm
dntb
vari
concentr
sah
lm
mm
potassium
phosphat
buffer
ph
contain
mm
edta
michaelismenten
kinet
estim
km
lm
mbpcpsahh
fusion
protein
km
lm
purifi
recombin
cpsahh
inhibit
recombin
cpsahh
adenosin
analog
specif
sahh
inhibitor
present
object
metallobetalactamas
mbl
mediat
resist
klebsiella
pneumonia
becom
emerg
problem
resist
often
associ
low
level
carbapenem
mic
may
misidentifi
studi
perform
investig
preval
mbl
blood
isol
k
pneumonia
collect
tertiari
care
hospit
year
method
consecut
k
pneumonia
isol
blood
cultur
inpati
medic
ward
surgic
ward
icu
depart
test
identifi
standard
method
mic
determin
broth
microdilut
method
accord
clsi
guidelin
mbl
product
screen
etest
mbl
allel
detect
pcr
presenc
class
integron
verifi
pcr
specif
primer
design
basi
conserv
segment
class
integron
result
twentyfour
isol
exhibit
reduc
suscept
resist
carbapenem
imipenem
imi
meropenem
mer
mic
rang
mcg
ml
two
isol
mic
imi
mcgml
thirteen
isol
mcgml
five
isol
mcgml
four
isol
mcgml
mic
mer
mcg
ml
one
isol
mcgml
eleven
isol
mcgml
five
isol
mcgml
four
isol
mcgml
three
isol
shown
produc
mbl
activ
etest
twentyfour
isol
found
posit
presenc
gene
isol
harbour
class
integron
differ
molecular
weight
carri
varieti
gene
confer
resist
antibiot
conclus
presenc
gene
k
pneumonia
blood
isol
high
result
confirm
spread
mbl
k
pneumonia
becom
clinic
concern
despit
fact
isol
remain
suscept
accord
clsi
breakpoint
continu
surveil
control
measur
necessari
order
elimin
mbl
molecular
detect
cefoxitin
resist
gene
cfxa
regulatori
sequenc
resist
element
j
soki
toth
z
bessenyei
e
urban
e
nagi
szege
hu
object
detect
level
cefoxitin
resist
detect
cfxa
resist
gene
character
structur
sequenc
resist
mobiliz
tranposon
possibl
involv
regul
cfxa
method
bacteroid
strain
examin
level
cefoxitin
resist
etest
method
screen
cfxa
upstream
hypothet
insert
element
transposas
tpi
gene
pcr
detail
analysi
upstream
region
cfxa
gene
amplifi
pcr
use
primer
conserv
region
subsequ
sequenc
result
cfxa
gene
found
isol
cefoxitin
mic
fell
either
intermedi
mgl
resist
categori
mgl
one
addit
strain
also
resist
cefoxitin
display
resist
carbapenem
two
element
sequenc
tpi
found
cfxaposit
strain
map
upstream
region
cfxa
gene
structur
correspond
refer
sequenc
b
vulgatu
strain
region
upstream
cfxa
gene
devoid
islik
sequenc
b
vulgatu
addit
bp
region
direct
invert
repeat
end
strain
upstream
region
could
amplifi
size
bp
insert
element
conclus
develop
method
could
detect
cephamycinspecif
resist
bacteroid
strain
demonstr
heterogen
region
resist
transposon
describ
preval
isless
structur
region
object
septemb
attack
anthrax
reemerg
diseas
major
case
cutan
mild
diseas
case
cutan
reaction
may
sever
threat
patient
life
method
case
diagnos
cutan
anthrax
last
year
evalu
present
diagnos
carri
exposur
clinic
present
compat
anthrax
gram
stain
posit
cultur
lesion
result
nine
case
male
femal
age
year
evalu
case
sever
form
cutan
anthrax
sever
form
toxem
shock
toxem
shock
mild
form
eight
patient
gave
histori
exposur
anim
die
one
patient
raw
leather
worker
incub
period
day
clinic
present
sever
form
cutan
anthrax
case
character
fever
hemorrhag
bulla
surround
extens
erythema
edema
leukocytosi
toxem
shock
observ
case
sever
cutan
lesion
right
arm
extens
nonpit
edema
lesion
shoulder
includ
posterior
anterior
chest
wall
anoth
case
small
lesion
anterior
neck
surround
extens
erythema
nonpit
edema
lesion
anterior
chest
wall
neck
face
respiratori
distress
case
also
low
systol
blood
pressur
mmhg
apathi
toxem
appear
leukocytosi
hypoalbuminemia
hyponatremia
high
level
crp
shock
resolv
intraven
fluid
infus
one
case
case
requir
dopamin
infus
intraven
fresh
plasma
given
case
intraven
penicillin
g
given
case
day
case
day
case
day
case
clindamycin
case
day
penicillin
allergi
case
mild
form
case
receiv
amoxicillin
day
case
receiv
procain
penicillin
intramuscularli
day
deep
tissu
necrosi
heal
larg
black
eschar
cm
diamet
develop
case
sever
cutan
anthrax
lesion
eschar
leav
surgic
week
diseas
week
diseas
wound
graft
object
viscer
leishmaniasi
rare
western
europ
morbid
mortal
low
immunocompet
may
fatal
immunosuppress
patient
control
infect
immun
achiev
gener
leishmaniaspecif
secret
ifna
consecut
activ
macrophag
kill
intracellular
amastigot
infect
reactiv
year
later
case
cellular
immunosuppress
method
describ
two
patient
reactiv
latent
infect
first
induct
chemotherapi
acut
lymphat
leukemia
second
treatment
steroid
result
first
patient
man
turkey
treat
newli
diagnos
bcell
cytarabin
idarubicin
develop
fever
neutropenia
mucos
diarrhoea
abdomin
cramp
patient
deterior
empir
treatment
broad
spectrum
antibiot
amphotericin
b
acut
abdomen
laparotomi
resect
duodenum
perform
histolog
reveal
intestin
leishmaniasi
despit
adequ
therapi
liposom
amphotericin
b
patient
develop
fatal
septic
shock
multiorganfailur
second
patient
swiss
woman
diagnosi
allopurinolinduc
hepat
liver
biopsi
show
fibrin
ring
granuloma
prednison
mgday
start
week
later
patient
readmit
pancytopenia
bone
marrow
aspir
reveal
leishmaniasi
identifi
leishmania
infantum
pcr
repeat
liver
biopsi
show
infiltr
leishmania
without
evid
fibrin
granuloma
shown
first
biopsi
histori
reveal
travel
malta
year
earlier
liposom
amphotericin
start
patient
develop
septic
shock
die
day
intens
care
unit
conclus
viscer
leishmaniasi
may
becom
frequent
non
endem
region
intern
travel
increas
number
immunosuppress
patient
reactiv
leishmaniasi
consid
particularli
patient
fever
neutropenia
pancytopenia
fever
steroid
nontyphoid
salmonella
invas
bloodstream
infect
resist
quinolon
andor
extend
spectrum
cephalosporin
countri
extens
use
antimicrobi
food
anim
w
kulwichit
chatsuwan
c
unhasuta
c
pulsrikarn
bangtrakulnonth
chongthaleong
bangkok
th
object
nalidix
acid
extend
spectrum
cephalosporin
resist
nontyphoid
salmonella
infect
grow
global
problem
worrisom
certain
countri
countri
enrofloxacin
veterinari
fluoroquinolon
extens
use
virtual
food
anim
addit
ceftiofur
veterinari
thirdgener
cephalosporin
also
wide
use
swine
treatment
also
diseas
prevent
complex
plasmid
capabl
carri
antimicrobialresist
virul
gene
packag
gener
principl
microb
sacrif
virul
resist
may
alway
appli
embark
explor
clinic
molecular
aspect
grow
problem
wish
report
pilot
survey
alert
medic
commun
method
archiv
nontyphoid
salmonella
isol
bacterem
patient
univers
hospit
januari
octob
bacterem
patient
nationwid
sent
nation
salmonella
shigella
center
first
half
enter
studi
collect
nonoverlap
etest
use
evalu
mic
nalidix
acid
ciprofloxacin
ceftriaxon
suscept
defin
use
clinic
laboratori
standard
institut
clsinccl
criteria
salmonella
result
bacteria
resist
antimicrobi
test
high
rate
tabl
choleraesui
isol
ceftriaxon
resist
also
express
high
level
nalidix
acid
resist
mic
lgml
thu
reduc
suscept
ciprofloxacin
mic
lgml
nalidix
acid
resist
isol
ciprofloxacin
mic
lg
ml
case
aortiti
ceftriaxon
resist
organ
result
fatal
ruptur
mycot
aneurysm
conclus
compar
suscept
pattern
past
current
nontyphoid
salmonella
infect
human
countri
obvious
resist
quinolon
cephalosporin
without
sacrif
virul
nalidix
acid
suscept
correl
well
reduc
suscept
ciprofloxacin
alarm
ceftriaxon
resist
salmonella
choleraesui
may
associ
inappropri
ceftiofur
usag
pig
farm
reconsider
probabl
major
revis
polici
antimicrobi
use
food
anim
variou
purpos
countri
warrant
object
q
fever
due
coxiella
burnetii
usual
found
profession
fever
diseas
present
acut
chronic
form
isol
c
burnetii
done
level
secur
laboratori
increas
valu
serolog
diagnosi
institut
aim
studi
detect
c
burnetii
anticoxiella
antibodi
molecular
serolog
method
among
risk
group
method
peopl
studi
male
femal
age
rang
year
among
peopl
veterinari
doctor
farm
worker
butcher
sera
collect
peopl
presenc
anticoxiella
burnetii
antibodi
studi
use
c
burnetii
elisa
igg
c
burnetii
elisa
igm
kit
vircel
spain
posit
equivoc
sampl
elisa
studi
ifa
ifa
test
done
use
coxiella
burnetii
phase
iii
kit
vircel
spain
presenc
c
burnetii
also
studi
case
pcr
use
specif
primer
tran
result
total
peopl
posit
equivoc
elisa
igm
respect
among
peopl
studi
peopl
posit
equivoc
elisa
igg
respect
elisa
posit
equivoc
sera
studi
ifa
case
igm
case
igg
presenc
confirm
igm
posit
case
also
posit
igg
one
case
c
burnetii
seroposit
signific
differ
c
burnetii
seroposit
among
three
profession
group
veterinari
doctor
farm
worker
butcher
p
case
pcr
posit
conclus
coxiella
seroposit
found
among
risk
group
higher
rate
report
among
gener
popul
turkey
reason
especi
among
risk
group
case
atyp
pneumonia
granulomat
hepat
fever
unknown
aetiolog
q
fever
thought
search
differenti
diagnosi
object
aim
studi
present
eleven
case
dermatophytos
caus
trichophyton
violaceum
new
emerg
pathogen
baix
llobregat
metropolitan
area
barcelona
summar
epidemiolog
microbiolog
clinic
data
method
report
base
eleven
case
mycot
infect
due
trichophyton
violaceum
baix
llobregat
area
januari
septemb
epidemiolog
clinic
laboratori
find
analyz
result
patient
attend
unit
dermatolog
sampl
submit
laboratori
cultur
ten
patient
children
four
women
six
men
age
rang
year
patient
femal
eight
patient
immigr
africa
other
patient
spanish
adult
patient
immunosupress
nine
patient
present
tinea
capiti
consist
spotti
alopecia
crust
format
two
case
present
tinea
involv
nose
cheek
skin
scrape
hair
sampl
cultur
sabouraud
dextros
agar
chloramphenicolcycloheximid
gentamycinechloramphenicol
growth
flat
violetcolour
coloni
detect
cultur
microscop
tangl
branch
irregular
hypha
note
absenc
microconidia
macroconidia
patient
treat
oral
antifung
drug
conclus
progress
increas
number
cutan
infect
caus
violaceum
observ
last
year
geograph
area
violaceum
isol
sinc
almost
case
occur
children
relat
immigr
spread
brother
demonstr
four
case
contradistinct
previou
report
nonpaediatr
patient
studi
immunosupress
incub
cultur
must
least
one
month
coloni
trichophyton
violaceum
extrem
slow
growth
object
listeria
monocytogen
foodborn
pathogen
capabl
caus
seriou
diseas
suscept
individu
recent
new
non
invas
form
listeriosi
caus
febril
gastroenter
peopl
predispos
condit
increas
public
health
signific
l
monocytogen
suggest
possibl
wider
rang
infect
vehicl
major
infect
factor
food
contamin
seem
occur
environ
process
plant
import
slaughter
facil
investig
epidemiolog
role
rumin
possibl
zoonos
sourc
listeri
pathogen
strain
method
l
monocytogen
strain
isol
northern
itali
sinc
isol
cattl
sheep
patient
sporad
clinic
listeriosi
food
product
subject
character
somat
flagellar
h
antigen
kit
seiken
denka
seiken
co
ltd
japan
strain
ribotyp
use
autom
system
result
found
repres
serotyp
ribotyp
offer
partial
independ
accur
subtyp
scheme
identifi
major
ribogroup
classifi
dupont
identif
pattern
number
dupid
share
human
feed
anim
isol
data
indic
varieti
l
monocytogen
ribotyp
shown
associ
human
sporad
epidem
listeriosi
world
commonli
present
rumin
case
studi
find
three
common
cluster
within
human
feed
anim
support
hypothesi
rumin
could
play
import
epidemiolog
role
reservoir
sourc
listeri
infect
human
be
object
ehrlichia
ruminantium
tickborn
intracellular
bacterium
parasit
endotheli
cell
caus
heartwat
rumin
sub
saharan
africa
french
indi
patient
method
immunocompromis
woman
becam
sick
week
pet
dog
die
biliari
fever
die
week
later
clinic
detail
avail
boy
initi
present
histori
headach
fever
present
gait
disturb
ataxia
progress
sleepi
rapidli
becam
comatos
ct
scan
brain
perform
stage
reveal
edema
hypodens
lesion
cortex
enceph
diagnos
transfer
icu
die
day
later
post
mortem
examin
reveal
extens
brain
vascul
promin
midbrain
pon
second
child
evid
tick
bite
die
januari
similar
symptom
although
treat
tick
bite
fever
dna
extract
acut
phase
serum
sampl
three
individu
subject
polymeras
chain
reaction
pcr
amplif
use
primer
specif
citrat
synthas
glta
gene
e
ruminantium
amplicon
appropri
size
clone
plasmid
vector
sequenc
directli
sequenc
sequenc
align
previous
determin
e
ruminantium
sequenc
check
genotyp
ident
sampl
two
patient
similarli
examin
presenc
rickettsia
spp
result
test
patient
neg
rickettsia
spp
three
patient
r
dna
sequenc
ident
known
e
ruminantium
genotyp
detect
acut
phase
serum
glta
sequenc
ident
welgevonden
stock
e
ruminantium
also
detect
one
patient
conclus
first
molecular
evid
ehrlichia
ruminantium
infect
occur
human
view
sever
infect
awar
physician
possibl
diagnosi
patient
bitten
tick
subsaharan
africa
e
ruminantium
endem
area
treatment
base
upon
doxycyclin
includ
children
symptomat
patient
howev
due
invas
lgvstrain
may
alway
detect
lesion
swab
sinc
lgv
associ
induct
strong
antibodi
respons
serolog
may
help
identifi
affect
patient
even
retrospect
character
predict
valu
serolog
lgv
serum
sampl
patient
without
c
trachomati
infect
analyz
use
differ
commerci
c
trachomati
antibodi
test
method
serum
specimen
patient
invas
c
trachomati
infect
lgv
n
epitheli
c
trachomati
infect
urethr
cervic
n
without
evid
infect
c
trachomati
n
test
antibodi
c
trachomati
complement
fixat
cf
lpsbase
genusspecif
eia
lpseia
mompbas
c
trachomatisspecif
eia
cteia
line
assay
recombin
antigen
la
presenc
absenc
c
trachomati
analyz
sda
anogenit
swab
obtain
patient
object
sever
epidemiolog
report
indic
typeb
diseas
close
connect
water
turkey
tularemia
case
seen
mostli
pharyng
form
isol
f
tularensi
dna
water
sampl
report
turkey
first
report
turkey
evalu
link
tularemia
outbreak
water
sourc
method
two
litr
water
sampl
everi
water
sourc
obtain
studi
taqman
nucleas
assay
water
sampl
put
cellulos
acet
filter
surfac
filter
wash
steril
distil
water
minut
shaker
lysi
buffer
guanidin
isothiocyan
na
acet
vv
sarcosil
ad
pellet
dna
isol
depend
bind
dna
glass
bead
glassmilk
bio
la
jolla
ca
perform
region
target
taqman
assay
specif
francisella
tularensi
includ
bp
fopa
bp
gene
encod
kda
lipoprotein
fopa
encod
kda
outer
membran
protein
primer
tamra
label
probe
f
tularensi
taqman
nucleas
test
use
taqman
nucleas
assay
perform
realtim
pcr
devic
quantica
techn
inc
uk
result
besid
network
water
natur
stream
water
avail
wide
use
drink
cook
purpos
rural
area
turkey
investig
water
possibl
sourc
infect
natur
spring
network
water
sampl
test
taqman
pcr
studi
water
sourc
sampl
five
differ
provinc
name
suluova
golcuk
edirn
duzc
zonguldak
site
abcd
respect
locat
least
km
total
l
water
filter
relat
water
sourc
five
outbreak
f
tularensi
dna
three
water
sampl
found
posit
site
site
c
site
site
b
site
e
water
sampl
neg
taqman
pcr
assay
conclus
studi
show
contagion
come
drink
water
outbreak
turkey
real
time
taqman
pcr
use
method
detect
dna
f
tularensi
water
sourc
object
aim
studi
identifi
potenti
factor
associ
infect
sourc
mode
transmiss
recent
outbreak
octob
tularemia
suluova
turkey
method
activ
surveil
initi
compat
case
suluova
counti
identifi
case
tularemia
match
casecontrol
studi
analysi
base
first
case
match
control
standard
questionnair
use
collect
inform
gener
demograph
exposur
known
sourc
tularemia
infect
well
potenti
risk
factor
relat
water
anim
ie
fish
farm
hunt
activ
environment
condit
hous
microagglutin
test
use
serolog
diagnosi
clinic
water
sampl
screen
evid
tularemia
agent
pcr
result
overal
attack
rate
singl
common
present
symptom
lymphadenopathi
present
follow
fever
sore
throat
report
pain
lymph
node
francisella
tularensi
shown
pcr
sampl
obtain
ulcer
lesion
two
patient
multivari
logist
regress
model
keep
domest
anim
garden
associ
risk
contract
diseas
ci
p
f
tularensi
detect
pcr
water
sampl
obtain
rivulet
pass
suluova
conclus
result
studi
show
casecontrol
studi
might
use
analys
epidem
identifi
sourc
infect
order
prevent
waterrel
zoonot
infect
water
sewerag
system
improv
object
tularaemia
zoonot
diseas
caus
gramneg
coccobacillu
francisella
tularensi
endem
northern
hemispher
notabl
europ
f
tularensi
bioterror
agent
declar
case
tularaemia
mandatori
franc
sinc
refer
centr
tickborn
diseas
bartonella
routin
test
f
tularensi
suspect
tick
born
rickettios
atyp
pneumonia
cat
scratch
diseas
report
epidemiolog
clinic
biolog
featur
tularaemia
diagnos
systemat
test
refer
laboratori
method
june
octob
enrol
patient
posit
serolog
andor
posit
polymeras
chain
reaction
assay
andor
posit
cultur
f
tularensi
blood
skin
lymph
node
liver
sampl
obtain
collect
epidemiolog
clinic
biolog
featur
outcom
treatment
patient
standardis
questionnair
use
chisquar
test
statist
analysi
result
eightyeight
case
fulfil
criteria
clinic
present
glandular
form
ulceroglandular
form
pneumon
form
digest
form
oculoglandular
form
pneumon
form
significantli
associ
risk
relaps
p
patient
develop
pneumon
form
p
farm
garden
bitten
tick
statist
independ
risk
factor
develop
tularaemia
p
respect
case
report
spring
associ
great
exposur
tick
bite
final
tetracyclin
often
use
treatment
form
tularaemia
studi
p
conclus
tularaemia
common
diseas
franc
often
misdiagnos
suspect
csd
atyp
pneumonia
tick
born
rickettios
clinic
featur
risk
factor
similar
report
endem
countri
herein
report
experi
anaerob
bacteremia
ab
oncohematolog
pt
period
episod
ab
identifi
differ
pt
male
femal
median
age
rang
yr
rate
ab
per
patient
admiss
account
bacterem
episod
occur
depart
studi
period
major
pt
refractoryrelaps
leukemia
lymphoma
receiv
bmt
procedur
infect
pt
neutropen
onset
ab
wbc
count
less
cellsmmc
sever
oral
mucos
follow
intens
chemotherapi
grade
case
bacterem
episod
occur
median
day
sever
neutropenia
rang
polymicrobi
pulmonari
infiltr
observ
pt
frequent
isol
fusobacterium
nucleatum
case
bacteroid
sp
case
peptostreptococcu
sp
case
clostridium
sp
case
first
line
antibiot
therapi
piperacillintazobactam
pt
carbapenem
glycopeptid
plu
ceftazidim
median
durat
therapi
day
rang
respons
rate
first
antibiot
treatment
overal
respons
mortal
ab
relat
caus
death
clostridium
sp
bacteremia
case
bacteroid
sp
bacteremia
case
fusobacterium
nucleatum
bacteremia
case
vitro
activ
antibiot
anaerob
piperacillin
imipenem
amoxacillinclavulan
clindamycin
identifi
risk
factor
infect
retrospect
casecontrol
studi
perform
case
control
pt
univari
analysi
reveal
sever
mucos
statu
refractoryrelaps
haematolog
diseas
significantli
associ
develop
ab
p
p
respect
data
confirm
rariti
ab
neutropen
pt
bacterem
episod
kind
infect
underestim
fatal
complic
b
fusobacterium
sp
bacteroid
sp
peptostreptococcu
sp
clostridium
sp
common
isol
caus
ab
oncohematolog
pt
c
predispos
condit
ab
sever
oropharyng
mucos
refractori
relaps
statu
haematolog
diseas
introduct
nontoxigen
strain
c
diphtheria
increasingli
recognis
caus
invas
diseas
bacteraemia
endocard
caus
strain
report
increas
frequenc
invas
diseas
septic
arthriti
splenic
abscess
mycot
cerebr
aneur
also
describ
date
least
case
nontoxigen
c
diphtheria
caus
endocard
report
worldwid
case
either
nativ
prosthet
heart
valv
iv
drug
abus
object
report
case
infect
endocard
caus
nontoxigen
c
diphtheria
patient
underli
congenit
heart
defect
occur
pretoria
academ
hospit
past
year
method
endocard
confirm
presenc
diphtheroid
organ
blood
cultur
patient
final
diagnosi
made
microscopi
gram
albert
stain
cultur
blood
agar
hoyl
medium
inhous
biochem
test
substanti
api
coryn
biomerieux
elek
test
toxin
product
perform
isol
result
age
patient
year
posit
blood
cultur
bactec
system
obtain
patient
multipl
occas
characterist
chines
letter
arrang
bacilli
seen
gram
albert
stain
metachromat
granul
inhous
biochem
test
valid
api
coryn
confirm
organ
c
diphtheria
var
gravi
elek
test
case
indic
toxin
product
sensit
number
antibiot
ampicillin
penicillin
erythromycin
gentamicin
piperacillin
cefuroxim
determin
kirbybau
disc
diffus
method
except
penicillin
ampicillin
resist
one
patient
antibiot
test
sensit
patient
treat
penicillin
gentamicin
parenter
surviv
without
complic
conclus
nontoxigen
c
diphtheria
infecti
pathogen
detect
coryneform
bacteria
blood
longer
dismiss
contamin
must
investig
failur
recognis
pathogen
delay
final
diagnosi
initi
appropri
chemotherapi
speci
identif
import
mortal
differ
differ
biotyp
import
organ
emerg
pathogen
underestim
object
aim
studi
investig
presenc
shiga
toxin
stx
produc
escherichia
coli
stec
faecal
sampl
camel
ie
anim
wide
farm
middl
east
africa
method
two
hundr
one
stool
rectal
sampl
collect
individu
anim
eastern
region
abu
dhabi
emir
unit
arab
emir
studi
dna
extract
mix
coliform
cultur
test
presenc
stx
gene
stx
pcr
posit
specimen
stec
identifi
appli
pcr
test
total
coloni
pool
decreas
size
stx
product
strain
determin
elisa
enterohaemolysin
product
investig
agar
plate
contain
wash
erythrocyt
isol
genotyp
pcr
use
primer
specif
recogn
gene
intimin
enterohaemolysin
enteroaggreg
plasmid
enteroaggreg
heatstabl
enterotoxin
east
cytoleth
distend
toxin
b
cytotox
necrotis
factor
gene
locat
yersinia
high
pathogen
island
fyua
primer
identifi
sequenc
put
stec
adher
factor
gene
saa
iha
toxb
efa
respect
stx
gene
isol
sequenc
h
antigen
isol
determin
type
pulsefield
gel
electrophoresi
follow
xbai
digest
genom
also
eric
pcr
result
specimen
anim
three
stxcarri
strain
recov
sampl
one
strain
isol
adult
anim
produc
detect
stx
carri
complet
gene
carri
gene
intimin
put
virul
factor
test
two
strain
hnt
indistinguish
type
method
use
isol
differ
farm
rectal
sampl
healthi
babi
camel
produc
stx
carri
gene
isol
secret
enterohaemolysin
gave
posit
pcr
reaction
primer
specif
put
adher
factor
gene
saa
iha
conclus
data
show
first
time
onehump
camel
whose
meat
often
unpasteuris
milk
frequent
consum
countri
middl
east
africa
also
carrier
stec
pose
potenti
health
risk
human
achiev
first
european
project
sever
group
streptococc
diseas
jasir
c
schalen
lund
se
object
main
object
improv
understand
sever
group
streptococc
ga
diseas
europ
method
enhanc
surveil
launch
januari
countri
questionnair
sent
hospit
laboratori
collect
patient
data
isol
criteria
inclus
patient
isol
ga
normal
steril
bodi
site
nonsteril
site
presenc
clinic
diagnosi
streptococc
toxic
shock
syndrom
necrotis
fasciiti
collect
isol
character
serolog
molecular
method
antibiot
suscept
determin
mic
etest
two
set
eqa
strain
antibiot
suscept
one
set
type
sent
particip
laboratori
result
case
identifi
consider
higher
anticip
around
uk
yield
annual
incid
similar
incid
document
sweden
denmark
finland
lower
particip
countri
incid
franc
reach
memm
type
distribut
ga
also
vari
markedli
countri
type
predomin
howev
overal
increas
new
invas
type
notic
high
rate
ml
antibiot
resist
countri
franc
itali
tetracyclin
resist
almost
countri
found
uk
intraven
drug
use
found
major
risk
factor
follow
previous
report
trend
franc
spread
clone
ga
type
resist
ml
drug
bacitracin
report
mostli
associ
puerper
sepsi
earli
result
pathogenesi
work
packag
identifi
low
antibodi
level
newli
describ
cell
wallattach
protein
ga
may
predispos
sever
ga
diseas
conclus
compar
data
across
europ
achiev
appar
overal
increas
invas
case
may
partli
depend
role
strepeuro
enhanc
establish
surveil
system
care
analysi
data
consid
countri
depend
nation
system
collect
data
treatment
strategi
case
regard
broad
distribut
emm
type
futur
develop
vaccin
base
protein
consid
need
work
group
valid
definit
new
emmtyp
subtyp
object
herp
simplex
viru
type
caus
agent
local
skin
infect
oral
ocular
neural
region
need
vaccin
wide
recogn
hsv
glycoprotein
gd
major
target
vaccin
studi
ifng
enhanc
tcell
cytotox
regul
major
histocompat
complex
mhc
class
ii
revers
regul
mhc
class
furthermor
high
level
ifng
indic
respons
regard
import
ifng
restrict
infect
abil
dna
subunit
vaccin
evalu
method
femal
balbc
mice
immun
micro
gram
gd
express
vector
dna
vaccin
x
cell
infect
recombin
express
baculoviru
subunit
vaccin
day
immun
balbc
mice
sacrifi
day
spleen
cell
cultur
plate
stimul
five
moi
inactiv
viru
differ
hour
stimul
h
total
rna
extract
cell
cdna
synthes
use
random
hexam
semiquantit
pcr
reaction
perform
use
ifng
intern
control
specif
primer
primer
design
differ
exon
gene
prevent
dna
contamin
pcr
product
evalu
banddensitomet
softwar
result
result
reveal
vaccin
infect
posit
control
mice
hr
invitro
stimul
compar
neg
control
show
signific
immun
ifng
product
kinet
hr
stimul
group
display
signific
differ
conclus
investig
show
although
hr
stimul
suffici
express
mrna
signific
detect
ifng
memori
tcell
hr
post
stimul
ca
nt
suffici
comparison
differ
vaccin
mice
group
immun
dna
subunit
vaccin
hr
nt
show
signific
differ
ifng
level
mmrv
vaccin
costeffect
hcw
turkey
object
investig
immun
statu
healthcarework
hcw
measl
rubella
mump
varicella
zoster
promot
adequ
vaccin
program
among
hcw
turkey
method
voluntari
hcw
two
hospit
one
children
hospit
gener
hospit
includ
studi
march
may
specif
ig
g
antibodi
measl
rubella
mump
varicella
zoster
virus
screen
quantit
use
immunosorb
enzymelink
assay
elisa
kid
result
three
hundr
sixti
three
heathcarework
hcw
particip
studi
two
hospit
physician
nurs
housekeep
staff
medic
technician
posit
rate
antibodi
measl
rubella
mump
varicella
statist
signific
differ
found
two
hospit
measl
rubella
varicella
hcw
children
hospit
found
suscept
mump
relationship
immun
measl
mump
rubella
varicella
two
hospit
gender
age
durat
work
profess
depart
work
posit
rate
past
histori
measl
rubella
mump
varicella
previou
mmr
varicella
vaccin
respect
overal
cost
prevaccin
screen
hcw
mmr
vaccin
suscept
person
approxim
assum
hcw
suscept
would
receiv
vaccin
mmr
cost
procedur
cost
prevaccin
screen
varicella
vaccin
suscept
hcw
cost
vaccin
hcw
conclus
major
hcw
immun
measl
mump
rubella
varicella
howev
hcw
turkey
seem
littl
knowledg
histori
diseas
vaccin
prevaccin
serolog
screen
seem
necessari
identifi
suscept
without
screen
test
mmr
vaccin
cost
effect
hcw
turkey
wherea
prevaccin
serolog
screen
cost
effect
varicella
object
background
high
preval
diseas
essenti
chang
child
organ
immunolog
reactanc
decreas
postvaccin
immun
effici
one
hand
increas
postvaccin
complic
frequenc
hand
observ
present
research
aim
investig
reason
occurr
postvaccin
complic
pc
hyperthermia
local
tissu
reaction
region
lymphaden
skin
rash
children
suffer
bronchial
asthma
ba
ba
combin
parasit
diseas
immunolog
deregul
method
pc
frequenc
bapati
bapati
infest
kind
parasit
enterobia
verm
ascaria
lumbr
giardia
int
compar
ba
parasit
diseas
diagnos
treat
accord
standard
requir
statist
import
distinct
estim
tcriterion
wilcocson
result
pc
fine
noninfest
bapati
infest
bapati
therewith
agedepend
result
observ
among
children
year
differ
year
group
less
within
year
supervis
patient
receiv
antiasthmat
antiparasit
treatment
accord
ba
graviti
parasit
speci
period
repeat
vaccin
carri
decret
age
whole
pc
frequenc
decreas
noninfest
bapati
infest
bapati
even
former
age
depend
kept
see
tab
note
tab
data
distinct
statist
signific
tcriterion
n
p
widespread
childhood
parasit
diseas
enterobiosi
ascariasi
giardiasi
significantli
influenc
postvaccin
answer
reason
reaction
vaccin
materi
presenc
antiparasit
antibodi
child
organ
parasit
antigen
complex
heterogen
owe
antiparasit
immun
answer
character
low
specif
contact
parasit
result
product
antibodi
capabl
cooper
parasit
epitop
also
cell
express
similar
molecul
import
clinician
provid
success
schedul
child
vaccin
parasitolog
inspect
necessari
antiparasit
treatment
promot
purpos
object
sever
acut
respiratori
syndrom
coronaviru
sarscov
etiolog
agent
novel
infecti
diseas
sar
sarscov
play
import
role
immun
respons
mediat
viru
bind
receptor
angiotensinconvert
enzym
recombin
adenoassoci
viru
raav
power
deliveri
vector
wide
use
gene
therapi
therefor
object
studi
detect
function
fragment
sarscov
use
aav
system
pursu
good
candid
develop
sar
vaccin
method
studi
raav
vector
encod
sarscov
develop
use
induc
sarscov
specif
antibodi
gene
rbd
four
sarscov
fragment
insert
aav
plasmid
gener
raav
vector
use
vaccin
mice
intramuscularli
evalu
immunogen
vivo
mous
sera
detect
elisa
specif
antibodi
sarscov
measur
neutral
assay
antibodi
neutral
activ
raav
encod
rbd
appli
immun
mice
intraderm
intranas
detect
abil
induc
antibodi
via
differ
vaccin
result
result
demonstr
vaccin
five
raav
vector
encod
sarscov
fragment
elicit
sarscov
specif
igg
antibodi
vaccin
mous
sera
antibodi
titer
time
maintain
antibodi
vari
differ
raav
vector
result
also
show
raav
encod
receptorbind
domain
rbd
provok
potent
prolong
antibodi
neutral
activ
indic
deliv
prolong
immun
respons
furthermor
intraderm
intranas
vaccin
raav
encod
rbd
induc
sarscov
specif
igg
antibodi
mous
sera
iga
antibodi
mous
lung
flush
illustr
live
vector
abl
elicit
specif
antibodi
respons
includ
respiratori
tract
local
immun
respons
differ
vaccin
pathway
conclus
studi
provid
novel
databas
raav
encod
sarscov
fragment
produc
high
sarscov
specif
antibodi
immun
mice
give
clue
worthwhil
studi
function
fragment
addit
result
raav
encod
rbd
elicit
specif
igg
iga
antibodi
neutral
activ
via
intramuscular
intraderm
intranas
vaccin
impli
live
vector
might
good
candid
develop
sar
vaccin
appropri
rabi
postexposur
treatment
receiv
patient
present
antirabi
treatment
unit
mj
pinidiyapathirag
wimalaratn
ragama
colombo
lk
object
increas
avail
access
rabi
post
exposur
treatment
pet
cost
born
govern
sri
lanka
purchas
antirabi
vaccin
increas
dramat
countri
spend
around
million
sri
lankan
rupe
euro
slr
rabi
pet
vaccin
alon
per
annum
amount
almost
one
tenth
countri
annual
expenditur
drug
vaccin
larg
proport
health
budget
spent
rabi
treatment
need
justif
henc
present
studi
carri
determin
appropri
rabi
pet
receiv
patient
present
tertiari
care
unit
method
hospit
base
descript
studi
carri
newli
commenc
antirabi
treatment
unit
nation
hospit
sri
lanka
nhsl
interview
administ
questionnair
assess
sociodemograph
characterist
patient
sever
exposur
health
seek
behaviour
follow
exposur
detail
treatment
taken
patient
registr
card
result
seek
patient
treatment
nhsl
given
day
report
exposur
anim
suspect
rabi
patient
studi
major
male
employ
belong
year
age
group
exposur
domest
dog
unvaccin
commonest
present
patient
present
treatment
within
first
hour
mean
time
durat
taken
day
sd
around
patient
wash
expos
area
soap
water
immedi
follow
exposur
practic
show
signific
associ
level
educ
p
exposur
dog
p
exposur
domest
anim
p
assess
appropri
pet
receiv
patient
studi
found
use
vaccin
inappropri
new
case
receiv
day
day
dose
antirabi
vaccin
conclus
appropri
antirabi
pet
receiv
altogeth
around
sampl
expert
predict
appropri
antirabi
treatment
countri
set
special
unit
treat
patient
requir
antirabi
treatment
help
optim
treatment
reduc
treatment
cost
long
run
solid
organ
rabi
infect
donor
transplant
six
individu
januari
five
german
hospit
rabi
postexposur
prophylaxi
pep
initi
health
care
worker
hcw
contact
rabi
infect
patient
object
investig
incid
advers
effect
rabi
pep
homogen
popul
method
pep
administ
accord
essen
schedul
immunglobulin
iu
per
kg
bw
purifi
chick
embryo
cell
vaccin
pcecv
day
standardis
followup
form
use
record
advers
effect
rabi
pep
advers
effect
occur
hour
vaccin
consid
result
four
hospit
complet
followup
data
total
individu
receiv
pep
collect
least
one
revers
local
advers
effect
record
case
local
pain
erythema
swell
malfunct
system
effect
record
case
tired
malais
headach
dizzi
fever
chill
nausea
vomit
myalgia
arthralgia
diarrhoea
paraesthesia
lymph
node
swell
persist
advers
effect
paraesthesia
artrial
fibril
two
hcw
two
hcw
symptom
suspici
mild
form
mening
symptom
revers
case
pep
interrupt
due
advers
effect
sever
headach
dizzi
paraethesia
allerg
reaction
wherea
incid
tired
malais
headach
dizzi
fever
declin
significantli
pvalu
vaccin
vaccin
incid
paraesthesia
chang
p
conclus
rabi
pep
safe
vaccin
hcw
incid
advers
effect
pep
accord
essen
schedul
includ
mild
advers
effect
frequent
describ
clear
high
incid
advers
effect
first
week
due
addit
administr
immunoglobulin
day
acceler
booster
reaction
led
effect
reoccurr
paraesthesia
vaccin
may
repres
advers
effect
specif
activ
immun
howev
rabi
pep
remain
effect
measur
prevent
rabi
alway
given
individu
possibl
expos
rabi
contain
secret
design
construct
express
vector
contain
immunogen
epitop
gp
protein
vaccin
candid
f
roodbari
f
mahboudi
f
sabahi
f
barkhordari
r
sarami
foroshani
ade
tehran
ir
introduct
effect
vaccin
urgent
need
stop
aid
epidem
worldwid
dna
vaccin
induc
conformationaldepend
antibodi
mimic
live
vaccin
without
pathogen
potenti
also
easili
made
polyval
form
base
identif
b
cell
epitop
viru
play
mani
import
role
hostviru
interact
pathogenesi
protein
consid
attract
vaccin
candid
immunogen
immunomodulatori
effect
confirm
materi
method
studi
express
vector
hygro
contain
immunogen
sequenc
control
ie
hcmv
promot
design
express
recombin
peptid
analys
eukaryot
system
cell
immunofluoresc
western
blot
confirm
presenc
express
protein
conclus
polyval
vector
use
anim
model
evalu
gener
effect
immun
respons
clinic
cours
studi
post
bcg
vaccin
aden
hamedi
velayati
mashad
tehran
ir
object
common
complic
post
bcg
vaccin
lymphadenopathi
lymphaden
usual
neck
axilla
aim
studi
evalu
variou
manifest
post
vaccin
adenopathi
effect
differ
treatment
modal
method
studi
infant
rang
age
month
within
year
patient
affect
post
bcg
vaccin
lymphaden
refer
pediatr
infecti
clinic
patient
follow
physic
examin
monthli
month
time
intervent
treatment
till
adenopathi
disappear
fistul
observ
durat
heal
affect
lymph
node
result
specif
treatment
perform
patient
cervic
axillar
lymph
node
lymph
node
resolv
spontan
within
month
patient
mention
resolut
occur
without
fistul
other
resolut
lymph
node
occult
patient
dissemin
aden
requir
needl
aspir
lymph
node
patient
resolv
month
oral
erythromycin
administ
three
patient
treatment
signific
affect
durat
conclus
gener
aden
post
bcg
vaccin
surgeri
needl
aspir
rare
need
clean
area
lymph
node
care
follow
patient
highli
recommend
introduct
product
effect
vaccin
formul
depend
avail
assay
measur
protect
immun
respons
antibodyand
complementmedi
phagocytosi
main
defenc
mechan
neisseria
meningitidi
method
therefor
newli
develop
phagocytosi
assay
base
flow
cytometri
flow
assay
use
sera
obtain
rabbit
postvaccin
bival
conjug
neisseria
meningitidi
serogroup
capsular
polysaccharid
cpsa
serogroup
b
outer
membran
vesicl
contain
pora
omvpora
omvpora
neisseria
meningitidi
serogroup
b
cpsa
control
done
order
evalu
potenti
efficaci
experiment
meningococc
vaccin
conjug
control
inject
intramuscularli
group
five
rabbit
booster
day
primari
immun
follow
group
use
control
cpsa
omvpora
normal
salin
serum
day
collect
store
next
analysi
phagocyt
function
intracellular
oxid
burst
gener
rabbit
pmn
neisseria
meningitidi
serogroup
b
measur
flow
cytomet
coulter
epicsxlprofil
usa
use
probe
respect
experi
nonheatinactiv
standard
strain
neisseria
meningitidi
serogroup
csbpi
b
csbpi
use
result
result
quantit
flow
cytometr
analysi
rabbit
pmn
function
hyperimmun
sera
glycoprotein
conjug
reveal
highli
signific
increas
opsonophagocyt
respons
serogroup
meningococci
day
comparison
cpsa
omvpora
control
group
p
opsonophagocyt
respons
serogroup
b
meningococci
conjug
show
signific
differ
comparison
omvpora
contain
control
p
conclus
result
indic
cpsa
omvpora
conjug
could
candid
bival
vaccin
toward
serogroup
b
meningococci
introduct
bacteri
mening
caus
differ
group
neisseria
meningitidi
still
one
seriou
health
problem
world
wide
method
present
investig
standard
serogroup
b
strain
nmeningitidi
csbpi
grown
controlledsubmerg
cultur
condit
ferment
contain
modifi
frantz
medium
cell
harvest
late
exponenti
growth
phase
outer
membran
vesicl
contain
pora
omvpora
extract
cell
wall
accord
deoxychol
extract
techniqu
purifi
sequenti
centrifug
ultracentrifug
step
molecular
evalu
omvpora
done
micrograph
scan
electron
microscop
sdspage
ident
omvpora
determin
doubl
diffus
gel
techniqu
use
hyperimmun
rabbit
antiomvpora
antisera
purifi
vesicl
nmeningitidi
serogroup
capsular
polysaccharid
cpsa
conjug
serogroup
b
omvpora
order
test
possibl
obtain
bival
serogroup
b
meningococcu
vaccin
conjug
control
inject
intramuscularli
group
five
rabbit
booster
day
primari
immun
follow
group
use
control
cpsa
plu
omvpora
cpsa
omvpora
iv
normal
salin
serum
collect
day
test
complement
mediat
bactericid
assay
elisa
titer
induct
protect
immunorespons
rabbit
model
result
micrograph
scan
electron
microscop
omvpora
retain
nativ
configur
structur
extract
procedur
purifi
vesicl
show
strong
band
kd
molecular
weight
run
polyacrylamid
gel
electrophoresi
sd
strong
precipit
line
hyperimmun
rabbit
anti
omvpora
antisera
purifi
vesicl
shown
doubl
diffus
gel
techniqu
result
immunolog
evalu
glycoprotein
conjug
reveal
signific
increas
serum
bactericid
titr
well
elisa
titr
serogroup
meningococci
day
comparison
cpsa
omvpora
control
group
bactericid
elisa
titr
serogroup
b
meningococci
conjug
show
signific
differ
comparison
omvpora
contain
control
result
indic
cpsaomvpora
conjug
could
candid
bival
vaccin
toward
serogroup
b
meningococci
efficaci
vaccin
serogroup
c
meningococc
diseas
one
shot
age
month
netherland
result
number
case
serogroup
b
meningococc
diseas
prevaccin
period
postvaccin
period
respect
number
case
serogroup
c
meningococc
diseas
prevaccin
period
postvaccin
period
respect
among
person
age
month
year
number
case
serogroup
c
diseas
reduc
case
prevaccin
period
three
case
postvaccin
period
three
patient
vaccin
number
serogroup
c
isol
among
person
younger
month
decreas
case
among
person
older
year
reduc
case
postvaccin
period
reduct
case
serogroup
c
diseas
among
nonvaccin
might
indic
herd
protect
although
bimonthli
distribut
case
serogroup
c
diseas
show
declin
start
alreadi
introduct
vaccin
independ
age
group
conclus
sinc
incid
meningococc
diseas
netherland
declin
partli
caus
natur
fluctuat
incid
serogroup
b
well
serogroup
c
meningococc
diseas
nevertheless
vaccin
serogroup
c
meningococc
diseas
one
shot
age
month
effect
contribut
significantli
declin
incid
meningococc
diseas
introduct
vaccin
case
serogroup
c
meningococc
diseas
longer
observ
among
vaccin
nrlbm
object
current
two
formul
pneumococc
vaccin
avail
prevent
invas
diseas
adult
children
howev
vaccin
protect
major
streptococcu
pneumonia
serotyp
highli
conserv
surfac
protein
vaccin
may
circumv
problem
method
pneumonia
surfac
protein
isol
mutanolysin
treatment
identifi
via
proteom
platform
ace
bioscienc
technolog
appli
includ
onedimension
twodimension
polyacrylamid
gelelectrophores
well
insolut
base
strategi
combin
mass
spectrometri
identifi
protein
extens
screen
process
includ
silico
vitro
vivo
valid
criteria
exampl
target
rna
detect
rtpcr
infect
tissu
sequenc
differ
pneumonia
serotyp
assess
possibl
role
infect
variabl
conserv
amongst
serotyp
final
five
candid
select
express
e
coli
purifi
immunis
experi
anim
efficaci
data
demonstr
mous
sepsi
model
mice
vaccin
candid
protein
challeng
pneumonia
strain
immunogen
test
appli
elisa
technolog
result
identifi
pneumonia
surfac
protein
five
protein
select
vaccin
candid
protein
detect
least
differ
serotyp
pneumonia
express
pneumonia
infect
moreov
least
two
candid
show
protect
sepsi
anim
model
p
ttest
cfuml
blood
challeng
pneumonia
compar
group
vaccin
unrel
protein
conclus
identifi
two
promis
pneumonia
vaccin
candid
ace
bioscienc
proteom
platform
valid
vivo
anim
sepsi
model
candid
excel
runner
novel
protein
base
pneumococc
vaccin
seropathotyp
adher
abil
inflammatori
effect
induc
cellular
substratum
enteropathogen
e
coli
strain
isol
aquat
environ
r
cernat
v
lazar
mc
balotescu
bucharest
ro
introduct
enter
pathogen
infect
human
gastrointestin
tract
eg
salmonella
e
coli
shigella
yersinia
rapidli
upregul
express
program
intestin
epitheli
cell
gene
product
chemoattract
activ
popul
leucocyt
import
onset
host
protect
mucos
inflammatori
respons
type
iii
secret
system
enteropathogen
e
coli
epec
strain
associ
abil
induc
secret
proinflamatori
cytokin
antimicrobi
peptid
cultur
intestin
epitheli
cell
purpos
serotyp
screen
virul
marker
investig
vivo
adher
capac
cellular
substratum
evalu
vitro
inflammatori
respons
induc
caco
epitheli
cell
infect
aquat
e
coli
strain
method
serotyp
accord
kauffmannwhit
scheme
pcrgenotyp
use
eaea
bfpa
eaf
gene
vitro
studi
adher
invas
capac
hela
cell
investig
cravioto
method
adher
inert
substratum
evalu
slime
test
rtpcr
express
level
gene
encod
gapdh
result
aquat
e
coli
strain
belong
typic
eae
bfpa
eaf
eae
eaf
genotyp
atyp
eae
bfp
eaf
genotyp
epec
nonepec
serogroup
adhes
inert
cellular
substratum
prove
gener
featur
aquat
epec
show
local
diffus
adher
pattern
affect
cellular
densiti
periton
liquid
variabl
composit
chronic
infect
mice
bacteri
product
cdf
type
exfoliant
toxin
mitogen
induc
effect
epitheli
cell
observ
epec
strain
induc
low
express
level
gapdh
gene
accord
valu
obtain
gapdh
minim
valu
minim
valu
ratio
conclus
predomin
aquat
environ
epec
strain
seropathovar
differ
clinic
epec
strain
rel
distinct
virul
profil
aquat
epec
strain
predominantli
induc
low
inflammatori
effect
caco
cell
might
due
involv
differ
cytokin
combin
studi
prove
aquat
media
repres
import
reservoir
sourc
dissemin
transfer
opportunist
pathogen
differ
virul
marker
includ
antibiot
resist
gene
major
implic
human
patholog
characteris
intestin
lactobacilli
potenti
secondgener
probiot
increas
interest
develop
second
gener
probiot
sgp
eg
applic
lactobacillu
speci
vaccin
deliveri
vector
effect
probiot
greatli
influenc
abil
persist
gut
properti
differ
among
variou
strain
therefor
besid
l
casei
l
plantarum
frequent
use
transform
strain
speci
test
object
character
intestin
lactobacilli
reflect
potenti
use
sgp
method
studi
includ
strain
isol
faec
healthi
children
strain
belong
cultur
collect
depart
microbiolog
univers
tartu
includ
ten
speci
homofer
lactobacillu
acidophilu
l
crispatu
l
delbrueckii
l
salivariu
heterofer
l
paracasei
l
plantarum
l
brevi
l
buchneri
l
coprophilu
l
fermentum
first
strain
test
autoaggreg
adhes
marker
promis
strain
test
resist
low
ph
ph
bile
content
thereaft
strain
best
characterist
select
test
resist
pancreatin
antibiot
suscept
pattern
differ
antibiot
result
strain
aggreg
degre
strongest
valu
among
strain
l
acidophilu
group
lowest
ph
toler
lactobacilli
l
acidophilu
strain
wherea
strain
nine
homofer
heterofer
strain
resist
ph
nearli
strain
resist
bile
concentr
six
time
physiolog
concentr
strain
resist
pancreatin
five
time
physiolog
concentr
two
l
plantarum
strain
differ
innat
resist
pattern
lactobacilli
reveal
resist
tetracyclin
due
possibl
mobil
genet
element
conclus
sever
human
homoand
heterofer
lactobacilli
particular
strain
l
acidophilu
l
paracasei
l
fermentum
possess
properti
requir
persist
gut
could
use
develop
novel
sgpthe
studi
support
commiss
european
union
biodef
immunolog
determin
diseas
pathogenesi
indian
leishmaniasi
method
exploit
flowcytometri
revers
transcriptas
pcr
rtpcr
microarray
technolog
character
immun
respons
radiolabel
cdna
probe
prepar
rna
isol
tissu
hybrid
nylon
membran
gene
array
chip
compris
cytokinereceptor
gene
clinic
sampl
collect
ka
serum
n
tissu
n
pkdl
serum
n
tissu
n
control
serum
n
tissu
n
result
analysi
circul
cytokin
use
cba
kit
show
significantli
elev
level
ifng
activ
ka
restor
control
valu
end
treatment
pkdl
serum
tnfa
found
significantli
elev
compar
ka
control
cytokin
level
compar
control
estim
tissu
level
rtpcr
reveal
signific
elev
messag
transcript
mention
cytokin
activ
ka
pkdl
compar
control
understand
broader
pictur
diseas
pathogenesi
exploit
microarray
technolog
analysi
mrna
level
cytokinereceptor
gene
result
show
alter
express
sever
cytokin
chemokin
receptor
cd
marker
apoptot
gene
regul
ifng
tnfa
tgfb
evid
array
interestingli
express
found
significantli
lower
ka
pkdl
also
valid
rtpcr
conclus
data
implic
role
sever
cytokin
pathogenesi
ka
pkdl
elev
level
ifng
coupl
low
level
indic
unrespons
stimuli
prevail
activ
diseas
high
level
serum
protein
messag
level
tnfa
pkdl
patient
suggest
investig
tnf
locu
indian
leishmaniasi
patient
warrant
sinc
polymorph
locu
associ
autoimmun
infecti
diseas
includ
leishmaniasi
associ
polymorph
gene
encod
human
innat
immun
factor
persist
nasal
staphylococcu
aureu
colonis
nasal
carriag
staphylococcu
aureu
provok
neutrophilmedi
inflammatori
host
respons
result
elev
concentr
antimicrobi
peptid
site
colon
polymorph
allel
frequenc
genotyp
gene
encod
innat
immun
factor
determin
volunt
n
known
aureu
carriag
statu
persist
carrier
intermitt
carrier
noncarri
determin
polymorph
noncod
part
alphaand
betadefensin
gene
promoterand
code
region
mannosebind
lectin
gene
heterozyg
genotyp
hnp
found
occur
frequent
among
persist
carrier
among
noncarri
p
carrier
differ
noncarri
baselin
level
hnp
peptid
product
well
versu
lgml
p
signific
associ
hnp
product
level
polymorph
document
allel
frequenc
mbl
gene
affect
aureu
nasal
colon
human
mbl
haplotyp
overrepres
persist
carrier
group
p
result
indic
overal
product
hnp
peptid
associ
protect
aureu
nasal
carriag
polymorph
gene
encod
innat
immun
factor
variat
allelicor
genotyp
frequenc
thereof
affect
aureu
nasal
colon
statu
human
interfer
pathogen
bacteria
cystic
fibrosi
sullivan
f
karpati
l
hjelt
b
wretlind
ce
nord
stockholm
se
object
investig
prevent
effect
alphahaemolyt
streptococci
recolon
airway
pseudomona
aeruginosa
patient
cystic
fibrosi
cf
therebi
reduc
number
treatment
antimicrobi
agent
method
saliva
sampl
healthi
children
n
healthi
adult
n
saliva
n
sputum
n
sampl
cfchildren
collect
saliva
sampl
dilut
inocul
select
agar
plate
streptococci
sputum
sampl
inocul
undilut
bloodagar
plate
streptococc
strain
differ
morpholog
collect
isol
pure
cultur
total
strain
alphahaemolyt
streptococci
identifi
test
initi
inhibit
growth
clinic
isol
three
strain
p
aeruginosa
one
strain
stenotrophomona
maltophilia
two
strain
staphylococcu
aureu
two
strain
burkholderia
cepacia
strain
inhibitori
activ
least
three
pathogen
kept
analys
test
perform
agar
overlay
techniqu
avoid
interf
factor
like
effect
ph
pathogen
use
clinic
isol
p
aeruginosa
noncf
cf
patient
abl
identifi
strain
clinic
sampl
streptomycin
resist
induc
result
strain
streptococci
strongest
inhibitori
effect
growth
pathogen
common
cfpatient
isol
healthi
children
adult
strain
isol
cfpatient
weak
inhibitori
effect
eight
strain
strongest
inhibitori
capac
one
exclud
extrem
product
extracellular
dextran
two
exclud
difficulti
induc
streptomycin
resist
remain
five
strain
identifi
streptococcu
orali
conclus
strain
alphahaemolyt
streptococci
identifi
inhibit
effect
p
aeruginosa
pathogen
common
cfpatient
vivo
interf
properti
strain
initi
test
mous
model
prevent
effect
strain
final
evalu
patient
suffer
cystic
fibrosi
intermitt
colon
p
aeruginosa
new
insight
role
platelet
antifung
host
defenc
c
rl
unterdorf
w
nussbaum
mp
dierich
innsbruck
background
observ
serotonin
ht
act
fungicid
aspergillu
speci
decreas
fungal
virul
vitro
human
ht
store
platelet
ht
concentr
granul
mm
data
coincid
increas
infect
rate
low
ht
level
certain
diseas
let
us
examin
role
platelet
antifung
host
defenc
method
investig
express
platelet
surfac
receptor
cd
p
cd
cd
follow
aspergillu
hypha
exposit
fluoresc
label
platelet
mix
fungi
ratio
incub
h
platelet
activ
adher
hypha
aspergillu
sp
investig
zeiss
dsm
scan
electron
microscop
sem
xtt
test
appli
assess
platelet
plateletsneutrophil
effect
viabil
influenc
fungal
growth
examin
assess
hyphal
elong
clinic
isol
aspergillu
fumigatu
n
aspergillu
terreu
n
use
studi
test
perform
triplic
repeat
three
time
result
aspergillu
spp
induc
platelet
activ
cd
cd
cd
antigen
clearli
induc
visual
fluoresc
microscopi
strain
depend
express
observ
spread
irregular
shape
platelet
hyphal
surfac
shown
sem
platelet
decreas
abil
hypha
reduc
xtt
coincub
polymorphonuclear
neutrophil
increas
fungal
damag
significantli
p
hyphal
elong
significantli
decreas
lm
platelet
comparison
untreat
hypha
lm
h
incub
conclus
impair
capac
fungi
reduc
xxt
express
membran
receptor
surfac
marker
platelet
activ
decreas
hyphal
elong
confirm
platelet
potenti
play
import
role
host
defenc
aspergillu
speci
role
mannosebind
lectin
suscept
infect
prematur
neonat
dzwonek
neth
j
hawdon
e
gulczynska
h
tchorzewski
turner
n
klein
london
uk
lodz
pl
background
infect
remain
one
frequent
clinic
complic
prematur
neonat
part
due
suboptim
host
defenc
present
studi
explor
impact
mannosebind
lectin
mbl
genotyp
phenotyp
suscept
infect
outcom
sepsi
method
mblexon
promot
polymorph
studi
pcr
follow
heteroduplexingmbl
serum
protein
level
measur
elisa
varieti
statist
test
utilis
appropri
analysi
wild
type
allel
denot
variant
allel
object
detect
protect
effect
oral
polybacteri
immunomodul
urostim
u
prophylaxi
wound
urinari
tract
infect
uti
urolog
patient
method
oral
polybacteri
immunomodul
compos
kill
cell
lysat
escherichia
coli
express
type
rpili
e
coli
r
mutant
proteu
mirabilli
klebsiella
pneumonia
enterococcu
faecali
use
patient
enrol
studi
receiv
oral
mg
u
daili
period
three
month
patient
two
group
urolog
patient
free
uti
urostim
administ
day
oper
result
prophylact
effect
u
term
hospit
acquir
wound
uti
record
basi
compar
studi
control
group
antibiot
prophylact
obtain
result
show
urostim
immunoprophylaxi
yeld
posit
result
urolog
practic
case
develop
complic
prevent
case
microbiolog
find
persist
control
group
number
complic
uncur
case
higher
consist
group
result
provid
evid
posit
immunomodul
effect
urostim
predominantli
treat
antibiot
uti
lead
appear
multiresist
strain
mainli
gramneg
spp
vaccin
administr
combin
antibiot
broaden
therapeut
opportun
urolog
patient
altern
approach
ssi
prevent
control
uti
mucos
vaccin
immunomodul
object
polymorphonuclear
cell
pmn
otherwis
known
neutrophil
bodi
first
line
defenc
bacteri
infect
antibiot
appear
modul
pmn
function
vitro
postantibiot
leukocyt
enhanc
pale
report
mechan
increas
bacteri
clearanc
pmn
vitro
due
sensit
bacteria
via
preexposur
antibiot
mous
thigh
infect
model
faropenem
far
previous
shown
activ
streptococcu
pneumonia
normal
vs
neutropen
mice
object
studi
test
whether
far
initi
pale
method
pale
conduct
use
far
therapeut
achiev
plasma
concentr
free
drug
haemophilu
influenza
well
submic
staphylococcu
aureu
far
remov
via
centrifug
bacteria
introduc
isol
pmn
sampl
taken
hour
incub
plate
bacteri
viabil
compar
agent
includ
amoxicillin
amoxicillin
clavulan
cefuroxim
result
far
produc
posit
pale
effect
studi
compar
effect
pmn
alon
pretreat
far
minut
follow
remov
drug
result
greater
reduct
viabl
cfu
pmn
aureu
h
influenza
viabl
coloni
count
reduc
level
detect
minut
bacteria
pretreat
far
expos
pmn
comparison
untreat
bacteria
presenc
pmn
reduct
cfu
far
treatment
submic
mic
aureu
show
reduct
cfu
comparison
control
conclus
brief
nonleth
exposur
bacteria
far
consider
enhanc
bactericid
activ
pmn
aureu
h
influenza
faropenem
may
enhanc
pmn
mediat
kill
select
organ
may
play
role
enhanc
leucocyt
mediat
kill
bacteria
sinc
faropenem
target
cell
wall
biosynthesi
submic
concentr
drug
may
affect
cell
morpholog
may
contribut
enhanc
kill
leucocyt
togeth
effect
may
explain
part
increas
efficaci
far
normal
vs
neutropen
host
light
microscop
appear
resid
macrophag
adren
gland
pregnant
nonpregn
guinea
pig
immunoendocrinolog
signific
e
ozbek
ozbek
erzurum
tr
object
macrophag
nonlymphoid
immun
cell
phagocytot
function
although
tissuespecif
macrophag
kupffer
cell
microglia
wellknown
knowledg
adren
macrophag
yet
document
textbook
aim
conduct
light
microscop
studi
show
resid
macrophag
adren
method
eight
nonpregn
eight
pregnant
guinea
pig
use
sacrif
anim
adren
promptli
remov
fix
bouin
solut
dehydr
ethanol
embed
paraffin
section
stain
haematoxylineosin
period
acidschiff
pa
examin
light
microscop
result
found
mani
macrophag
primarili
zona
reticulari
close
medulla
adren
especi
adjac
sinusoid
stellat
appear
due
cytoplasm
process
extend
cell
bodi
cytoplasm
stain
yellowish
suggest
rich
lipofussin
pigment
granul
pa
indic
excess
lysosom
content
saw
much
adren
macrophag
pregnant
anim
comparison
nonpregn
conclus
macrophag
recent
thought
favour
cell
interact
neuroendocrin
organ
immun
system
also
secret
cytokin
immun
respons
whole
organ
usual
affect
reflect
neuroendocrin
metabol
alter
one
effect
immun
stimul
elev
glucocorticoid
blood
level
known
glucocorticoid
releas
adrenocort
cell
betaadrenerg
receptor
character
within
adren
cortex
indic
suscept
sympathet
stimul
regulatori
function
medullar
product
steroid
secret
cortic
cell
may
henc
present
expect
mediat
paracrin
manner
cytokin
releas
macrophag
tumour
necrosi
factor
tnf
alpha
interleukin
il
may
influenc
adrenocort
steroidogenesi
medullari
catecholamin
recent
shown
tnfalpha
direct
acthindepend
stimulatori
effect
corticosteron
secret
rat
macrophag
may
pivot
role
bidirect
immuneadrenocort
commun
within
adren
final
resid
macrophag
adren
wait
document
textbook
blood
lymphocyt
subset
patient
tickborn
enceph
predict
tickborn
enceph
tbe
clinic
cours
problemat
usual
therefor
sever
immunolog
paramet
look
sever
prognosi
certain
phase
clinic
form
tbe
aim
aim
studi
chang
immunolog
paramet
tbe
patient
provid
addit
prognost
inform
cours
patholog
process
patient
method
patient
tbe
treat
infectolog
center
latvia
includ
studi
diagnosi
tbe
confirm
elisa
enzygnost
antitb
igm
blood
andor
cerebrospin
fluid
detect
lymphocyt
subpopul
blood
perform
flow
cytometri
method
tradit
clinic
criteria
use
detect
sever
tbe
result
analysi
chang
number
lymphocyt
subset
patient
moder
tbe
mening
dynam
show
follow
decreas
level
tlymphocyt
acut
stage
contrari
reconvalesc
p
decreas
level
activ
tlymphocyt
acut
stage
reconvalesc
p
decreas
level
hladr
activ
blymphocyt
acut
stage
reconvalesc
p
decreas
level
helper
acut
stage
reconvalesc
p
suppressor
acut
stage
contrari
reconvalesc
p
analysi
chang
number
lymphocyt
subpopul
patient
sever
tbe
meningoenceph
dynam
show
follow
decreas
level
tlymphocyt
acut
stage
compar
reconvalesc
p
decreas
level
hladr
activ
blymphocyt
acut
stage
reconvalesc
p
decreas
level
helper
acut
stage
contrari
reconvalesc
p
conclus
signific
timedepend
chang
blood
lymphocyt
subset
tbe
cours
observ
differ
lymphocyt
subpopul
moder
sever
tbe
clinic
form
found
syphili
transmit
sexual
blood
transfus
serious
diseas
high
risk
complic
congenit
infect
laboratori
diagnosi
larg
base
serolog
test
immunoassay
wide
use
syphili
screen
highli
sensit
easili
autom
studi
compar
perform
architect
syphili
assay
routin
screen
protocol
studi
sera
sampl
syphili
antibodi
request
current
protocol
screen
syphili
antibodi
laboratori
includ
immunoassay
detect
total
specif
igg
igm
antibodi
enzygnost
syphili
dade
behr
reactiv
sampl
test
tpha
method
tpha
syphili
biokit
discrep
result
resolv
lineblot
immunoassay
innolia
syphili
innogenet
architect
syphili
immunoassay
detect
antitreponem
igg
igm
antibodi
integr
architect
robot
platform
onehundredninetynin
sampl
categor
reactiv
follow
screen
protocol
sampl
reactiv
architect
syphili
seventeen
sampl
tpha
confirm
lineblot
sera
reactiv
architect
syphili
median
lower
median
tpha
reactiv
sampl
twohundredtwentyon
sampl
neg
screen
protocol
one
sampl
reactiv
architect
consid
fals
reactiv
contrast
enzygnost
dade
behr
found
five
sampl
fals
reactiv
accord
result
architect
syphili
demonstr
sensit
specif
posit
predict
valu
neg
valu
conclus
remark
excel
perform
architect
syphili
assay
use
syphili
serolog
screen
test
speed
autom
make
recommend
test
laboratori
high
load
routin
object
increas
bodi
evid
monocyt
chemoattract
play
major
role
pathogenesi
renal
diseas
involv
initi
progress
tubulointerstiti
damag
late
evid
human
correl
glomerular
express
degre
renal
damag
inflammatori
noninflammatori
model
glomerular
injuri
patient
method
studi
role
pathogenesi
progress
acut
pyelonephr
febril
infant
month
age
initi
dmsa
scan
patient
reveal
renal
lesion
patient
followup
scan
perform
month
later
patient
show
revers
lesion
three
renal
scar
nine
mcug
perform
patient
reveal
signific
vesicureter
reflux
grade
iii
mild
reflux
grade
ii
two
infant
respect
measur
plasma
level
lincoplex
human
cytokin
chemokin
kit
use
luminex
xmap
technolog
admiss
patient
three
day
initi
treatment
result
increas
significantli
patient
diagnosi
urinari
tract
infect
compar
pgml
control
p
compar
valu
patient
normal
dmsa
patient
renal
lesion
observ
either
remain
high
increas
patient
whose
dmsa
abnorm
affect
initi
treatment
group
patient
especi
patient
end
renal
scar
followup
scan
similar
result
found
group
patient
sever
vesicureter
reflux
also
observ
decreas
treatment
although
normal
level
group
patient
whose
dmsa
scan
initi
normal
also
decreas
small
group
patient
revers
lesion
dmsa
conclus
find
show
level
increas
infant
febril
urinari
tract
infect
increas
pronounc
patient
true
renal
damag
appar
chemoattract
apart
experiment
proven
role
direct
elicitor
inflammatori
respons
induc
cytokin
adhes
molecul
express
kidney
may
also
play
clinic
role
prognosi
acut
renal
damag
maedivisna
mv
slow
lentiviru
infect
sheep
common
mediterranean
region
europ
small
field
trial
use
inactiv
whole
viru
vaccin
alun
iceland
mv
strain
carri
one
natur
infect
sheep
flock
cypru
one
femal
twin
lamb
femal
twin
pair
vaccin
birth
week
later
month
age
twin
serv
unvaccin
control
vaccin
twin
kept
flock
natur
condit
bled
regularli
month
later
twin
seroneg
nine
vaccin
two
unvaccin
twin
mother
twin
pair
seroconvert
time
birth
lamb
eight
twin
pair
unvaccin
twin
seroconvert
month
age
vaccin
twin
month
three
pair
twin
seroconvert
month
age
two
pair
vaccin
twin
becam
infect
earlier
sibl
twin
pair
born
seroneg
mother
vaccin
twin
infect
later
unvaccin
sibl
month
four
pair
vaccin
twin
infect
earlier
sibl
two
pair
twin
seroconvert
earli
year
life
virul
iceland
vaccin
strain
differ
low
slow
mv
strain
isol
sheep
flock
slight
crossreact
local
strain
vaccin
strain
detect
serolog
test
yet
vaccin
vaccin
appar
delay
possibl
case
prevent
natur
infect
month
heavili
contamin
environ
object
prevent
hepat
b
viru
hbv
transmiss
reli
partli
vaccin
high
risk
subject
numer
among
patient
attend
free
anonym
hiv
test
site
faht
purpos
assess
risk
profil
vaccin
histori
serolog
statu
repres
sampl
high
risk
patient
attend
faht
pari
method
sampl
anonym
patient
file
randomli
select
among
file
patient
attend
faht
pital
bichat
claud
bernard
pari
year
sociodemograph
profil
risk
factor
vaccin
histori
serolog
profil
patient
depict
use
descript
statist
result
among
patient
one
risk
factor
hbv
infect
henc
test
hbv
femal
male
mean
age
sd
year
birth
countri
franc
subsaharan
africa
north
africa
european
countri
other
hbv
risk
factor
multipl
sexual
partner
origin
high
medium
endem
area
histori
sexual
transmit
diseas
profession
exposur
histori
transfus
intraven
drug
use
nearli
third
patient
histori
complet
hbv
vaccin
report
incomplet
ongo
vaccin
remain
known
histori
vaccin
hbv
serolog
show
patient
natur
vaccineinduc
immun
hb
antigen
carrier
thu
high
risk
patient
hbv
immun
conclus
patient
high
risk
hbv
infect
numer
among
attend
faht
french
larg
citi
nearli
two
third
patient
hbv
immun
thu
faht
consult
appear
good
opportun
identifi
patient
offer
hbv
vaccin
object
literatur
major
studi
consid
diencephal
telencephal
locat
virus
correl
histopatholog
find
minor
attent
paid
brainstem
structur
involv
regul
autonom
function
aim
studi
identifi
brainstem
genom
sequenc
seri
neurotrop
virus
hiv
jcv
bkv
ebv
cmv
detect
histopatholog
find
ascrib
viral
infect
method
brainstem
subject
die
acut
opiat
intox
studi
histolog
immunohistochem
antibodi
gfap
stain
case
realtim
pcr
search
viral
sequenc
perform
histopatholog
find
compar
pcrposit
neg
brainstem
mannwhitney
method
among
differ
level
section
oneway
anova
newmannkeul
test
result
sampl
sequenc
hiv
provir
dna
identifi
one
hivposit
sampl
dna
also
found
anoth
sampl
bkv
dna
detect
hivneg
sampl
genom
sequenc
also
found
anoth
sampl
cmv
sequenc
detect
hivposit
neg
brainstem
show
presenc
oedema
perivascular
parenchym
inflammatori
infiltr
microgli
prolifer
sporad
microgli
nodul
perivascular
infiltr
numer
major
cellular
hivposit
brainstem
mean
index
perivascular
infiltr
sd
vs
p
mainli
compos
tcell
differ
detect
among
differ
level
section
conclus
result
confirm
brainstem
tropism
hiv
demonstr
also
bkv
cmv
possibl
locat
district
moreov
studi
show
report
literatur
diencephal
telencephal
structur
also
brainstem
hivposit
presymptomat
subject
histopatholog
find
due
locat
viru
nervou
tissu
object
qtc
interv
prolong
electrocardiograph
ecg
abnorm
may
caus
sever
arrhythmia
includ
torsad
de
point
ventricular
fibril
mani
drug
administ
hivposit
patient
accord
author
hiv
infect
induc
qtc
interv
prolong
aim
studi
calcul
frequenc
qtc
prolong
cohort
hivinfect
outpati
identifi
risk
factor
associ
ecg
abnorm
method
infecti
diseas
unit
perform
ecg
record
consecut
hivinfect
subject
follow
outpati
clinic
subject
follow
data
collect
demograph
featur
risk
factor
hiv
infect
ongo
therapi
prophylaxi
cardiolog
risk
factor
cell
count
hiv
viraemia
result
main
haematochem
test
ecg
evalu
two
independ
cardiologist
qtc
calcul
nest
casecontrol
studi
perform
use
case
patient
qtc
sec
male
sec
femal
control
hiv
infect
subject
match
gender
age
less
year
associ
qtc
interv
prolong
potenti
risk
factor
evalu
term
adjust
odd
ratio
aor
confid
interv
ci
use
multivari
logist
model
result
cohort
ecg
abnorm
record
subject
twentytwo
subject
male
femal
show
qtc
interv
prolong
multivari
analysi
follow
variabl
associ
presenc
long
qtc
use
cotrimoxazol
prophylaxi
p
jiroveci
pneumonia
aor
ci
efavirenz
part
current
antiretrovir
regimen
aor
ci
presenc
serum
triglycerid
level
mgdl
aor
ci
conclus
accord
data
qtc
interv
prolong
associ
use
drug
commonli
administ
hivinfect
patient
cotrimoxazol
efavirenz
role
low
serum
triglycerid
level
need
investig
clinician
perform
strict
cardiolog
followup
hiv
infect
subject
situat
may
potenti
result
qt
prolong
lifethreaten
arrhythmia
preval
paediatr
septicaemia
tertiari
hospit
tanzania
object
septicaemia
common
caus
hospit
morbid
death
children
septicaemia
caus
drugresist
organ
difficult
treat
studi
assess
preval
septicaemia
children
muhimbili
nation
hospit
dare
salaam
tanzania
impact
microbi
aetiolog
antimicrobi
suscept
hiv
coinfect
clinic
outcom
method
prospect
cohort
studi
august
august
investig
consecut
admiss
children
age
year
sign
system
infect
blood
cultur
obtain
bacteri
isol
identifi
standard
method
suscept
test
disk
diffus
method
blood
taken
malaria
hiv
test
hiv
posit
antibodi
test
patient
younger
month
verifi
determin
rna
clinic
data
obtain
standard
questionnair
patient
record
department
record
result
septicaemia
bacteria
fungi
confirm
cultur
children
symptom
system
infect
frequent
isol
klebsiella
pneumonia
n
escherichia
coli
n
variou
salmonella
enterica
serotyp
n
staphylococcu
aureu
n
e
faecium
n
e
fecali
n
candida
spp
malaria
found
test
includ
patient
concomit
septicaemia
malaria
associ
lower
casefat
rate
septicaemia
particularli
gramneg
septicaemia
multidrugresist
includ
extendedspectrum
betalactamas
phenotyp
common
gramneg
isol
associ
casefat
rate
excess
hiv
infect
present
patient
test
multipl
regress
model
recoveri
gramneg
bacteria
ci
esbl
phenotyp
ci
hiv
coinfect
ci
independ
associ
fatal
outcom
conclus
malaria
appear
slightli
common
caus
system
infect
children
tanzanian
hospit
septicaemia
carri
significantli
higher
casefat
rate
partli
widespread
multidrugresist
particularli
gramneg
bacteria
object
aim
studi
elucid
pathogenesi
highli
activ
antiretrovir
therapi
haart
associ
lipodystrophi
investig
effect
antiretrovir
drug
adipocyt
differenti
gene
express
profil
method
preadipocyt
wide
use
vitro
model
adipogenesi
induc
matur
adipocyt
treat
nucleosid
revers
transcriptas
inhibitor
nrti
proteas
inhibitor
pi
adipocyt
differenti
studi
oil
red
stain
wherea
gene
express
profil
evalu
dna
microarray
quantit
rtpcr
analys
result
standard
adipogen
differenti
protocol
pi
significantli
inhibit
adipocyt
differenti
demonstr
cell
viabil
assay
oil
red
stain
quantif
wherea
nrti
mild
effect
adipogenesi
gene
express
profil
analysi
show
treatment
nrti
modul
express
transcript
factor
could
play
key
role
determin
adipocyt
phenotyp
pi
also
modul
gene
express
toward
inhibit
adipocyt
differenti
upregul
wnt
signal
gene
downregul
express
gene
encod
master
adipogen
transcript
factor
eg
cebpalpha
ppargamma
oestrogen
receptor
gamma
adipocytespecif
marker
eg
adiponectin
leptin
mrap
conclus
studi
indentifi
new
gene
modul
pi
nrti
differenti
adipocyt
abnorm
express
gene
includ
master
adipogen
transcript
factor
gene
involv
lipid
metabol
cell
cycl
control
could
contribut
understand
pathogenesi
haartassoci
lipodystrophi
indetermin
hiv
western
blot
profil
may
proceed
g
saliba
matheron
f
damond
pari
fr
object
western
blot
wb
wide
accept
confirmatori
assay
detect
hiv
antibodi
indetermin
wb
reactiv
occur
certain
individu
mani
diagnosi
criteria
interpret
wb
test
alreadi
propos
among
three
mainli
appli
worldwid
world
health
organis
center
diseas
control
prevent
cdc
american
red
cross
arc
criteria
criteria
use
institut
conduct
review
studi
check
appli
cdc
arc
criteria
subject
indetermin
hiv
profil
would
help
us
better
interpret
statu
tri
determin
altern
mean
case
uncertainti
method
review
retrospect
chart
patient
test
hiv
februari
may
institut
indetermin
wb
result
biorad
reinterpret
profil
accord
arc
cdc
criteria
result
patient
identifi
women
men
origin
central
africa
mean
age
year
two
pregnant
women
given
arv
treatment
prevent
potenti
mother
child
transmiss
hiv
incomplet
pattern
wb
accord
criteria
make
hiv
statu
indetermin
appli
cdc
arc
diagnosi
criteria
reinterpret
wb
result
show
obviou
discrep
eight
patient
show
posit
profil
six
accord
cdc
three
accord
arc
one
patient
posit
arc
cdc
simultan
eight
patient
posit
elisa
screen
test
bioradbiomerieux
vida
hiv
non
conclus
wb
pattern
three
criteria
among
band
screenedfor
wb
gag
env
gene
product
reactiv
frequent
encount
compar
pol
gene
product
reactiv
patient
neg
hiv
rna
screen
blood
test
initi
none
prove
posit
long
term
follow
test
conclus
appli
cdc
arc
criteria
reinterpret
indetermin
hiv
wb
profil
accord
show
tremend
discrep
nt
prove
conveni
altern
advanc
work
experi
think
advis
least
screen
plasma
hiv
rna
case
neg
result
solid
argument
potenti
hiv
infect
insist
necess
long
term
follow
hiv
drug
approv
fda
dozen
reach
least
earli
stage
clinic
develop
hiv
therapeut
domain
path
market
success
compound
long
costli
sometim
ineffici
elia
zerhouni
md
director
nih
set
translat
research
prioriti
mani
nih
institut
form
offic
program
acceler
progress
discoveri
market
fda
believ
new
product
develop
toolkitcontain
power
new
scientif
technic
method
anim
computerbas
predict
model
biomark
safeti
effect
new
clinic
evalu
techniquesi
urgent
need
improv
predict
effici
along
critic
path
laboratori
concept
commerci
product
pharsight
conduct
hiv
project
use
modelbas
drug
develop
techniqu
past
seven
year
develop
phase
cover
critic
issu
trial
design
dose
select
trial
sequenc
develop
strategi
experi
cover
mechan
action
includ
proteas
inhibitor
nnrti
nrti
two
novel
mechan
present
review
best
practic
applic
tool
provid
quantifi
insight
hiv
drug
develop
decis
case
exampl
show
integr
relev
submodel
estim
key
paramet
trial
data
simul
candid
trial
design
key
paramet
critic
hiv
includ
patient
adher
complianc
prescrib
regimen
compartment
pharmacokinet
paramet
viral
inhibit
invivo
viru
immun
cell
characterist
depend
patient
popul
trial
characterist
dropout
rate
hiv
diseas
model
vari
complex
discuss
togeth
present
view
advantag
disadvantag
complex
vs
simpler
model
hiv
model
typic
includ
minimum
uninfect
cell
activ
infect
cell
latent
infect
cell
multipl
viral
strain
differenti
equat
describ
viruscel
interact
time
includ
resist
develop
goal
present
give
audienc
improv
abil
use
modelbas
drug
develop
techniqu
acceler
hiv
develop
decis
object
serolog
respons
pneumocysti
jiroveci
pj
develop
person
childhood
purpos
blind
retrospect
studi
determin
preval
pj
harbour
respiratori
tract
children
acut
respiratori
tract
infect
whether
clinic
laboratori
characterist
separ
without
pj
method
nasopharyng
aspir
npa
collect
children
hospit
hvidovr
amag
hospit
includ
npa
patient
episod
avail
analysi
one
hivinfect
child
pcp
exclud
episod
receiv
diagnosi
lower
respiratori
tract
infect
lrti
upper
respiratori
tract
infect
urti
median
age
day
rang
male
sampl
analys
use
closedtub
quantit
realtim
pcr
use
fluoresc
probe
detect
enzymat
carryov
prevent
extern
intern
control
includ
posit
sampl
rerun
confirm
clinic
data
collect
review
medic
record
observ
pjposit
case
occur
patient
inter
quartil
age
rang
day
infant
age
day
age
quartil
ci
time
like
children
younger
day
age
quartil
harbour
pj
infant
age
day
age
quartil
ci
time
like
multivari
analysi
infant
hospit
episod
urti
ci
time
like
harbour
pj
infant
lrti
multivari
analysi
copi
number
detect
pjposit
sampl
normal
distribut
logarithm
transform
suggest
one
biolog
phenomenon
conclus
found
preval
pj
among
children
admit
symptom
requir
diagnost
npa
could
repres
either
colon
subclin
overt
infect
knowledg
previou
evid
clinic
ill
specif
symptom
connect
primari
infect
immunocompet
children
data
suggest
pj
may
present
selflimit
urti
infant
infect
acquir
earli
life
increas
report
gynecomastia
among
hivinfect
patient
treat
highli
activ
antiretrovir
therapi
epidemiolog
clinic
correl
suggest
pathogenet
investig
r
manfredi
l
calza
f
chiodo
bologna
background
gynecomastia
g
emerg
untoward
event
patient
treat
haart
method
crosssect
studi
perform
around
hivinfect
patient
p
treat
antiretrovir
refer
centr
identifi
case
g
relat
administr
least
consecut
month
haart
assess
possibl
correl
g
spectrum
clinic
laboratori
therapeut
variabl
includ
advers
effect
haart
p
true
g
distinguish
lipomastia
ultrasonographi
assay
consid
evalu
p
predispos
condit
endocrin
diseas
alcohol
abus
liver
cirrhosi
use
drug
possibl
predispos
g
care
rule
result
twentyon
evalu
hivinfect
male
p
popul
develop
true
g
age
seven
p
never
receiv
proteas
inhibitor
pi
contain
therapi
efavirenzbas
regimen
appar
prompt
g
p
pi
worsen
disturb
p
abandon
pi
efavirenz
consid
nucleosid
analogu
na
p
develop
g
treatment
conduct
dual
isol
na
compar
differ
adminst
na
stavudin
seem
commonli
use
compound
also
taken
longest
time
p
complet
hormon
workup
detect
signific
abnorm
save
one
p
slight
fsh
lh
testosteron
anomali
normal
prolactin
level
consid
eventu
correl
common
haartinduc
disturb
form
lipodystrophi
concurr
p
g
hypertriglyceridemia
hypercholesterolemia
hyperglycemia
found
p
respect
subsequ
followup
spontan
amelior
g
never
observ
notwithstand
eventu
haart
modif
due
local
hypersthesia
two
p
resort
surgeri
conclus
g
probabl
underestim
problem
set
haart
frequent
associ
g
haartrel
dysmetabol
suggest
possibl
common
pathogenet
caus
insulin
resist
glucos
intoler
hivinfect
subject
proteas
inhibitor
treatment
three
oral
hypoglycem
drug
comparison
l
calza
r
manfredi
f
chiodo
bologna
introduct
haartrel
dysmetabol
alter
recent
emerg
frequenc
clinic
correl
consid
proteas
inhibitor
pi
treat
patient
p
high
preval
insulinresist
hyperinsulinemia
found
versu
lower
incid
alter
glucos
toler
frank
diabet
method
aim
random
prospect
studi
assess
frequenc
hyperglycemia
p
treat
haart
efficacysafeti
gliclazid
versu
metformin
versu
rosiglitazon
p
alter
glucos
metabol
two
hundr
p
start
pibas
haart
regimen
year
prospect
follow
month
evalu
p
fast
glycemia
repeatedli
normal
start
novel
haart
p
entir
studi
period
p
hyperglycemia
persist
month
resist
month
dietaryexercis
program
random
receiv
gliclazid
mg
day
metformin
mg
twice
daili
rosiglitazon
mgday
followedup
month
result
first
month
elev
serum
fast
glucos
level
found
evalu
p
followup
period
glucos
abnorm
often
mild
sever
p
mgdl
follow
moder
sever
p
mgdl
sever
hyperglycemia
mgdl
never
observ
p
hyperglycemia
associ
find
elev
cpeptid
level
mean
valu
ngml
glycosil
haemoglobin
mean
valu
hypertriglyceridemia
mean
level
mgdl
signific
associ
includ
proport
advanc
age
year
bmi
prolong
overal
exposur
antiretrovir
haart
regimen
advanc
hiv
diseas
signific
correl
emerg
abnorm
glucos
metabol
use
singl
antihiv
compound
month
gliclazid
metformin
rosiglitazon
therapi
mean
drop
mean
glycemia
p
p
mg
dl
p
respect
observ
versu
baselin
level
absenc
signific
differ
among
three
test
drug
conclus
pibas
haart
may
relat
moder
nonneglig
risk
hyperglycemiahyperinsulinemia
oral
hypoglycem
drug
either
gliclazid
metformin
rosiglitazon
prove
equal
effect
preliminari
experi
advanc
lethal
acut
myelogen
leukaemia
hiv
diseas
favour
manag
haart
r
manfredi
sabbatani
f
chiodo
bologna
introduct
extrem
infrequ
episod
hivassoci
acut
myelogen
leukaemia
aml
describ
case
report
hivinfect
patient
p
suddenli
develop
dyshomogen
isoechogen
tender
left
thyroid
mass
associ
dysphagia
fever
appear
amlsuggest
peripher
blood
smear
concurr
increas
ldh
level
hiv
infect
control
haart
regimen
viral
replic
suppress
count
cellsll
thyroid
fine
needl
aspir
detect
numer
blast
bone
marrow
studi
disclos
xy
inv
aml
methaphas
immunophenotyp
analysi
cell
express
monocyt
receptor
myeloid
marker
lead
diagnosi
acut
aml
fab
stage
ct
scan
disclos
multipl
upper
pulmonari
metastas
cytarabinedaunorubicin
cours
deliv
togeth
growth
factor
bloodplatelet
transfus
antimicrobi
prophylaxi
haart
neutropeniarel
shaemolyticuscorynebacterium
jk
febril
bacteremia
occur
week
later
control
antibioticsantifung
remark
improv
generalloc
signssymptom
parallel
complet
normal
blood
cell
count
week
ten
week
chemotherapi
marrow
aspir
confirm
diseas
remiss
consolid
cytarabindaunorubicin
cycl
deliv
chemotherapyassoci
leukopeniathrombocytopenia
correct
empir
levofloxacinfluconazol
avoid
superinfect
remiss
maintain
month
peripher
blood
cell
count
recov
hiv
diseas
remain
stabl
repeat
marrow
aspir
karyotyp
studi
metaphas
immunophenotyp
examin
prove
normal
although
chromosom
transloc
remain
conclus
less
case
hivassoci
aml
describ
major
monocytemyelomonocyt
phenotyp
type
aml
repres
case
outcom
strongli
relat
count
advanc
fab
stage
initi
massiv
thyroid
involv
p
literatur
analogu
best
knowledg
prompt
differenti
diagnosi
intrins
opportunist
neoplast
thyroid
disord
besid
lack
consensu
aml
prognost
factor
gener
popul
absenc
control
trial
guid
decisionmak
hiv
set
howev
induct
chemotherapi
associ
haart
appear
indic
hivinfect
p
aml
introduct
control
data
avail
longterm
evolut
patient
p
isol
dual
nucleosid
nucleotid
analogu
na
antiretrovir
therapi
although
phenomenon
still
exist
daili
clinic
practic
notwithstand
antiretrovir
guidelin
includ
regimen
sinc
due
demonstr
suboptim
potenc
method
refer
centr
p
still
dual
na
treatment
nearli
treat
one
result
p
dual
na
therapi
sinc
least
month
major
receiv
zidovudinelamivudin
follow
lamivudinestavudin
zidovudinedidanosin
didanosinestavudin
lamivudinetenofovir
major
p
never
receiv
haart
regimen
remain
p
came
tripl
therapi
usual
refus
advers
event
intoler
strongli
deni
adjunct
anoth
third
antihiv
drug
last
month
observ
viremia
rang
undetect
hivrna
copiesml
mean
hivrna
copiesml
lymphocyt
count
rang
cellsll
mean
cellsll
clinic
signssymptom
hiv
diseas
progress
becam
appar
prolong
isol
dual
na
therapi
discuss
stabl
hiv
diseas
cours
longterm
isol
dual
na
therapi
consist
observ
nine
year
introduct
haart
regimen
base
least
three
differ
antiretrovir
compound
longterm
nonprogressor
p
receiv
notprop
antihiv
therapi
earli
nineti
proport
low
efficaci
dual
isol
na
suffici
contain
diseas
evolut
also
resist
develop
howev
great
major
p
still
receiv
obsolet
antiretrovir
therapi
requir
introduc
haart
base
three
differ
drug
base
virolog
immunolog
marker
updat
guidelin
antiretrovir
therapi
prone
continu
outoftheschem
regimen
absenc
control
trial
rais
question
remain
unansw
longterm
balanc
among
hiv
infect
immunologicgenet
background
even
suboptim
effect
two
na
probabl
requir
treatment
intensif
two
nonnucleosid
hiv
revers
transcriptas
inhibitor
significantli
differ
dysmetabol
profil
efavirenz
nevirapin
r
manfredi
l
calza
f
chiodo
bologna
background
dysmetabol
emerg
featur
treat
hiv
infect
poor
inform
exist
nonnucleosid
hiv
revers
transcriptas
inhibitor
nnrti
use
method
among
patient
p
treat
haart
month
metabol
pattern
nnrti
assess
three
differ
scenario
first
one
includ
p
drug
start
nnrtibas
regimen
second
one
includ
broad
spectrum
p
pretreat
therapeut
line
still
third
group
repres
p
ad
first
time
nnrti
undergo
salvag
regimen
includ
drug
includ
pi
result
p
treat
efavirenz
e
compar
p
take
nevirapin
n
prospect
observ
survey
last
month
multivari
analysi
serum
lipidglucos
level
metabol
anomali
among
p
antiretrovir
hypertriglyceridemia
common
p
e
versu
n
group
consid
experienc
p
introduc
nnrti
first
time
frequenc
hypertriglyceridemia
appear
greater
e
group
p
earli
develop
p
e
versu
n
p
also
p
salvag
haart
rate
hypertriglyceridemiahypercholesterolemiahyperglycemia
test
greater
among
p
treat
e
versu
n
p
time
peak
alter
earlier
e
group
compar
p
receiv
e
p
n
frequenc
high
triglyceridecholesterolglucos
level
greater
etreat
p
p
grade
lipodystrophi
present
pretreat
p
improv
occur
nnrti
introduct
seven
p
e
group
versu
p
n
p
prolong
followup
show
e
may
resolv
might
prompt
dysmetabol
two
avail
nnrti
notabl
differ
toxic
profil
pathway
differ
nnrti
dysmetabol
pattern
deserv
indepth
pathogenet
studi
opportun
relat
late
first
aid
diagnosi
paradox
increas
frequenc
time
haart
r
manfredi
l
calza
f
chiodo
bologna
background
notwithstand
avail
haart
aid
notif
continu
occur
increas
preval
patient
p
missedneglect
underli
condit
method
aid
case
notifi
sinc
year
compar
found
decad
preced
haart
avail
result
compar
prehaart
era
drop
frequenc
overal
aid
case
occur
mean
pyear
decad
pyear
p
togeth
increas
mean
age
p
femal
gender
p
sexual
versu
iv
transmiss
p
proport
immigr
p
p
haart
era
evid
drop
frequenc
interest
opportunist
diseas
link
lymphocyt
count
cellsll
proport
rise
tuberculosi
pneumonia
lymphoma
neoplasm
observ
candida
esophag
pcariniii
pneumonia
remain
steadili
first
two
notifi
aidsrel
condit
haart
avail
follow
diagnos
neurotoxoplasmosi
wast
syndrom
aidsdementia
complex
p
multipl
aidsdefin
diseas
also
aid
diagnos
made
death
even
show
paradox
increas
frequenc
absolut
number
haart
era
versu
prior
decad
p
differ
found
hivassoci
immunodefici
surprisingli
underli
antihiv
therapi
common
event
versu
haart
era
p
sinc
recent
year
aid
notif
tend
increasingli
associ
first
hiv
infect
diagnosi
conclus
face
p
suspect
opportun
clinician
maintain
elev
suspect
advanc
miss
untreat
hiv
diseas
continu
attent
help
rapid
recognit
appropri
manag
p
benefit
haart
sinc
remain
unawar
remov
underli
diseas
background
immigr
recent
phenomenon
itali
caus
sudden
arriv
wave
foreign
citizen
refuge
individu
escap
civil
war
phenomenon
great
concern
due
socioeconom
cultur
health
care
impact
method
prospect
survey
chart
patient
p
hospit
follow
dayhospit
dh
basi
infecti
diseas
ward
allow
us
assess
frequenc
admiss
immigr
extrawestern
europ
ewe
analyz
multipl
variabl
relat
epidemiolog
clinic
featur
result
rate
p
immigr
ewe
show
signific
increas
among
inp
lesser
extent
later
dh
admiss
year
p
inp
p
dh
p
around
p
came
africa
follow
eastern
europ
asia
america
compar
admiss
featur
citizen
p
come
abroad
differ
found
durationintens
assist
hiv
diseas
prevail
among
regular
admiss
dh
access
follow
acutechron
hepat
cn
respiratori
tract
infect
std
hivinfect
immigr
frequent
aid
present
p
alreadi
antihiv
therapi
frequenc
hivassoci
admiss
show
differ
consid
sixyear
period
p
ewe
increas
frequenc
tuberculosi
skinsoft
tissu
infect
exanthem
gastroentericparasit
diseas
malaria
p
conclus
inform
screen
continu
monitor
phenomenon
strongli
warrant
improv
sustain
socialcultur
network
plan
health
resourc
alloc
defin
adequ
target
prevent
measur
manag
hyperlipidaemia
relat
antiretrovir
therapi
novel
statin
rosuvastatin
pilot
studi
r
manfredi
l
calza
f
chiodo
bologna
background
hypolipidem
drug
therapi
becom
recommend
hivinfect
patient
p
haartassoci
hyperlipidemia
sever
tend
persist
long
time
although
select
singl
compound
often
difficult
potenti
drugdrug
interact
includ
antihiv
compound
method
aim
prospect
open
studi
assess
efficaci
safeti
novel
potent
statin
rosuvastatin
mgday
therapi
hivinfect
p
treat
haart
elev
hypercholesterolemia
last
six
month
respons
hypolipidem
diet
anequ
physic
exercis
program
interim
analysi
plan
week
result
seventeen
p
enrol
follow
least
week
end
observ
period
mean
reduct
serum
triglycerid
level
rang
cholesterol
rang
achiev
compar
baselin
valu
p
signific
drop
mean
ldl
cholesterol
level
also
obtain
versu
baselin
rang
well
increas
hdl
cholesterol
rang
p
conclus
compar
clinic
studi
novel
potent
statin
rosuvastatin
demonstr
hylipidem
activ
significantli
greater
compar
atorvastatin
simvastatin
pravastatin
associ
contain
risk
pharmacolog
interact
molecul
metabol
liver
cytochrom
includ
hiv
proteas
inhibitor
preliminari
experi
rosuvastatin
prove
effect
manag
haartrel
mix
dyslipidemia
spectrum
favour
activ
extend
ldl
hdl
cholesterol
level
absenc
untoward
clinic
andor
laboratori
advers
event
tertiari
lue
one
p
recogn
hiv
infect
diagnos
followup
period
case
syphili
found
p
alreadi
awar
hiv
seroposit
consid
preced
period
p
lue
diagos
togeth
known
hiv
diseas
p
compar
episod
diagnos
case
occur
sinc
significantli
increas
frequenc
p
increas
hiv
sexual
transmiss
p
decreas
mean
p
age
p
observ
last
figur
countertend
compar
known
increas
mean
age
hivinfect
p
therefor
underli
hivlu
coinfect
tend
occur
proport
younger
life
age
signific
differ
among
two
studi
group
emerg
p
gender
immigr
use
haart
specif
combin
adher
level
hiv
diseas
stage
concurr
diseas
chronic
hepat
opportun
virologicalimmunolog
hiv
diseas
cours
typic
syphili
present
includ
meningoenceph
acutesubacut
hepat
character
even
case
diagnos
period
make
prompt
recognit
difficult
conclus
health
care
worker
engag
manag
hiv
std
maintain
elev
clinic
suspicion
sinc
misseddelay
diagnosi
syphili
hiv
may
respons
diseas
progress
increas
sexual
spread
infect
educ
campaign
need
care
reapprais
includ
prevent
messag
target
popul
still
remain
risk
acquir
std
hiv
object
aim
studi
evalu
preval
osteopenia
osteoporosi
cohort
patient
hiv
infect
assess
possibl
correl
demograph
variabl
select
antiretrovir
associ
method
patient
enrol
among
adult
subject
hiv
infect
refer
tertiari
care
outpati
centr
bologna
itali
bone
miner
densiti
measur
lumbar
spine
femor
proxim
head
dual
energi
xray
absorptiometri
dexa
techniqu
result
total
hivinfect
patient
male
femal
enrol
subject
antiretrovir
therapi
receiv
three
nucleosid
revers
transcriptas
inhibitor
nrti
treat
two
nrti
plu
one
nonnucleosid
revers
transcriptas
inhibitor
nnrti
remain
patient
receiv
two
nrti
plu
one
proteas
inhibitor
pi
overal
preval
osteopenia
osteoporosi
accord
lumbar
tscore
respect
osteoporosi
significantli
frequent
male
femal
versu
mean
valu
lumbar
tscore
significantli
lower
pitreat
patient
subject
receiv
three
nrti
nnrtibas
antihiv
regimen
p
conclus
alter
bone
metabol
associ
hiv
infect
probabl
multifactori
pathogenesi
accord
experi
bone
mass
loss
seem
significantli
prompt
male
gender
pibas
therapi
prospect
studi
conduct
extens
patient
seri
certainli
need
better
understand
epidemiolog
clinic
featur
ethiopathogenesi
outcom
bone
metabol
abnorm
associ
hiv
infect
object
analyz
origin
countri
diagnos
diseas
immunovirolog
characterist
hivsubtyp
seroposit
individu
patient
method
develop
data
base
analys
group
hiv
immigr
attend
inpati
last
year
hiv
subtyp
perform
phylogenet
analysi
proteasa
retrotranscriptas
gene
plasma
specimen
statist
studi
done
spss
result
nation
could
evalu
subject
forti
one
subsaharian
africa
equatori
guinea
nigeria
camerun
south
america
ecuador
brasil
peru
colombia
anoth
european
countri
asia
marocco
forti
infect
heterosexu
contact
hiv
diagnos
hospitalis
time
case
frequent
diagnos
diseas
tuberculosi
subject
candidiasi
pneumonia
malaria
posit
antibodi
hepat
c
viru
hcv
detect
patient
hepat
b
viru
hbv
activ
syphili
mean
cell
cell
per
r
mean
viral
load
copiesml
r
subtyp
b
recogn
patient
none
african
subtyp
recombin
recogn
subtyp
specimen
recombinantstherefor
clade
g
ag
recombin
frquent
variant
respect
moreov
intersubtyp
recombin
pol
gene
appear
case
carri
nonb
subtyp
nonb
strain
infect
african
contrast
south
american
european
carri
uniformli
subtypeb
variant
relationship
hivsubtyp
clinic
manifest
conclus
rel
high
proport
nonb
variant
mostli
carri
clade
g
sequenc
caus
infect
studi
popul
regardless
subtyp
great
number
subject
acquir
hiv
infect
heterosexu
contact
know
hiv
infect
elev
viral
load
develop
serious
ill
epidemiolog
implic
plasma
viremia
quantif
suscept
antiretrovir
drug
clinic
implic
presenc
variant
collect
need
studi
object
immigr
hiv
infect
emerg
health
problem
countri
object
analys
epidemiolog
clinic
immunovirolog
characterist
hospitalis
patient
method
review
clinic
histori
nonspanish
hiv
patient
hospitalis
last
year
data
base
develop
first
episod
studi
hiv
subtyp
perform
pathogenet
analysi
proteasa
retrotranscriptas
gene
plasma
specimen
statist
studi
done
spss
result
patient
repres
admiss
first
episod
patient
anoth
hospitalis
number
rang
mean
episod
person
nation
could
evalu
patient
forti
one
subsaharian
africa
mainli
equatori
guinea
nigeria
south
america
mainli
ecuador
anoth
european
countri
asia
marocco
mean
age
year
r
men
infect
heterosexu
contact
hiv
diagnos
hospitalis
time
case
receiv
haart
forti
patient
serious
ill
cell
less
per
mm
less
per
mm
relationship
immunodepress
origin
countri
found
hivsubtyp
b
isol
patient
none
african
twentynin
peopl
nonb
subtyp
mainli
g
case
african
frequent
diagnos
diseas
tuberculosi
mainli
dissemin
subject
oral
andor
oroesophag
candidiasi
pneumonia
malaria
relationship
diagnos
diseas
origin
countri
apart
malaria
diagnos
african
sixtyeight
patient
discharg
without
problem
nearli
diagnos
cdc
mean
diseas
diagnos
patient
r
subject
pass
away
conclus
hivinfect
immigr
attend
hospit
africa
south
america
nonb
subtyp
predomin
acquir
infect
heterosexu
contact
nearli
know
infect
immunodepress
aid
defin
ill
admiss
poor
respons
trimethoprimsulfamethoxazol
hivinfect
patient
pneumocysti
jiroveci
pneumonia
concurr
opportunist
infect
p
werarak
ratanasiri
sungkanuparph
kiertiburanakul
bangkok
th
object
pneumocysti
jiroveci
pneumonia
pcp
remain
common
opportunist
infect
patient
infect
human
immunodefici
viru
hiv
trimethoprimsulfamethoxazol
tmpsmx
effect
drug
treat
pcp
nevertheless
patient
poor
respons
treatment
drug
aim
studi
contribut
factor
poor
respons
tmpsmx
hivinfect
patient
pcp
method
retrospect
review
medic
laboratori
record
adult
hivinfect
patient
diagnos
pcp
receiv
tmpsmx
first
regimen
poor
respons
defin
puls
rate
min
blood
pressur
mmhg
respiratori
rate
min
need
oxygen
therapi
oxygen
satur
day
treatment
result
total
hivinfect
patient
pcp
review
eightyf
patient
men
mean
age
year
median
cell
count
rang
cellsmm
patient
receiv
antiretrovir
therapi
patient
receiv
pcp
prophylaxi
develop
pcp
steroid
given
approxim
patient
patient
poor
respons
among
patient
good
respons
patient
concurr
opportunist
infect
wherea
patient
poor
respons
concurr
opportunist
infect
vs
p
common
concurr
opportunist
infect
pulmonari
tuberculosi
patient
cryptococc
mening
bacteri
sepsi
salmonella
infect
cytomegalovir
pneumonia
patient
poor
respons
longer
median
length
stay
good
respons
rang
day
vs
rang
day
p
overal
mortal
rate
patient
patient
die
poor
respons
group
patient
concurr
opportunist
infect
also
higher
mortal
rate
patient
pcp
alon
vs
p
conclus
high
rate
concurr
opportunist
infect
among
hivinfect
patient
pcp
especi
poor
respons
tmpsmx
convey
high
mortal
morbid
rate
earli
recognit
concurr
infect
patient
present
pcp
appropri
therapi
essenti
issu
impact
occult
hbv
infect
hiv
patient
antiretrovir
therapi
result
patient
followup
plasma
hbv
dna
detect
case
pcr
patient
first
observ
followup
hbvdna
posit
frequent
found
patient
antibodi
hbv
without
p
twentyeight
patient
experienc
hepat
flare
followup
event
occur
frequent
patient
show
hbvdna
hbvdna
neg
vs
p
patient
hbvdna
posit
first
observ
treat
haart
contain
lamivudin
becam
hbvdna
neg
followup
four
turn
hbvdna
posit
show
hepat
flare
lamivudin
treatment
two
lamivudin
discontinu
hypothes
gener
signal
pathway
target
specif
stage
stage
life
cycl
result
inhibit
infect
method
use
infect
jurkat
cell
helodermin
use
stimul
total
phosphotyrosin
ptyr
contain
protein
assess
use
western
immunoblot
malachit
green
assay
use
measur
protein
tyrosin
phosphatas
ptp
activ
polymeras
chain
reaction
pcr
use
detect
viral
cdna
circl
examin
use
nest
pcr
region
viral
cdna
provir
integr
analysi
use
nest
pcr
base
ltr
region
alu
repeat
host
dna
pcr
product
cut
hinfi
hybrid
radioact
ltr
probe
identifi
singl
fragment
predict
size
pseudoenvelopetyp
viru
nef
gene
replac
luciferas
luc
gene
use
measur
level
transcript
result
western
blot
indic
agonist
decreas
basal
level
ptyrcontain
protein
observ
support
show
increas
ptp
activ
ptp
activ
transient
invers
proport
inhibitori
effect
infect
sustain
inhibitori
effect
cell
requir
daili
treatment
agonist
result
sustain
ptp
activ
agonist
affect
entri
revers
transcript
viral
rna
howev
transcript
integr
significantli
inhibit
agonist
treat
cell
circl
format
provir
integr
profoundli
inhibit
conclus
agonist
strong
inhibitor
infect
interf
provir
integr
inhibitori
effect
correl
gener
signal
result
activ
ptp
activ
ptp
effect
format
viral
cdna
instead
may
halt
integr
cdna
host
dna
studi
elucid
exact
signal
pathway
target
respons
block
abil
proviru
integr
may
provid
insight
pathogenesi
viru
well
lead
novel
futur
treatment
hivaid
dramat
chang
surviv
death
rate
aid
evolut
antiretrovir
therapi
pari
accord
data
calendar
period
divid
period
monotherapi
transit
dual
therapi
haart
earli
haart
late
haart
octob
cox
regress
calendar
period
model
timedepend
covari
use
hr
progress
death
given
period
compar
calendar
period
refer
monotherapi
adjust
confound
variabl
cox
regress
stratifi
age
transmiss
categori
cell
count
initi
aid
defin
ill
es
adi
use
result
pwa
contribut
year
risk
mortal
rate
per
patient
year
declin
monotherapi
transit
dual
therapyhaart
earli
haart
late
haart
period
adjust
hr
progress
death
reach
minimum
late
haart
period
hr
differ
decreas
hr
progress
death
found
age
hr
decreas
mark
late
haart
period
across
hiv
transmiss
categori
includ
intraven
drug
user
among
pwa
diagnos
tuberculosi
hr
decreas
significantli
late
haart
period
decreas
earlier
stronger
adi
also
progress
multifoc
leucoencephalopathi
hiv
dementia
tumour
sinc
haart
introduct
decreas
hr
stronger
pwa
cell
count
compar
cell
count
conclus
surviv
continu
increas
sinc
introduct
haart
howev
heterogen
accord
cell
count
aid
diagnosi
adi
studi
suggest
cardiovascular
diseas
risk
emerg
hiv
resist
affect
mortal
pwa
two
strain
meca
posit
pvl
posit
strain
detect
popul
structur
aureu
strain
isol
hiv
patient
appear
strongli
overlap
aureu
isol
healthi
individu
geograph
region
conclus
hiv
patient
increas
risk
persist
nasal
carriag
aureu
compar
healthi
individu
male
sex
smoke
pcp
prophylaxi
use
antiretrovir
therapi
independ
determin
persist
aureu
nasal
carriag
cohort
hivpati
pvl
posit
strain
found
circul
preval
mrsa
low
uniqu
aureu
clone
specif
cohort
identifi
pulmonari
hypertens
among
hiv
posit
subject
find
latium
region
registri
method
latium
region
registri
ph
hiv
infect
patient
creat
april
aim
collect
case
ph
accord
classif
occur
among
popul
adult
hivposit
patient
care
latium
idu
ie
subject
patient
mean
pulmonari
arteri
pressur
pap
mmhg
rest
mmhg
exercis
assess
transthorac
echocardiographi
includ
registri
patient
follow
data
ascertain
demograph
cdc
classif
hiv
risk
factor
hiv
rna
sign
symptom
nyha
class
antiretrovir
cardiovascular
treatment
ecg
find
result
upto
octob
total
case
ph
hiv
posit
patient
record
present
sign
symptom
suggest
ph
remain
found
rais
pap
valu
echocardiograph
screen
hivposit
patient
without
cardiovascular
sign
symptom
perform
one
centr
male
mean
age
year
rang
seven
hivrel
ph
subject
accord
cdc
classif
patient
class
class
b
class
c
mean
cell
count
rang
median
hiv
rna
copi
ml
rang
nineteen
patient
nyha
class
b
c
respect
mean
pap
mmhg
among
asymptomat
symptomat
patient
respect
two
patient
die
oneyear
follow
conclus
new
effect
antiretrovir
drug
decreas
mortal
hiv
infect
howev
emerg
syndrom
includ
cardiopulmonari
involv
repres
concern
hiv
infect
patient
found
preval
ph
among
popul
hiv
infect
patient
neglig
moreov
ph
occur
patient
cell
count
higher
cellsmm
earli
diagnosi
ph
lead
benefici
treatment
clinician
awar
risk
cardiopulmonari
involv
phase
hiv
infect
proteinuria
tenofovirexpos
nonexpos
patient
audit
screen
process
within
unit
kingdom
hiv
cohort
associ
variabl
statist
test
use
nonparametr
test
proteinuria
defin
mgdl
urinari
protein
detect
dipstick
urin
test
least
occas
audit
period
result
casenot
review
ci
least
urinalysi
record
ci
one
ci
two
ci
three
record
patient
least
urinalysi
male
caucasian
mean
count
cellsml
count
cellsml
hiv
viral
load
hiv
copiesml
proteinuria
found
patient
proteinuria
detect
frequent
patient
current
take
tenofovir
versu
p
frequenc
urinalysi
current
tenofovir
expos
nonexpos
individu
account
find
one
urinalysi
perform
tenofovir
expos
non
expos
group
respect
two
urinalys
three
urinalys
p
length
tenofovir
use
length
haart
use
tenofovir
significantli
associ
proteinuria
case
renal
impair
identifi
discuss
audit
show
urinalysi
suboptim
perform
proteinuria
frequent
find
overal
expect
tenofovir
use
associ
proteinuria
recognis
advers
effect
commonli
use
antiretrovir
emphasis
import
audit
standard
care
hiv
practic
metaanalysi
frequenc
side
effect
haart
drug
andreassen
l
vidal
u
pielmeier
aalborg
dk
tel
aviv
il
object
highli
activ
antiretrovir
therapi
haart
compris
combin
one
three
drug
caus
sever
side
effect
lower
patient
life
qualiti
threaten
continu
therapi
determin
frequenc
side
effect
haart
drug
enabl
us
predict
effect
haart
combin
whole
trace
specif
side
effect
back
drug
like
caus
method
meta
analysi
side
effect
report
clinic
trial
haart
conduct
includ
sourc
nih
web
site
control
clinic
trial
branch
manufactur
disclosur
assum
frequenc
given
side
effect
given
haart
combin
sum
frequenc
drug
combin
allow
us
formul
determin
frequenc
side
effect
regress
problem
regress
coeffici
frequenc
side
effect
per
drug
depend
variabl
observ
frequenc
linear
regress
coeffici
confid
interv
determin
use
spss
result
total
entri
patient
includ
yield
inform
individu
haart
drug
side
effect
control
trial
sever
branch
repres
one
entri
per
branch
averag
entri
report
given
side
effect
rang
entri
kidney
stone
entri
increas
alanin
transaminas
although
entri
side
effect
zero
frequenc
may
mention
report
frequenc
side
effect
rang
osteopenia
diarrhoea
averag
given
side
effect
exampl
entri
report
sever
vomit
averag
frequenc
haart
drug
entri
drug
signific
p
frequenc
sever
vomit
abacavir
amprenavir
lamivudin
indinavir
ritonavir
neg
frequenc
lamivudin
may
due
true
reduct
vomit
could
due
breakdown
assumpt
addit
frequenc
ie
due
interact
drug
model
fit
sever
vomit
satisfactori
r
squar
conclus
meta
analysi
publish
clinic
trial
give
indic
frequenc
haart
drug
caus
side
effect
limit
data
allow
frequenc
side
effect
determin
drug
object
analys
cohort
hivinfect
children
contamin
via
motherto
child
transmiss
time
transfer
adult
care
method
retrospect
studi
children
follow
nice
sinc
discoveri
hivinfect
follow
variabl
analys
demograph
characterist
immunovirolog
data
tcell
count
viral
load
resist
test
clinic
statu
stage
lipodystrophi
psychosoci
aspect
treatment
adher
educ
psycholog
behaviour
assess
famili
context
result
children
infect
birth
follow
regular
basi
paediatr
depart
die
age
eighteen
becam
adult
sinc
follow
infecti
diseas
depart
mean
age
year
known
durat
hiv
infect
year
median
valu
recent
tcell
count
viral
load
log
detect
limit
copiesml
patient
one
child
never
receiv
antiretrovir
treatment
receiv
least
differ
treatment
combin
regard
current
treatment
never
took
proteas
inhibitor
receiv
combin
includ
fusion
inhibitor
least
one
pi
nucleosid
analogu
six
children
cdc
stage
b
c
sixteen
display
sever
lipodystrophi
patient
major
treatment
complianc
difficulti
may
explain
high
preval
rate
resist
mutat
one
child
pass
final
school
certif
none
live
parent
mother
orphan
conclus
crosssect
retrospect
studi
illustr
difficulti
manag
young
adult
frequent
virolog
failur
appear
multifactori
treatment
adher
difficulti
psycholog
behaviour
disord
relat
adolesc
famili
disrupt
optim
use
antiretrovir
combin
accompani
psycholog
support
children
famili
could
improv
patient
futur
present
appear
sever
compromis
background
blood
exposur
incid
pose
risk
healthcar
worker
public
health
despit
sever
guidelin
nation
intern
counsellor
often
differ
opinion
regard
risk
caus
incid
littl
known
influenc
counsellor
background
profess
medic
train
propos
treatment
relat
cost
healthcar
system
object
studi
influenc
counsellor
profess
assess
blood
exposur
incid
subject
subject
includ
infecti
diseas
specialist
id
forens
specialist
fs
public
health
depart
medic
microbiologist
mm
occup
health
practition
ohp
aid
specialist
hospit
set
method
survey
sent
five
differ
kind
counsellor
netherland
ask
question
assess
differ
kind
blood
exposur
incid
well
prophylaxi
treatment
would
consid
adequ
prevent
transmiss
blood
born
pathogen
indic
administr
immunoglobulin
post
exposit
prophylaxi
test
sourc
time
limit
action
question
question
rank
hepat
b
viru
hbv
hepat
c
viru
hcv
hiv
risk
result
survey
sent
return
taken
account
hbv
risk
counsel
ohp
mm
gener
show
aggress
way
treatment
p
hcv
risk
counsel
gener
id
aggress
p
hiv
counsel
far
aggress
treatment
group
p
seven
total
twelv
question
differ
signific
conclus
differ
group
counsellor
assess
similar
blood
exposur
incid
differ
differ
shown
three
blood
born
virus
differ
influenc
risk
transmiss
blood
born
virus
cost
healthcar
system
well
care
inform
given
patientsalthough
preval
blood
born
virus
netherland
rel
low
nation
agreement
protocol
regard
counsel
treatment
blood
exposur
incid
essenti
object
aciclovir
acv
safe
effect
drug
manag
infect
herp
simplex
varicellazost
virus
approxim
dose
excret
urin
unchang
remaind
metabolit
cmmg
cmmg
may
caus
acv
neurotox
recent
studi
correl
serum
cmmg
concentr
cn
symptom
known
whether
symptom
also
correl
csf
cmmg
concentr
describ
simpl
hplc
assay
appear
suitabl
monitor
serum
csf
cmmg
level
pharmacokinet
studi
monitor
may
indic
action
need
prevent
develop
toxic
method
chromatographi
perform
mm
hplc
column
mobil
phase
octan
sulphon
orthophosphor
acid
pump
mlmin
sampl
mix
equal
volum
perchlor
acid
left
min
centrifug
g
min
ml
supernat
inject
cmmg
detect
uv
absorb
nm
quantifi
refer
extern
standard
identif
characteris
also
measur
nm
data
analys
chromatographi
manag
system
result
retent
time
rt
cmmg
approxim
min
acv
min
assay
reproduc
mg
l
intraassay
cv
interassay
cv
linear
rang
mgl
accuraci
recoveri
serum
approxim
csf
fluid
limit
detect
quantif
mgl
mgl
respect
rt
height
area
ratio
ratio
height
differ
wavelength
identifi
peak
cmmg
interfer
seen
clinic
sampl
contain
antimicrobi
agent
serum
patient
receiv
acv
cmmg
detect
level
mgl
acv
level
sampl
pair
ratio
cmmg
acv
lower
postdos
predos
case
higher
unchang
conclus
assay
suitabl
monitor
cmmg
level
conduct
pharmacokinet
studi
biolog
fluid
clinic
sampl
cmmg
level
approach
acv
rate
convers
appear
variabl
case
cmmg
level
rose
rapidli
may
possibl
identifi
subset
patient
clinic
condit
cmmg
monitor
indic
particularli
among
patient
renal
failur
object
investig
occurr
hbsag
reactiv
instrument
shortterm
hepat
b
vaccin
method
serum
sampl
patient
neither
hbv
vaccin
person
hbv
histori
collect
day
day
first
hbv
engerixtm
lg
ml
vaccin
sampl
test
presenc
hbsag
architect
architect
hbsag
test
kit
axsym
instrument
hbsag
test
kit
verif
hbsag
posit
result
done
architect
hbsag
confirmatori
test
kit
final
complet
hbv
statu
patient
investig
month
first
hbv
vaccin
result
clinic
specimen
patient
test
day
first
hbv
vaccin
sera
test
architect
hbsag
test
kit
sera
test
hbsag
axsym
instrument
found
posit
hbsag
hbsag
posit
result
confirm
architect
hbsag
confirmatori
test
kit
day
first
vaccin
sera
reinvestig
assay
sampl
still
found
posit
hbsag
architect
final
hbv
statu
investig
month
first
vaccin
show
neg
hbsag
result
specimen
increas
protect
hbv
surfac
antibodi
conclus
architect
hbsag
test
kit
hbsag
axsym
instrument
known
sensit
method
detect
hbsag
clinic
sampl
follow
clinic
serum
sampl
show
transient
hbsag
reactiv
sampl
architect
sampl
axsym
instrument
shortterm
hbv
vaccin
possibl
occurr
hbsag
shortterm
hbv
vaccin
import
fact
routin
diagnost
laboratori
object
develop
panel
human
antirubella
immunoassay
high
throughput
autom
platform
architect
rubella
igg
assay
intend
use
quantit
measur
igg
antibodi
rubella
viru
human
sera
plasma
aid
determin
immun
statu
rubella
viru
architect
rubella
igm
assay
intend
use
qualit
measur
igm
antibodi
rubella
viru
human
serum
plasma
aid
diagnosi
primari
acut
infect
method
prototyp
rubella
assay
architect
instrument
twostep
immunoassay
util
rubella
whole
viru
coat
paramagnet
microparticl
captur
antirubella
antibodi
acridinium
label
monoclon
antibodi
conjug
direct
human
igg
igm
util
detect
sampl
pregnant
women
blood
donor
hospit
patient
iggigm
screen
neg
sampl
known
rubella
igm
posit
sampl
vaccin
serial
bleed
seroconvers
panel
test
new
architect
rubella
assay
comparison
abbott
axsym
rubella
igg
igm
assay
discrep
sampl
test
addit
rubella
igg
igm
onmarket
assay
resolv
consensu
result
architect
rubella
igg
show
resolv
rel
sensit
resolv
rel
specif
compar
axsym
popul
describ
n
architect
rubella
igm
assay
show
resolv
rel
sensit
resolv
rel
specif
compar
axsym
popul
describ
n
seroconvers
sensit
architect
rubella
igg
igm
assay
equival
better
axsym
rubella
igg
igm
assay
respect
architect
rubella
igg
igm
assay
exhibit
equival
greater
sensit
axsym
rubella
igg
igm
assay
serial
bleed
well
vaccin
conclus
perform
new
architect
rubella
igg
igm
assay
better
equival
axsym
rubella
igg
igm
assay
object
preliminari
evalu
panel
human
anticytomegaloviru
cmv
immunoassay
autom
architect
instrument
method
three
cmv
assay
architect
instrument
twostep
immunoassay
util
cmv
viru
lysat
coat
paramagnet
microparticl
captur
human
anticmv
antibodi
cmv
igm
assay
contain
viral
lysat
recombin
protein
pp
coat
onto
paramagnet
particl
acridiniumlabel
monoclon
antibodi
direct
human
igg
igm
util
human
anticmv
antibodi
detect
sampl
pregnant
women
blood
donor
hospit
patient
transplant
recipi
seroconvers
panel
test
new
architect
cmv
assay
comparison
best
class
onmarket
cmv
assay
perform
architect
cmv
igg
igm
assay
compar
abbott
axsym
cmv
igg
igm
assay
sampl
discrep
result
test
two
addit
cmv
igg
cmv
igm
assay
resolv
consensu
perform
architect
cmv
igg
avid
assay
evalu
comparison
radim
cmv
igg
avid
assay
clinic
inform
result
architect
cmv
igg
assay
resolv
rel
sensit
resolv
rel
specif
compar
axsym
cmv
igg
popul
describ
n
seroconvers
sensit
architect
cmv
igg
igm
assay
equival
better
refer
cmv
igg
igm
assay
test
resolv
specif
cmv
igm
assay
blood
donor
pregnant
women
architect
cmv
igg
avid
assay
use
avicomp
technolog
display
clinic
specif
cmv
immun
blood
donor
pregnant
women
n
clinic
sensit
avid
assay
seroconvers
panel
bleed
drawn
within
month
postseroconvers
clinic
sensit
specif
architect
cmv
igg
avid
superior
refer
avid
assay
conclus
perform
three
new
architect
cmv
immunoassay
better
equival
refer
assay
epitop
specif
igg
respons
epsteinbarr
viru
capsid
protein
among
differ
age
group
object
determin
igg
avid
viral
capsid
antigen
vca
frequent
use
diagnosi
acut
epsteinbarr
viru
ebv
infect
estim
seroconvers
age
epidemiolog
studi
recombin
protein
synthet
peptid
differ
size
often
use
diagnost
target
aim
studi
compar
igg
respons
antigen
epitop
locat
posit
aa
express
gst
fusion
protein
locat
posit
model
synthet
peptid
vca
among
differ
age
group
materi
method
total
serum
sampl
adult
normal
blood
donor
serum
sampl
children
age
rang
old
analys
commerci
avail
antiebvvca
igg
enzym
immunoassay
diagnost
system
russia
ebvvca
igg
posit
sampl
addit
test
presenc
igg
specif
region
individu
determin
igg
avid
perform
urea
dissoci
agent
serum
sampl
divid
group
less
month
old
n
month
year
old
n
year
old
n
year
old
n
year
old
n
year
old
n
year
old
n
result
epitopespecif
distribut
antivcaigg
activ
signific
differ
term
igg
level
group
adult
igg
avid
group
adult
tabl
conclus
specif
igg
respons
differ
antigen
epitop
locat
vca
ebv
differ
igg
level
igg
avid
among
variou
age
group
result
strongli
indic
select
antigen
epitop
natur
diagnost
target
routin
avid
determin
anti
vca
igg
may
critic
point
design
eia
protocol
clinic
epidemiolog
studi
object
tickborn
enceph
viru
tbev
pathogen
human
flaviviru
endem
part
europ
asia
detect
specif
antibodi
base
diagnosi
tbevinfect
recent
studi
shown
necess
improv
exist
tbevtest
regard
sensit
specif
major
manufactur
use
cultur
antigen
virion
purifi
protein
produc
central
european
type
tbev
naidorff
strain
common
problem
approach
insuffici
puriti
antigen
problem
recognit
tbevtyp
sibirean
fareast
possibl
cross
reactiv
anoth
flavivirus
studi
investig
antigen
properti
new
recombin
protein
correspond
domain
iii
tbev
ige
protein
domain
iii
highli
antigen
consist
primarili
linear
epitop
high
degre
homolog
among
type
tbev
method
recombin
polypeptid
compris
aa
region
tbev
igeprotein
produc
e
coli
gstfusion
protein
assay
condit
detect
antitbevigg
optimis
reduc
possibl
fals
posit
fals
neg
result
two
group
sera
use
evalu
sensit
specif
test
serum
sampl
tbevinfect
individu
collect
european
part
russia
n
sera
normal
blood
donor
n
specimen
previous
test
igg
antitbev
activ
commerci
avail
eia
result
sera
tbevinfect
patient
posit
eia
new
recombin
protein
averag
signal
cutoff
ratio
sampl
normal
blood
donor
sera
neg
assay
sensit
calcul
assay
specif
conclus
recombin
protein
deriv
cterm
ige
tbev
use
studi
demonstr
signific
potenti
diagnost
reagent
eia
detect
specif
igg
tbev
serum
specimen
background
epsteinbarr
viru
ebv
human
herp
viru
infect
establish
latenc
blymphocyt
primari
infect
lead
lifelong
past
infect
normal
asymptomat
ebv
express
number
gene
howev
epsteinbarr
nuclear
antigen
viral
protein
character
ebv
pastinfect
object
aim
studi
evalu
diagnost
relev
new
artifici
protein
compos
antigen
epitop
ebv
develop
evalu
screen
enzym
immunoassay
eia
detect
igg
activ
ebv
serum
specimen
materi
method
two
potenti
antigen
epitop
protein
predict
bioinformat
analysi
mosaic
two
antigen
domain
protein
aa
aa
express
e
coli
hybrid
protein
glutathion
stransferas
develop
assay
detect
antibodi
assay
condit
optimis
reduc
possibl
fals
posit
fals
neg
result
new
iggeia
evalu
use
serum
specimen
obtain
ebv
pcr
posit
patient
n
hivinfect
individu
n
normal
blood
donor
bd
n
pcr
posit
specimen
addit
test
igg
activ
commerci
avail
eia
base
fulllength
ebv
nuclear
antigen
specif
estim
ebv
neg
sampl
n
result
ebv
pastinfect
pcr
posit
patient
confirm
detect
high
avid
igg
ebv
viral
capsid
antigen
vca
ebv
pcr
posit
patient
igg
antibodi
novel
eia
concord
commerci
avail
eia
frequenc
igg
antibodi
investig
group
follow
health
blood
donor
hivinfect
individu
children
specif
assay
around
conclus
recombin
protein
compris
theoret
predict
antigen
epitop
protein
demonstr
signific
potenti
diagnost
reagent
new
eia
highli
specif
diagnost
assay
detect
igg
activ
serum
specimen
combin
vca
igg
igm
may
use
tool
routin
diagnosi
acut
ebv
infect
ebv
immun
statu
rapid
detect
rotaviru
children
comparison
vikia
rotaadeno
diarlex
mb
two
immunochromatograph
test
h
crehalet
f
vandenesch
freydier
lyon
fr
purpos
purpos
studi
compar
two
immunochromatograph
test
vikia
rota
adeno
franc
diarlex
mb
centrifug
orion
diagnostica
use
rotaviru
detect
case
gastroenter
episod
paediatr
method
stool
sampl
total
test
frozen
stool
studi
retrospect
fresh
stool
studi
prospect
decemb
august
frozen
stool
select
contain
bacteria
yeast
respons
diarrhoea
select
contain
rotaviru
use
laboratori
routin
method
diarlex
mb
stool
rapid
test
perform
day
condit
pital
debrouss
refer
method
ideia
rotaviru
dako
perform
blind
mode
result
frozen
stool
vikia
produc
result
refer
method
diarlex
mb
produc
two
fals
neg
result
fresh
stool
vikia
produc
two
noninterpret
result
two
fals
neg
diarlex
mb
produc
two
noninterpret
result
two
fals
neg
three
frozen
stool
vikia
pose
methodolog
problem
associ
migrat
strip
resolv
second
assay
frozen
stool
contain
bacteria
yeast
crossreact
detect
two
test
stool
refer
method
vikia
diarlex
mb
detect
stool
posit
rotaviru
sensit
specif
valu
posit
predict
valu
neg
predict
valu
vikia
test
diarlex
mb
test
respect
statist
signific
differ
observ
either
two
test
test
refer
method
conclus
equal
term
perform
vikia
test
offer
simpler
rapid
methodolog
evalu
rubella
igg
igm
assay
new
vidia
instrument
l
grangeotkero
c
vauloupfel
clamart
fr
object
aim
present
studi
evalu
perform
new
vidia
rubella
igg
igm
assay
fulli
autom
vidia
instrument
easi
use
high
level
traceabl
materi
sensit
specif
vidia
rub
igg
franc
evalu
serum
sampl
comparison
vida
rub
igg
franc
axsym
rubella
igg
abbott
usa
access
rubella
igg
beckman
coulter
usa
assay
perform
vidia
rub
igm
franc
also
evalu
comparison
axsym
rubella
igm
abbott
usa
platelia
rubella
igm
tmb
biorad
usa
assay
serum
sampl
discrep
resolv
consid
patient
clinic
data
avail
well
complementari
test
western
blot
igg
discrep
avid
test
igm
discrep
result
sensit
vidia
rub
igg
sensit
method
vidia
rub
igm
rel
sensit
compar
axsym
rubella
igm
resolut
discrep
absolut
sensit
close
comparison
platelia
rubella
igm
rel
sensit
take
account
clinic
inform
avid
result
absolut
sensit
close
specif
vidia
rub
igg
specif
establish
fact
sampl
posit
vidia
neg
compar
method
found
posit
western
blot
take
account
absolut
sensit
found
rel
specif
vidia
rub
igm
determin
comparison
axsym
rubella
igm
platelia
rubella
igm
assay
respect
resolut
discrep
absolut
specif
close
conclus
two
evalu
assay
vidia
rub
igg
vidia
rub
igm
show
excel
sensit
specif
rna
extract
respiratori
sampl
use
nuclisen
easymag
system
p
van
deursen
verhoeven
p
de
bie
jacob
boxtel
nl
object
enhanc
made
rna
extract
procedur
sputum
bal
sampl
use
dnase
activ
object
studi
measur
efficaci
new
rna
extract
procedur
recoveri
rna
respiratori
sampl
combin
nuclisen
easymag
system
method
total
sampl
sputum
bal
includ
studi
sampl
treat
proteinas
k
dnase
order
liquefi
sampl
next
treat
sampl
extract
nuclisen
easymag
system
effici
extract
procedur
measur
spike
intern
control
rna
addit
rsv
spike
concentr
sputum
sampl
extract
sampl
analys
real
time
nasba
use
nuclisen
easyq
rsv
b
assay
nuclisen
easyq
mycoplasma
pneumonia
assay
sampl
respect
result
rsv
detect
sampl
spike
rsv
inhibit
detect
intern
control
rna
measur
sampl
test
conclus
studi
rsv
rna
intern
control
rna
effici
detect
respiratori
sampl
enhanc
rna
extract
procedur
use
dnase
activ
use
procedur
might
increas
sensit
detect
viral
bacteri
rna
respiratori
sampl
howev
remain
test
follow
studi
evalu
autom
sampl
process
use
magna
pure
lc
instrument
use
coba
amplicor
hcv
ver
test
palladino
kay
perth
au
object
determin
limit
detect
linear
reproduc
correl
clinic
result
coba
amplicor
hcv
test
ca
hcv
use
magna
pure
lc
mplc
autom
specimen
prepar
method
rang
analyt
standard
clinic
specimen
use
determin
evalu
paramet
follow
limit
detect
linear
replic
member
dilut
panel
intern
standard
hcv
rna
cover
rang
iuml
reproduc
replic
hcv
iuml
intern
standard
hcv
rnaconcord
split
sampl
analys
clinic
specimen
test
use
method
sampl
prepar
sampl
prepar
perform
use
total
nucleic
acid
isol
kit
roch
diagnost
australia
autom
mplc
roch
diagnost
australia
platform
accord
modifi
inhous
valid
protocol
nucleic
acid
clinic
sampl
also
extract
duplic
use
coba
amplicor
hcv
test
roch
diagnost
australia
manual
sampl
prepar
protocol
test
hcv
perform
use
coba
amplicor
hcv
test
roch
diagnost
australia
roch
coba
amplicor
roch
diagnost
australia
accord
manufactur
instruct
result
perform
criteria
ca
hcv
assay
follow
sampl
prepar
mplc
determin
preliminari
result
date
demonstr
linear
across
rang
hcv
rna
level
test
iuml
accept
lower
limit
detect
compar
manufactur
claim
sensit
manual
process
sampl
iuml
clinic
specimen
test
use
method
specimen
prepar
result
concord
specimen
resolut
discord
result
sensit
specif
ca
hcv
follow
mplc
specimen
prepar
respect
compar
manual
specimen
prepar
conclus
mplc
instrument
suitabl
front
end
platform
use
coba
amplicor
hcv
test
modifi
protocol
use
total
nucleic
acid
isol
kit
mplc
result
reliabl
laboursav
method
extract
nucleic
acid
perform
ca
hcv
pcr
test
sampl
process
mplc
compar
sampl
process
manual
background
human
cytomegaloviru
hcmv
import
pathogen
capabl
establish
lifelong
persist
infect
normal
remain
asymptomat
previou
studi
indic
sequenc
variat
among
cmv
strain
frequent
occur
even
highli
conserv
gene
region
genet
variat
function
import
gene
may
complic
cmv
diagnost
object
purpos
work
design
primer
probe
simultan
realtim
pcr
diagnost
genotyp
cmv
materi
method
studi
serum
sampl
obtain
pregnant
women
sampl
children
cmv
congenit
infect
use
viru
dna
extract
use
magna
pure
dna
purif
kit
roch
indianapoli
usa
set
primer
direct
gn
go
gb
cmv
gene
set
probe
realtim
detect
lidhtcycl
instrument
roch
indianapoli
usa
design
evalu
genotyp
carri
sequenc
analysi
abi
avant
genet
analyz
instrument
abi
foster
citi
ca
usa
phylogenet
analysi
nucleotid
sequenc
conduct
clastal
x
tamuranei
substitut
model
grow
tree
base
neighbourjoin
tree
build
method
maximum
parsimoni
method
implement
mega
packag
result
realtim
pcr
analysi
gene
detect
cmv
activ
isol
among
analyz
sampl
pcr
test
previous
describ
primer
gn
go
gb
gene
reveal
posit
sampl
accordingli
pcr
test
sensit
defin
quantit
cmv
control
abi
foster
citi
ca
usa
sensit
pcr
test
gene
copi
per
phylogenet
analysi
region
sequenc
demonstr
region
could
success
use
viru
genotyp
realtim
fret
test
divid
analyz
sampl
two
group
melt
peak
like
laboratori
strain
davi
melt
peak
like
town
laboratori
adapt
strain
two
pair
specif
hybridis
probe
cover
two
mutat
insid
gene
region
use
confirm
conclus
nest
pcr
primer
gene
incorpor
realtim
fret
analys
describ
provid
sensit
specif
assay
detect
cmv
clinic
isol
gene
serv
target
simultan
detect
genotyp
cmv
use
realtim
pcr
opportun
detect
human
papilloma
viru
type
patholog
sampl
patient
cervic
cancer
pcr
rflp
method
p
maleknejad
shahsavan
tehran
ir
object
infect
human
papilloma
viru
hpv
frequent
sexual
transmit
diseas
world
wide
hpv
type
consid
import
caus
cervic
cancer
studi
carri
detect
hpv
type
among
patholog
block
patient
cervic
cancer
tehran
method
primer
f
att
ata
aac
aaa
cac
r
gta
tct
acc
aca
gta
f
type
tat
gat
ttr
cag
ttt
att
r
yka
gaa
aac
ttt
tcc
type
design
sequenc
hpv
genebank
access
number
use
pcr
primer
produc
amplicon
size
bp
respect
pcr
product
digest
bamhi
ecori
fragment
separ
electrophoresi
agaros
gel
result
human
papilloma
viru
dna
detect
case
hpv
type
common
one
follow
hpv
type
digest
pcr
product
bamhi
ecori
differenti
type
respect
amplicon
type
one
restrict
site
one
enzym
use
conclus
hpv
type
predomin
infect
studi
rate
countri
still
lower
countri
croatia
australia
spain
china
howev
compar
previou
studi
iran
infect
type
show
increas
case
infect
squamou
cell
carcinoma
statist
signific
correl
infect
hpv
type
develop
squamou
cell
carcinoma
p
relat
found
type
pcr
pcrrflp
sensit
use
identif
type
papiloma
viru
differenti
type
nanochip
system
accompani
electron
microchip
four
distinct
step
biotinyl
captur
oligonucleotid
complementari
seven
respiratori
virus
well
option
intern
control
electron
target
specif
site
across
cartridg
dilut
rtpcr
reaction
electron
bias
set
pad
compris
full
set
captur
oligonucleotid
allow
gener
amplicon
hybridis
complementari
captur
sequenc
addit
rtpcr
reaction
sequenti
bias
uniqu
set
site
across
cartridg
passiv
hybridis
use
set
bifunct
discrimin
oligonucleotid
half
molecul
bind
specif
amplicon
half
bind
report
molecul
fluorescentlylabel
report
oligonucleotid
allow
detect
amplicon
result
analyt
sensit
copiesml
copi
reaction
viral
specimen
equival
matrix
neg
patient
eluant
achiev
rva
kit
seven
system
individu
infect
simul
dual
infect
analyt
sensit
copiesml
achiev
crossreact
organ
virus
known
give
flulik
symptom
observ
total
patient
sampl
analyz
hexaplex
assay
rva
kit
comparison
hexaplex
assay
rva
kit
yield
clinic
sensit
object
nucleic
acidbas
assay
sensit
cultur
antigen
test
detect
respiratori
viral
infect
specif
antivir
treatment
avail
develop
provid
better
effici
given
earli
onset
symptom
highlight
need
quick
diagnosi
multiplex
molecular
assay
base
revers
transcript
combin
real
time
pcr
lc
real
time
assay
prodess
waukesha
wi
develop
use
rapidli
detect
rna
respiratori
syncyti
virus
rsv
influenza
virus
ia
b
ib
nasal
wash
bronchoalveolar
lavag
specimen
singl
test
method
test
sampl
children
adult
known
infect
either
rsv
n
influenza
virus
n
b
n
determin
cultur
singl
classic
pcr
sampl
posit
parainfluenza
virus
neg
respiratori
viru
sampl
spike
intern
control
ic
carri
revers
transcript
amplif
glass
capillari
light
cycler
instrument
roch
appli
scienc
meylan
franc
realtim
supermix
contain
mulv
revers
transcriptas
appli
biosystem
foster
citi
ca
platinium
taq
polymeras
invitrogen
carlsbad
ca
primer
complementari
highli
conserv
region
genet
sequenc
respiratori
virus
duallabel
exonucleas
probe
rsv
fam
ia
cal
orang
ib
cal
red
ic
fluoresc
signal
measur
rsv
ia
ib
ic
channel
nm
nm
nm
nm
respect
result
sampl
posit
rsv
influenza
influenza
b
detect
lc
real
time
assay
ct
valu
rang
speci
determin
accord
specif
channel
analysi
agreement
expect
sampl
found
dualli
posit
amplif
detect
respiratori
viru
neg
sampl
posit
parainfluenza
viru
posit
sampl
assay
turn
around
time
min
conclus
data
suggest
lc
real
time
assay
rapid
sensit
specif
multpliex
pcr
test
diagnosi
infect
rsv
influenza
b
virus
object
routin
use
nucleic
acid
amplif
test
identifi
parainfluenza
viru
influenza
viru
b
respiratori
syncyti
viru
human
metapneumoviru
chlamyophila
pneumonia
mycoplasma
pneumonia
bordetella
pertussi
patient
respiratori
sampl
period
also
includ
broad
rang
pcr
detect
coronavirus
sampl
aim
studi
estim
impact
coronavirus
respiratori
pathogen
norwegian
popul
method
multiplex
rtpcr
subsequ
probe
hybridis
use
identifi
parainfluenza
viru
influenza
viru
b
respiratori
syncyti
viru
human
metapneumoviru
hexaplex
prodess
usa
patient
respiratori
sampl
cdna
gener
hexaplex
procedur
also
amplifi
coronaviru
specif
primer
coronaviru
pcr
product
sequenc
identifi
type
coronaviru
real
time
pcr
detect
chlamyophila
pneumonia
mycoplasma
pneumonia
bordetella
pertussi
perform
sampl
result
period
march
sampl
analys
two
third
sampl
pathogen
found
sampl
one
three
bacteria
found
infect
human
metapneumoviru
peak
incid
decemberjanuari
posit
rate
respect
infect
influenza
virus
peak
incid
februarymarch
posit
rate
respect
total
sampl
posit
coronaviru
peak
incid
januaryfebruari
posit
rate
respect
addit
coronavirus
three
type
two
type
four
type
detect
sampl
contain
one
pathogen
coronaviru
posit
sampl
anoth
viru
also
detect
coronaviru
posit
sampl
also
contain
anoth
respiratori
pathogen
conclus
winter
month
infect
coronaviru
high
incid
popul
patient
respiratori
ill
suggest
viru
import
caus
respiratori
tract
infect
coronaviru
posit
sampl
also
contain
anoth
result
posit
control
pcr
establish
use
roch
hsv
iii
templat
dna
posit
diagnosi
pcr
made
use
cut
copi
templat
dna
adjust
near
futur
asr
qualif
test
hsv
among
patient
sampl
show
neg
result
method
show
posit
show
clearli
posit
pcr
viral
cultur
show
peak
pcr
design
hsv
iii
posit
rang
unabl
diagnos
posit
compar
cut
copi
viral
cultur
show
posit
pcr
show
posit
viral
cultur
low
peak
pcr
conclus
realtim
pcr
rapid
test
hsv
iii
diagnosi
clinic
virolog
laboratori
high
sensit
compar
tradit
viral
cultur
method
group
show
posit
pcr
viral
cultur
dna
sequenc
would
perform
experi
progress
result
share
futur
introduct
cchf
viral
zoonot
diseas
viru
nairoviru
genu
bunyavirida
famili
diseas
transmit
human
infect
tick
bite
contact
viru
contamin
tissu
blood
discharg
mammal
mortal
rate
could
earli
treatment
ribavirin
sharpli
decreas
rate
method
period
june
octob
serum
sampl
suspect
patient
cchf
sent
arbovirus
lab
nation
center
pasteur
institut
iran
analyz
serolog
elisa
method
specif
igm
igg
molecularli
rtpcr
method
detect
fragment
segment
viru
genom
result
suspect
human
case
case
posit
serolog
molecularli
case
igm
posit
case
rtpcr
posit
igm
posit
person
also
rtpcr
posit
posit
die
among
igm
posit
rtpcr
posit
igm
neg
igm
posit
case
age
rang
year
sistanbaluchestan
provinc
igm
posit
case
infect
provinc
isfahan
provinc
far
provinc
second
third
infect
provinc
expos
profess
farmer
worker
housewif
butcher
discuss
consid
result
cchf
import
haemorrhag
fever
iran
concern
preval
diseas
precaut
must
taken
profession
relat
livestock
slaughter
domest
anim
handl
carcass
survey
carri
shown
due
short
viremia
period
probabl
fund
viru
genom
serum
sampl
decreas
hand
certain
patient
die
fulminantli
enough
time
gener
immun
respons
viru
genom
detect
molecular
method
molecular
method
togeth
serolog
method
cchf
suspect
patient
best
way
diagnos
diseas
compar
evalu
vida
liaison
toxoplasmosi
cytomegaloviru
rubella
panel
french
univers
hospit
mj
carl
c
enault
l
lachaud
charachon
fr
object
aim
present
studi
evalu
perform
vida
liaison
toxoplasmosi
cytomegaloviru
rubella
panel
routin
condit
laboratori
materi
studi
perform
week
sera
either
laboratori
routin
site
sampl
collect
toxoplasmosi
sera
cytomegaloviru
rubella
igg
test
evalu
perform
vida
toxo
igg
ii
vida
toxo
igm
vida
cmv
igg
vida
cmv
igm
rub
igg
vida
assay
marci
letoil
franc
comparison
liaison
toxo
igg
liaison
toxo
igm
liaison
cmv
igg
liaison
cmv
igm
liaison
rub
igg
assay
diasorin
saluggia
itali
vida
toxo
igg
cmv
igg
avid
liaison
toxo
igg
cmv
igg
avid
assay
use
case
igg
igm
posit
result
sera
toxoplasmosi
cmv
complementari
test
perform
case
discrep
immunofluoresc
isaga
elisa
test
addit
follow
paramet
assess
system
instrument
set
mainten
time
result
ergonom
gener
practic
result
correl
obtain
rubella
igg
cmv
igg
toxo
igg
avid
assay
cmv
toxoplasmosi
good
system
regard
cmv
obtain
discrep
result
igg
found
igm
perfect
correl
avid
test
system
found
regard
toxoplasmosi
observ
discrep
result
igg
igm
avid
sampl
equivoc
method
vida
system
specif
igm
detect
fact
liaison
result
show
frequent
specif
residu
igm
detect
ergonom
system
show
advantag
disadvantag
inconveni
decis
choos
one
two
system
relat
organis
strategi
accord
laboratori
specif
panel
avail
conclus
result
obtain
studi
demonstr
vida
specif
diagnosi
acut
cmv
toxoplasmosi
infect
even
liaison
adapt
high
throughput
routin
test
two
system
easili
integr
use
laboratori
background
aim
sensit
fundament
analyt
requisit
assay
surfac
antigen
hbsag
hepat
b
viru
hbv
sinc
determin
hbsag
carri
blood
donat
screen
screen
diagnosi
gener
popul
assay
specif
also
import
lowpreval
set
aim
investig
diagnost
accuraci
two
autom
chemiluminesc
immunoassay
hbsag
abbott
architect
ortho
vitro
select
repositori
specimen
materi
method
select
serum
sampl
gave
repeat
reactiv
routin
screen
assay
hbsag
abbott
axsym
hbsag
classifi
true
fals
posit
accord
result
confirmatori
neutral
assay
andor
serolog
clinic
criteria
specimen
assay
code
architect
vitro
hbsag
differ
lab
result
report
center
result
sampl
divid
two
group
fals
posit
axsym
neg
vitro
neg
architect
b
true
posit
neutral
virem
posit
marker
histori
hbv
infect
architect
assay
gave
posit
result
specimen
neg
patient
clear
hbsag
acut
infect
contrast
vitro
assay
posit
case
grayzon
neg
neg
interestingli
sampl
neg
vitro
show
strong
reactiv
architect
samplecutoff
sco
ratio
three
show
also
strong
reactiv
antihb
muiml
suggest
possibl
presenc
surfac
antigen
escap
mutat
conclus
assay
hbsag
architect
analys
accur
discrimin
true
fals
posit
wherea
vitro
assay
gave
surprisingli
high
rate
fals
neg
case
probabl
due
lower
analyt
sensit
remain
seven
specimen
show
strong
posit
hbsag
axsym
architect
hbsag
neg
vitro
may
relat
limit
capabl
recogn
hbsag
mutant
report
literatur
opinion
urgent
clarifi
preval
clinic
impact
surfac
antigen
variant
current
epidemiolog
set
itali
well
countri
antihepat
b
vaccin
polici
establish
evalu
new
assay
simultan
detect
hcv
core
antigen
antihcv
antibodi
carlo
c
forniel
n
chueca
alvarez
c
bernal
granada
es
object
serolog
hcv
diagnosi
may
present
fals
neg
result
window
period
reduc
hcv
rna
hcv
core
ag
new
elisa
techniqu
simultan
detect
hcv
core
ag
antihcv
antibodi
studi
evalu
laboratori
routin
use
materi
method
sera
antihcv
antibodi
request
receiv
laboratori
seroconvers
panel
serum
sampl
analys
sampl
test
routin
assay
detect
antihcv
antibodi
assay
ortho
hcv
elisa
new
one
detect
hcv
core
ag
antihcv
antibodi
simultan
assay
monolisa
hcv
agab
ultra
biorad
posit
sera
confirm
recombin
immunoblot
innolia
de
innogenet
result
number
posit
neg
sera
techniqu
howev
sera
diverg
result
shown
follow
tabl
consid
routin
techniqu
refer
agab
assay
sensit
specif
neg
sera
posit
one
present
index
far
cut
consid
seroconvers
panel
case
combin
assay
reduc
window
period
conclus
new
assay
simultan
detect
hcv
core
ag
antihcv
antibodi
present
good
sensit
specif
valu
differenti
well
posit
neg
result
make
valuabl
assay
routin
diagnosi
allow
earli
detect
hcv
infect
comparison
molecular
serolog
assay
diagnosi
hcv
infect
c
forniel
carlo
n
chueca
f
c
bernal
granada
es
object
differ
assay
avail
hcv
infect
diagnosi
treatment
followup
antihcv
antibodi
hcvrna
viral
load
genotyp
free
hcv
core
antigen
new
elisa
techniqu
simultan
detect
hcv
core
ag
antihcv
antibodi
evalu
sensit
assess
consid
potenti
influenc
rnavhc
free
vhc
core
ag
viral
load
infect
genotyp
materi
method
total
posit
anti
hcvantibodi
sera
test
simultan
detect
hcv
core
ag
antihcv
antibodi
use
monolisa
hcv
agab
ultra
biorad
hcv
core
antigen
analys
elisa
trackc
ortho
serum
hcv
rna
measur
pcr
coba
amplicor
roch
hcv
genotyp
carri
innolipa
result
sampl
posit
new
combin
assay
sensit
diverg
sera
test
confirm
recombin
immunoblot
posit
neg
therefor
true
posit
sensit
among
posit
sera
hcv
rna
hcv
ag
posit
although
paramet
detect
time
shown
arnag
arn
ag
arnag
arnag
preval
genotyp
assay
perform
influenc
infect
genotyp
conclus
techniqu
simultan
detect
hcv
ag
antihcv
ab
good
sensit
influenc
hcv
infect
genotyp
presenc
free
hcv
ag
rna
viral
load
also
good
discrimin
capac
posit
result
therefor
could
use
routin
microbiolog
laboratori
evalu
autom
multiplex
assay
heterophil
antibodi
comparison
latex
agglutin
test
assess
epsteinbarr
viru
induc
infecti
mononucleosi
c
lingenfelt
villarr
kaur
h
scholz
hercul
us
object
detect
heterophil
antibodi
specif
antibodi
epsteinbarr
viru
ebv
antigen
proven
use
categor
patient
histori
infecti
mononucleosi
patient
acut
infect
patient
evid
prior
remot
infect
patient
reactiv
latent
infect
object
studi
compar
result
fluorescencebas
autom
multiplex
assay
heterophil
determin
result
acquir
convent
latex
agglutin
spot
test
method
use
biorad
bioplex
system
fulli
autom
high
throughput
multiplex
platform
report
detect
igm
antibodi
heterophil
antigen
compar
wampol
monolatex
test
qualit
subject
methodolog
bioplex
result
report
semiquantit
index
valu
rel
neg
posit
calibr
sampl
three
intern
qualiti
control
bead
evalu
simultan
verifi
instrument
chemistri
perform
supplement
tradit
qualiti
control
sampl
calibr
curv
check
multiplex
assay
use
specimen
instrument
process
one
hundr
patient
sampl
per
hour
result
serum
specimen
n
nonrandomli
select
analyz
assay
method
sera
posit
heterophil
antibodi
compar
monolatex
assay
bioplex
gave
sensit
specif
overal
agreement
six
sampl
initi
categor
falseneg
three
falseposit
upon
repeat
test
discrep
specimen
autom
test
system
exhibit
sensit
specif
overal
agreement
monolatex
test
chang
statu
five
nine
discrep
sampl
highlight
difficulti
interpret
visual
readout
statu
chang
discrep
sampl
observ
autom
system
addit
bioplex
system
excel
precis
cv
less
sampl
near
cutoff
conclus
two
heterophil
assay
system
show
excel
concord
bioplex
system
howev
offer
practic
advantag
allow
rapid
fulli
autom
evalu
heterophil
igm
ebv
antibodi
background
manag
therapi
hepat
c
viru
hcv
infect
base
quantit
measur
hcv
rna
decis
treatment
discontinu
basi
log
declin
week
wide
accept
rule
aim
method
present
studi
evalu
perform
complet
autom
system
coba
ampliprepcoba
taqman
capctm
roch
diagnost
branchburg
nj
hcv
rna
quantif
clinic
serum
specimen
capctm
real
time
polymeras
chain
assay
reli
autom
nucleic
acid
extract
serum
follow
rna
captur
use
magnet
particl
purif
elut
system
report
lower
detect
limit
iuml
dynam
rang
iuml
capctm
result
compar
quantif
hcv
genotyp
signal
amplif
assay
base
branch
dna
bdna
technolog
versant
quantit
bayer
diagnost
tarrytown
ny
detect
limit
iuml
dynam
rang
iuml
result
sixtythre
clinic
specimen
patient
hcv
infect
studi
two
assay
concord
r
mean
sd
interassay
differ
log
iuml
howev
capctm
valu
analyz
genotyp
mean
sd
interassay
differ
bdna
follow
genotyp
n
genotyp
n
genotyp
n
genotyp
n
log
iuml
thu
appear
valu
obtain
capctm
gener
log
lower
bdna
genotyp
capctm
detect
hcv
rna
sampl
iuml
bdna
capctm
level
log
six
capctmbdnaspecimen
genotyp
infect
patient
conclus
capctm
show
good
correl
bdna
better
sensit
crucial
manag
antihcv
therapi
particularli
genotyp
howev
seem
capctm
underestim
hcv
rna
level
genotyp
clinic
relev
decis
clinic
manag
patient
base
measur
hcv
rna
level
hcv
rna
declin
patient
antihcv
therapi
object
viruscel
interact
could
monitor
standard
way
direct
infect
cell
count
optic
luminesc
microscop
way
timeand
effortconsum
requir
addit
colour
cell
cultur
sampl
prepar
process
take
hour
reliabl
method
suffici
monitor
small
part
specimen
surfac
take
account
result
previou
experiment
investig
field
may
suppos
practic
everi
stage
viruscel
interact
could
describ
object
quantit
manner
use
fractal
approach
correspond
origin
instrument
method
studi
interact
herp
simplex
viru
strain
specif
cell
cultur
modifi
addit
proteolysi
inhibitor
eaminocapro
acid
eaca
acyclovir
taken
variou
concentr
monolay
cell
cultur
place
glass
support
describ
sampl
wash
hank
solut
afterward
fix
ethanol
fractal
microscop
includ
singlemod
intens
stabil
spectraphys
hene
laser
mw
output
wavelength
micron
diffract
pattern
dp
sampl
taken
use
olympu
digit
camera
introduc
use
usb
cabl
port
pentium
iv
comput
fractal
dimens
dp
evalu
automat
express
manner
minut
per
sampl
result
main
result
experi
cours
multifract
type
dp
cluster
regist
minim
size
fractal
cluster
element
practic
cell
mkm
mkm
dp
pictur
target
fourier
transform
object
real
pictur
viruscel
system
obtain
revers
fourier
transform
dp
conclus
propos
devic
method
applic
highli
competit
laboratori
clinic
antivir
research
well
drug
design
test
process
due
high
sensit
express
charact
data
take
precis
quantit
way
data
process
comparison
hcv
genotyp
subtyp
determin
use
innolipa
hcv
ii
laboratorydevelop
hcv
sequenc
procedur
gabella
allic
varetto
f
pittaluga
v
ghisetti
turin
background
genotyp
subtyp
hepat
c
viru
hcv
clinic
relev
epidemiolog
prognosi
therapeut
manag
hcv
infect
object
compar
hcv
genotyp
subtyp
clinic
sampl
use
establish
line
probe
assay
innolipa
hcv
ii
innogenet
ghent
b
laboratorydevelop
hcv
direct
sequenc
protocol
seq
abi
prism
method
twentyf
clinic
sampl
crossrepres
hcv
genotyp
analys
innolipa
direct
sequenc
method
librari
hcv
prototyp
n
construct
bioedit
clustalw
use
align
phylogenet
analysi
sampl
concord
genotyp
subtyp
determin
compar
commerci
test
hcv
sequenc
hcv
viral
load
quantifi
sampl
use
bdna
technolog
versant
hcv
rna
assay
result
provid
genotyp
determin
sampl
concord
innolipa
genotyp
determin
discrep
result
occur
sampl
misclassifi
genotyp
innolipa
versu
genotyp
sampl
seq
subtyp
concord
much
lower
seq
provid
subtyp
determin
clinic
sampl
one
sampl
subtyp
innolipa
classifi
type
without
subtyp
innolipa
account
subtyp
sampl
sampl
seq
classifi
sampl
subtyp
n
n
n
n
n
n
n
n
one
sampl
misclassifi
innolipa
allow
classif
sampl
subtyp
n
n
n
n
n
subtyp
sampl
averag
sd
viral
load
genotyp
log
iuml
signific
differ
observ
accord
genotyp
distribut
conclus
sequenc
protocol
provid
hcv
genotyp
determin
sampl
therefor
suitabl
determin
hcv
genotyp
clade
clinic
sampl
patient
hcv
infect
sequenc
allow
much
wider
subtyp
determin
clade
particularli
genotyp
compar
commerci
establish
innolipa
hcv
ii
assay
hcv
subtyp
sequenc
provid
relev
tool
epidemiolog
purpos
surveil
nosocomi
transmiss
hcv
high
risk
unit
comparison
immulit
antihav
igm
antihav
total
abbott
axsym
assay
c
lee
lo
angel
us
monitor
presenc
igm
antibodi
hepat
viru
hav
proven
benefici
identifi
acut
earli
event
infect
individu
similarli
measur
total
antibodi
respons
hav
shown
advantag
identifi
previou
exposur
ongo
viral
infect
chemiluminesc
enzym
immunoassay
develop
dpc
immulit
autom
analys
detect
igm
total
antibodi
hav
serum
plasma
purpos
studi
evalu
perform
immulit
assay
compar
abbott
axsym
havabm
havab
initi
studi
immulit
antihav
total
assay
evalu
sampl
use
abbott
axsym
havab
assay
refer
comparison
demonstr
rel
sensit
specif
overal
agreement
separ
studi
immulit
antihav
igm
assay
compar
abbott
havabm
assay
sampl
result
indic
rel
sensit
specif
agreement
respect
compar
refer
assay
exhibit
intraassay
precis
ratio
respect
interassay
precis
sampl
respect
data
indic
immulit
antihav
igm
antihav
total
assay
perform
compar
abbott
axsym
assay
suggest
suitabl
dpc
assay
serolog
detect
igm
total
antibodi
hepat
viru
introduct
health
bill
england
later
next
year
subsequ
code
practic
give
firm
statutori
foot
accept
best
practic
evid
base
polici
guidanc
infect
prevent
control
healthcar
set
requir
roll
programm
evid
base
infect
prevent
control
polici
ensur
polici
procedur
continu
review
updat
assist
process
nation
resourc
infect
control
nric
wwwnricorguk
ongo
project
develop
infect
profession
singl
access
point
exist
evid
base
resourc
infect
prevent
control
project
fund
uk
depart
health
endors
uk
nation
electron
librari
infect
neli
wwwneliorguk
digit
librari
bring
togeth
best
avail
qualiti
apprais
onlin
evidencebas
resourc
investig
treatment
prevent
control
infecti
diseas
nation
polici
guidanc
document
avail
nric
well
templat
aid
write
local
polici
evid
base
inform
avail
organis
set
clinic
practic
task
mode
transmiss
diseasesorgan
level
evid
resourc
clearli
note
well
region
coverag
infect
control
resourc
qualiti
apprais
ad
portal
mani
resourc
full
review
written
infect
profession
addit
algorithm
easi
access
templat
adapt
meet
local
need
implement
onlin
discuss
resourc
allow
debat
review
ensur
issu
address
resourc
intend
replac
local
infect
prevent
control
policiesguid
assist
write
andor
updat
achiev
standardis
approach
evid
use
progress
develop
nric
excel
feedback
infect
control
profession
posit
roughli
uniqu
user
per
month
octob
although
site
contain
primarili
uk
polici
guidanc
research
concept
interest
era
global
challeng
includ
need
joint
work
collabor
colleagu
infect
prevent
control
intern
independ
review
computeris
system
alert
organ
alert
condit
surveil
method
essenti
tool
method
implement
guidelin
identifi
evalu
lesson
learn
hh
campaign
exist
worldwid
extens
literatur
review
expert
advic
sever
consult
meet
renown
intern
expert
field
practition
well
patient
industri
repres
organ
achiev
consensu
strategi
result
meet
gpsc
guidelin
hh
hc
integr
intervent
field
blood
surgic
procedur
inject
water
wast
manag
safeti
differ
compon
challeng
implement
sever
countri
pilot
test
phase
expect
mutual
reinforc
among
differ
action
optim
hh
promot
essenti
element
implement
healthcar
worker
educ
appropri
techniqu
indic
hh
system
chang
alcoholbas
handrub
avail
point
care
water
access
qualiti
appropri
use
glove
monitor
system
impact
evalu
staff
feedback
administr
support
tool
made
avail
educ
model
tailor
cultur
background
valid
formul
local
product
alcoholbas
handrub
poster
glove
use
guid
monitor
model
patient
inform
leaflet
conclus
first
time
hh
global
promot
cornerston
seri
infect
control
intervent
goal
reduc
hai
worldwid
regardless
type
hc
set
level
countri
develop
key
element
must
consid
achiev
standard
implement
meet
minimum
requir
success
evidencebas
strategi
pilot
test
phase
repres
remark
ad
valu
guidelin
hh
hc
valid
revis
issu
final
version
base
lesson
learn
object
glove
use
reus
crucial
issu
significantli
affect
health
care
worker
complianc
hand
hygien
hh
practic
within
advanc
draft
world
health
organ
guidelin
hh
health
care
recent
issu
specif
section
dedic
topic
perspect
promot
hh
worldwid
method
indic
glove
use
advantag
disadvantag
glove
use
patient
care
analyz
extens
literatur
review
consult
intern
expert
glove
reus
avoid
stock
disrupt
still
realiti
sever
set
worldwid
method
glove
reprocess
also
discuss
result
expert
acknowledg
wear
glove
potenti
barrier
perform
hh
indic
patient
care
situat
glove
neveralway
use
care
identifi
need
nonsteril
rather
steril
glove
evalu
opportun
continu
glovewear
patient
care
consid
miss
opportun
hh
indic
glove
reus
avoid
occur
situat
limit
resourc
follow
step
perform
evalu
process
verifi
reason
need
reus
safe
handl
contamin
glove
healthcar
worker
reprocess
guarante
select
process
surgic
latex
glove
reus
examin
purpos
andor
surgic
doubleglov
reprocess
decontamin
chlorin
solut
cleans
soap
water
autoclav
steril
steam
highlevel
disinfect
integr
test
air
water
fill
solut
sticki
glove
excess
tear
ruptur
provid
conclus
issu
glove
use
reus
care
consid
plan
hh
promot
campaign
healthcar
indic
contraind
wear
glove
care
detail
educ
activ
case
glove
reus
care
evalu
process
togeth
adequ
reprocess
method
alway
perform
possibl
decontamin
glove
alcoholbas
hand
rub
health
care
contact
isol
precaut
place
investig
research
issu
introduct
volum
alcoholbas
hand
disinfect
abhd
use
current
consid
perform
indic
hospit
infect
control
infect
control
first
prioriti
issu
mani
hellen
hospit
aim
studi
locat
area
problemat
term
infect
control
hospit
fleme
gener
hospit
bed
use
data
abhd
consumpt
besid
want
assess
result
relev
intervent
mount
abhd
dispens
everi
patient
room
method
use
data
pharmaci
comput
abhd
distribut
variou
depart
hospit
data
collect
period
begin
second
half
first
half
consumpt
express
litr
patient
day
result
consumpt
liter
patient
day
semest
figur
furthermor
abhd
use
medic
surgic
depart
differ
signific
studi
period
p
pair
test
worth
note
semest
dispens
abhd
mount
everi
patient
room
conclus
mount
abhd
disinfect
dispens
everi
patient
room
result
signific
increas
abhd
consumpt
hospit
whole
b
impact
increas
nosocomi
infect
rate
current
evalu
c
seem
surgic
depart
personnel
reluct
use
hand
disinfect
first
target
group
educ
infect
control
hospitalacquir
infect
hospitalwid
preval
studi
london
hospit
n
desai
b
houston
e
stewart
j
ikonnen
watt
chuttars
eltringham
london
uk
object
conduct
hospitalwid
preval
infect
studi
determin
rel
valu
alert
organ
vers
alert
condit
surveil
detect
hospit
acquir
infect
hai
method
novemb
addit
exist
alert
organ
surveil
recommend
uk
depart
health
infect
control
team
perform
panhospit
preval
studi
day
captur
patient
treat
bacteri
infect
drug
chart
review
inpati
primari
inclus
criterion
treatment
antibiot
patient
receiv
antivir
antifung
agent
antibiot
prophylaxi
exclud
case
followedup
review
medic
note
interview
patient
clinic
staff
member
review
cultur
result
medic
microbiolog
databas
avail
result
bed
survey
occupi
patient
receiv
antibiot
male
femal
inpati
year
old
total
antibiot
prescrib
patient
receiv
three
agent
critic
care
group
highest
percentag
patient
antibiot
follow
specialist
medicin
renal
patient
followedup
among
highest
rate
infect
wound
follow
respiratori
tract
infect
bacteraemia
ten
patient
multipl
infect
overal
preval
infect
hospit
acquir
studi
period
ratio
patient
alert
organ
hai
versu
nonalert
organ
approxim
approxim
patient
alert
organ
hai
use
ratio
estim
patient
hospitalacquir
infect
king
conclus
current
surveil
methodolog
recommend
uk
depart
health
detect
one
quarter
patient
treat
hai
highlight
need
increas
alert
condit
surveil
inform
strategi
target
resourc
appropri
manag
hai
surveil
nosocomi
bloodstream
infect
ra
leth
jk
aarhu
dk
object
establish
electron
system
surveil
nosocomi
bloodstream
infect
bsi
provid
feedback
clinician
purpos
reduc
frequenc
bsi
retrospect
describ
rate
bsi
hospit
period
method
patient
admit
aarhu
univers
hospit
skejbi
period
includ
hospit
compris
bed
includ
depart
paediatr
obstetr
gynaecolog
infecti
diseas
cardiolog
nephrolog
urolog
thorac
surgeri
intens
care
unit
bsi
defin
growth
pathogen
blood
concomit
treatment
patient
antibiot
regist
nosocomi
bsi
infect
must
appear
later
hour
admiss
unless
patient
readmit
within
day
gone
surgic
procedur
within
day
new
bsi
episod
defin
growth
new
pathogen
day
previou
pathogen
growth
pathogen
day
first
detect
combin
data
patientadministr
system
laboratori
inform
system
drug
databas
electron
patient
medic
record
number
new
episod
nosocomi
bsi
per
bedday
calcul
month
glide
averag
bsi
episod
within
last
month
also
calcul
monthli
result
overal
hospit
rate
bsi
chang
monthli
glide
averag
bsi
rang
episod
per
bedday
rate
new
episod
higher
juli
compar
month
observ
period
bsi
rate
individu
depart
chang
time
one
depart
season
distribut
bsi
observ
pronounc
differ
bsi
specif
microorgan
observ
within
depart
conclus
surveil
nosocomi
bsi
base
combin
data
variou
electron
hospit
registri
costeffect
provid
document
trend
sudden
chang
rate
bsi
hospit
overal
individu
clinic
depart
importantli
system
provid
mean
monitor
consequ
chang
procedur
reduc
rate
nosocomi
bsi
morbid
mortal
confer
evalu
nosocomi
infect
hospit
mortal
demori
decost
lomm
fr
object
author
aim
determin
relationship
hospit
death
nosocomi
infect
ni
morbid
mortal
confer
method
studi
made
st
philibert
hospit
lomm
franc
patient
death
decemb
may
mortal
rate
medic
record
consecut
patient
die
least
h
admiss
review
caus
death
ni
diseas
sever
admiss
ni
onset
contribut
ni
death
assess
expert
comiti
includ
hospit
physician
dealt
patient
result
median
age
year
male
patient
diseas
cancer
case
shock
heart
failur
respiratori
diseas
liver
diseas
cirrhosi
infecti
diseas
violent
death
seventi
two
patient
present
least
one
nosocomi
infect
bacteriemia
pneumonia
urinari
tract
infect
infect
surgicalsit
infect
infect
mortal
attribut
ni
case
death
consid
prevent
case
attribut
ni
conclus
base
consensu
thorough
review
patient
clinic
stori
studi
confirm
ni
increas
risk
death
scale
use
nation
level
number
death
attribut
ni
franc
would
reach
consid
prevent
improv
healthcar
qualiti
morbid
mortal
confer
need
hospit
identifi
circumst
might
associ
onset
sever
ni
contribut
death
prevent
measur
target
point
preval
nosocomi
infect
western
greec
e
jelastopulu
f
mesolara
c
petropoulo
kardara
detoraki
patra
erymanthia
gr
object
purpos
studi
estim
frequenc
nosocomi
infect
ni
region
western
greec
determin
impact
differ
risk
factor
aim
prioritis
infect
control
measur
develop
detail
incid
surveil
ni
method
acut
care
hospit
wgreec
invit
particip
two
oneday
preval
studi
laboratori
public
health
univers
patra
suppli
hospit
questionnair
includ
demograph
clinic
data
written
instruct
clinic
physician
nurs
assign
collect
data
day
survey
confirm
presenc
ni
onsit
observ
total
number
inpati
number
site
ni
well
data
individu
risk
factor
record
statist
analys
perform
use
spss
result
total
hospitalis
patient
regist
two
studi
male
femal
identifi
ni
mean
age
year
region
preval
record
ni
rang
facil
differ
special
overal
highest
preval
found
neurosurgeri
intens
medicin
mean
interv
admiss
onset
ni
day
survey
ni
locat
frequent
urinari
tract
follow
pneumonia
surgic
site
septicaemia
overal
patient
ni
predispos
factor
cardiovascular
diseas
diabet
cancer
total
number
ni
confirm
microbiolog
laboratori
frequent
isol
microorgan
e
coli
enterococci
aureu
conclus
studi
reveal
compar
low
overal
preval
ni
remark
differ
hospit
clinic
fact
may
due
comprehens
medic
reason
also
due
underreport
ni
certain
clinic
howev
studi
highlight
need
repeat
pointpreval
survey
seem
accept
cheap
easi
way
assess
ni
rate
adequ
educ
hospit
staff
enhanc
surveil
contribut
improv
infect
control
programm
enabl
effect
intervent
reduc
risk
factor
ni
object
describ
seri
staphylococciinfect
prosthet
joint
hip
knee
total
replac
treat
debrid
prosthesi
retent
plu
longterm
levofloxacin
rifampicin
method
prosthesisjoint
infect
due
staphylococc
speci
defin
isol
staphylococci
least
two
cultur
consecut
sampl
joint
aspir
surgic
intraop
specimen
debrid
procedur
least
three
cultur
three
differ
day
discharg
sinu
tract
presenc
clinic
criteria
patient
receiv
therapi
st
outcom
see
tabl
lost
followup
sideeffect
acut
renal
failur
skin
rash
degre
accept
therapeut
recommend
orthopaedist
surgeon
index
satisfact
perceiv
qualiti
part
patient
high
infecti
diseas
specialist
must
main
role
manag
patient
prosthet
joint
infect
narrow
collabor
differ
specialist
involv
care
patient
essenti
obtain
best
possibl
result
predict
valu
oral
colonis
candida
yeast
onset
nosocomi
infect
elderli
hospitalis
patient
fanello
jp
bouchara
v
delbo
e
parot
sauteron
anger
fr
incid
nosocomi
yeast
infect
increas
markedli
past
decad
especi
among
elderli
present
studi
therefor
initi
order
determin
predict
valu
oral
colonis
yeast
onset
nosocomi
candida
infect
elderli
hospit
patient
year
also
clarifi
promot
factor
infect
establish
relationship
intens
oral
carriag
onset
yeast
infect
prospect
cohort
studi
patient
women
men
mean
age
year
survey
yeast
colonis
infect
sampl
collect
everi
four
day
four
site
mouth
intrins
extrins
factor
might
promot
infect
record
patient
puls
field
gel
electrophoresi
perform
c
albican
isol
infect
patient
poor
nutrit
statu
observ
patient
hyposaliv
colonis
rate
c
albican
heavi
carriag
yeast
cfu
observ
patient
incid
nosocomi
colonis
reach
nosocomi
infect
patient
infect
suffer
oral
candidiasi
princip
risk
factor
colonis
dental
prosthesi
poor
oral
hygien
antibiotherapi
risk
factor
infect
addit
alreadi
mention
colonis
endocrin
diseas
poor
nutrit
statu
prolong
hospitalis
high
coloni
count
genotyp
reveal
persontoperson
transmiss
two
patient
thu
studi
demonstr
signific
associ
oral
colonis
onset
yeast
infect
elderli
hospit
patient
therefor
oral
sampl
collect
admiss
antifung
